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ABSTRACT 
 
Diabetic Retinopathy (DR) is a leading cause of visual impairment (VI) in the working 
population. Minor ethnic groups are at increased risk of diabetes. Diabetic Retinopathy 
In Various Ethnic groups in the United Kingdom (DRIVE UK) is a cross-sectional 
study to estimate the prevalence of DR, VI and associated risk factors for sight 
threatening diabetic retinopathy (STDR) in Afro-Caribbeans (AC) and South Asians 
(SA) compared to Caucasians. People with diabetes in two regions in the United 
Kingdom who were screened and/or treated for DR from September 2008 to September 
2009 were included in this study. VI and severe visual impairment (SVI) were defined 
as Snellen visual acuity of ≤ 6/18 and ≤ 6/60 respectively. DR was graded according to 
National Screening Committee (NSC) for diabetes guidelines UK.   
There were 57,144 people on the diabetic register, of which retinopathy data was 
available from 50,285 (88.1%) subjects (type 1 n=3,323, type 2 n=46,962). In type 1 
and type 2 diabetes, any DR was detected in 53.1%, 39.5%, diabetic maculopathy in 
13.1%, 8.4% and STDR in 9.91%, 4.0% of people respectively. STDR was significantly 
more prevalent in the SA (10.3%) and AC (11.5%) populations compared to Caucasians 
(5.5%). Overall VI was significantly higher in the ethnic minority population. A total of 
7.5% (95% CI 7.3, 7.8) people with diabetes were not eligible for driving based on their 
visual acuity, 3.4% (95% CI 3.2, 3.5) were classified as VI and 0.4% (95% CI 0.33, 
0.44) as SVI. Risk factors for STDR were found to include longer duration of diabetes 
and higher mean HbA1c.   
This study provides information that could be used to help develop future service 
frameworks and guidelines for local health bodies responsible for delivery of end user 
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services. The study also supports the need to explore the role of inflammatory, genetic 
and epigenetic factors as markers for ethnic differences in DR and potential treatment 
avenues for diabetic retinopathy.  
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1.1 Introduction 
 
Increasing epidemiological evidence suggests that there is a global increase in the 
prevalence of diabetes. It is no longer a problem in developed nations but people with 
diabetes in developing countries such as India, China and Brazil will soon outnumber 
other nations because of increasing population and changing life styles (Wild et al., 
2004). With this, the prevalence of microvascular and macrovascular complications due 
to diabetes, and hence that of diabetic retinopathy, is also expected to increase. 
Evidence from previous major epidemiologic studies in the United States (US) suggests 
that ethnic minorities are at increased risk of diabetes and its related complications 
(Harris et al., 1998, Wong et al., 2006).  In the United Kingdom (UK), increasing 
immigration, mainly from developing countries, has resulted in a shift in the population 
demographics in metropolitan cities like London and other highly populated regions 
such as parts of Yorkshire and Birmingham.  
Countries like the UK have well established national screening programmes for diabetic 
retinopathy (DR) and all primary care trusts (PCTs) are expected to have screening 
uptake rates of > 98%, ideally 100% (www.retinalscreening.nhs.uk). The service 
objectives of screening programmes include early detection of sight threatening disease 
and timely referral of these patients to medical retina services for treatment, with the 
primary aim to decrease the rate of blindness due to diabetes related ocular 
complications by offering timely treatment. It is therefore useful to identify high risks 
groups to enable appropriate resource allocation.  
The UK Prospective Diabetic Study (UKPDS) study performed over 2 decades ago 
indicated that there is no difference in incident DR in newly diagnosed diabetes in 
22 
 
different ethnic groups (Kohner et al., 1998), but a recent study in Birmingham 
comparing prevalence of DR and sight threatening diabetic retinopathy (STDR) showed 
a much higher prevalence of DR and macular oedema (MO) in South Asians (SA) 
(Raymond et al., 2009). The two main minor ethnic groups in UK are Afro-Caribbeans 
(AC) and SA (India, Pakistan, Bangladesh and Sri Lanka) (Office for National Statistics 
UK, 2007). Most of the information on the prevalence of DR and its impact on visual 
impairment (VI) in Afro-Caribbean ethnic groups is provided by Barbados Eye Study 
(BES) and Multi-Ethnic Study on Atherosclerosis (MESA) performed in US.  
The data on the differences in risk factors and response to treatment of DR in different 
ethnic minorities is also limited (Raymond et al., 2009). End stage complications of 
diabetic retinopathy result in severe visual impairment (SVI) which severely impacts on 
quality of life and leads to loss of productive life-years. Afro-Caribbeans are 
particularly at risk of hypertension and end-stage renal disease (ESRD). There is paucity 
of data on the relation of ESRD and DR with particular reference to ethnic groups 
(Lopes, 2009).  It is therefore important to have data on the UK-specific ethnic 
variations in prevalence of diabetic retinopathy, risk factors and treatment response of 
DR to understand the impact on the already stretched health resources. 
1.2 Diabetes  
 
Diabetes is a chronic metabolic disorder caused by defects in insulin production or 
insulin resistance in the peripheral tissue. The two major types of diabetes are: 
Type 1 diabetes mellitus (T1D) is characterized by absolute deficiency of insulin due to 
immune-mediated destruction of pancreatic β cells. The development of T1D is thought 
to be triggered by environmental factors in genetically susceptible subjects. Several 
23 
 
lines of evidence indicate a rather complex genetics for T1D with the strongest risk 
associated within the human leukocyte antigen (HLA) region (Alizadeh and Koeleman, 
2008, Barrett et al., 2009). This region has both susceptible and protective haplotypes 
and the relative contribution of these haplotypes and their interactions with 
environmental determinants and other genetic loci might partially explain the ethnic 
variations in the frequency of this disease (Ikegami et al., 2008). 
Type 2 diabetes mellitus (T2D) is a growing worldwide problem with World Health 
Organisation (WHO) estimates suggesting that 300 million people will be affected by 
2025. It is characterised by peripheral insulin resistance (primarily imbalance between 
calorie intake and energy expenditure resulting in reduced whole body insulin 
sensitivity), impaired regulation of hepatic
 
glucose production, and declining ß-cell 
function, eventually leading to ß-cell failure. Both environmental factors including 
changing population lifestyle (urbanisation, calorie excess, physical inactivity) and 
genetic factors (38 individual susceptibility loci identified via genome wide association 
studies) have been implicated as causative factors (Petrie et al., 2011).    
Others forms include gestational diabetes, which is due to glucose intolerance in 
females during pregnancy.  Diabetes may also result from drug-induced genetic defects 
in the production by beta cells, endocrinopathies or chemicals. 
1.3 Prevalence of diabetes 
 
Recent estimates indicated there were 171 million people in the world with diabetes in 
the year 2000 and this is projected to increase to 366 million by 2030 (International 
Diabetes Federation, 2009).  
24 
 
1.3.1 Prevalence of type 1 diabetes  
T1D predominantly affects population of European ancestry, the highest rates being 
reported in Finland and Sardinia (Borchers et al., 2010). Asian and sub-Saharan African 
countries report low frequency although some Asians countries (Kuwait and China) 
have recently presented high rates (Moussa et al., 2005, Zhang et al., 2008a).  The 
SEARCH for Diabetes in Youth Study provided recent prevalence rates for youths aged 
0–19 years with T1D from different ethnic groups in the US. The prevalence rates per 
1000 indicate that T1D remains a Caucasian dominated disease: 2.00 in non-Hispanic 
white subjects, 1.31 for African-Americans, 0.99 for Hispanics, 0.94 for Navajos, and 
0.52 for Asians and Pacific Islander (Mayer-Davis et al., 2009, Borchers et al., 2010). 
Similarly Europe and Diabetes study (EURODIAB) across Europe and the Diabetes 
Mondiale study (DiaMond) group worldwide both have reported an increased 
prevalence of T1D in all countries with the exception of Central America and West 
Indies (EURODIAB, 1994, Karvonen et al., 2000). Prevalence among children under 
the age of 15 years is predicted to rise to 160,000 in 2020. Recently, a national survey in 
England noted that 22,947 people under
 
the age of 18 years have diabetes and this is 
mostly type 1. The incidence of T1D in children younger than 15 years is also 
increasing. The rapid increase in the incidence of T1D has been almost a global 
phenomenon during the last few decades (Green and Patterson, 2001). This may 
represent a true increase resulting from changing environmental or lifestyle factors, or 
be due to improvement in case ascertainment with the existence of diabetic registers 
across Europe and America, and more reports from developing countries (Figure 1.1). 
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Figure 1.1:  Age-standardized incidence of type 1 diabetes in children under 
14 years of age (per 100 000 per year). Countries are arranged in descending order 
according to the incidence. Source: The DiaMond Project Group, Incidence and 
trends of childhood T1D worldwide 1990–1999 (DiaMond study group, 2006) 
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1.3.2 Prevalence of type 2 diabetes  
T2D was once considered a disease of the west, but is now a global health priority. The 
International Diabetes Federation has predicted that up to 80% of the disease burden 
will affect low- and middle-income countries. More than 60% of the world's population 
with diabetes will come from Asia, because it remains the world's most populous region 
(International Diabetes Federation, 2009) (Figure 1.2). The number of individuals with 
diabetes  in each South East Asian country will increase substantially in coming decades 
(Table 1.1) (International Diabetes Federation, 2009). Between 70 to 90% of known 
diabetic patients have T2D. An estimated 50% more remain undiagnosed (Nabarro, 
1988, Simmons et al., 1989). In the UK white population, rates of known diabetes range 
from 2 - 4%. T2D is commoner in ethnic minority peoples who also often have poor 
glycaemic control.  They are also more likely to develop complications of the disease 
(Adams et al., 2008, Harris et al., 1998, Saydah et al., 2007). T2D is also common in 
those who are socio-economically deprived (Strodl and Kenardy, 2006).  
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Figure 1.2: Estimated and projected global prevalence of diabetes. AFR indicates 
African region, EUR: Europe, MENA: Middle East and North Africa, NAC: North 
America and Caribbean, SACA: South and Central American, SEA: South East 
Asia, WP: Western Pacific Region. Source: (International Diabetes Federation, 
2009) 
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Table 1.1: Estimated and projected per cent population prevalence of diabetes in 
South East Asia 
 
Population in 
2010 (20-79) Estimated diabetes prevalence (%) 
000's 2010 2030 
Bangladesh 93,862 6.6 7.9 
Bhutan 413 3.6 4.6 
India 713,498 7.8 9.3 
Maldives 186 7.3 - 
Mauritius 877 16.2 19.8 
Nepal 15,556 3.9 5.2 
Pakistan 93,644 9.1 10.5 
Sri Lanka 13,339 10.9 13.5 
 Source: (International Diabetes Federation, 2009) 
1.4 Diabetic retinopathy 
 
Diabetic retinopathy is a chronic and progressive sight-threatening disease of the retinal 
microvasculature associated with the prolonged hyperglycaemia and other conditions 
linked to diabetes mellitus such as hypertension, impaired cholesterol and lipid profile 
and nephropathy. 
1.4.1 Clinical signs and pathogenesis of diabetic retinopathy 
Clinically two distinct changes can be identified: retinopathy and maculopathy. 
Retinopathy is a disorder that progresses from no retinopathy to presence of 
haemorrhage or microaneurysm, as seen in non proliferative diabetic retinopathy 
(NPDR). These changes can develop in severity with associated vascular changes such 
as beading and intra-retinal microvascular abnormality (IRMA) to sight threatening 
proliferative diabetic retinopathy (PDR) characterised by formation of new vessels 
around optic disc (NVD) or elsewhere (NVE) (See Figure 1.3a and 1.3b). Maculopathy 
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(M) can be minimal or sight threatening when it involves the centre of eye, fovea (See 
Figure 1.4a and 1.4b).  
 
 
Figure 1.3 (a & b): Fundus photographs with various retinal lesions seen in 
retinopathy. Source: Diabetic Eye Complication Screening Services (DECS), 
London. 
The clinical signs of the disease are (RCOPhth, 2005):   
Microaneurysms: These are focal dilation of the venous end of capillaries. 
Histologically they represent out pouching of capillary endothelium with loss of 
Figure 1.3a 
Preretinal 
haemorrhage and 
NVE 
Hard exudate near 
the fovea 
Cotton wool spot 
Superficial 
haemorrhage 
Figure 1.3b 
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supporting pericytes. On clinical examination they appear as tiny red dots, most 
commonly temporal to the macula but can occur anywhere in retina. 
Hard exudates: These are the result of precipitation of lipoproteins due to an 
abnormally leaky capillary bed or microaneurysms. They appear as yellow lipid 
deposits and appear in a circular pattern around foci of leaking capillaries. 
Haemorrhages: These occur due to the rupture of weakened capillaries.  They appear as 
small dots or larger blot haemorrhages when present within the densely packed deeper 
layers of the retina, or flame shaped when in the superficial retina nerve fibre layer.  
Venous beading, looping and duplication: These are seen near the areas of capillary non 
perfusion and signify severe ischemia.   
Intraretinal microvascular abnormalities (IRMA): These represent either new vessel 
growth or remodelling of pre-existing vessels through endothelial cell proliferation 
within the retinal tissues to act as shunts through areas of non-perfusion.  
Cotton wool spots: These are fluffy white lesions that represent infarcts of the nerve 
fibre layer with associated stasis in axoplasmic flow. 
New Vessel Disc (NVD) or New Vessel Elsewhere (NVE): These are the hallmarks that 
represent the extreme spectrum of the disease (PDR). They appear as arcade of 
abnormal structures which are new vessels commonly arising on the optic disc (NVD) 
or elsewhere on the retina (NVE). They appear at the junction of perfused and non 
perfused retina and cause visual disruption as they are highly fragile and permeable. 
They either grow along the surface of the retina or as scaffolding along the posterior 
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vitreous surface. Important features of proliferative retinopathy include 
neovascularization, and pre-retinal and vitreous haemorrhages. 
Macular Oedema (MO): This is defined as the retinal thickening within one disc area of 
the macula. Clinically, it is diagnosed using stereoscopic fundus examination and 
objectively using optical coherence tomography (OCT) (Figure 1.4a and 1.4b). 
 
Figure 1.4 (a & b): Fovea appearance on optical coherence tomography: a) 
Normal, b) With hard exudates and macular thickening  
Figure 1.4a 
Figure 1.4b 
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1.4.2 Classification of DR  
Classification and grading of severity of DR have been based on ophthalmoscopically 
visible signs of increasing severity, ranked on a stepwise scale from no retinopathy 
through various stages of NPDR to advanced proliferative disease. These have 
developed from the original Airlie House classification developed for the Early 
Treatment Diabetic Retinopathy Study (ETDRS) aimed at grading retinopathy in the 
context of overall severity of ophthalmoscopic signs (Early Treatment Diabetic 
Retinopathy Study Research Group, 1991). A reduced version of the ETDRS 
classification aimed at countries without systematic screening programmes has recently 
been endorsed by the American Academy of Ophthalmology Guidelines Committee 
(Wilkinson et al., 2003), and used in clinical trials.  The latter classification was 
developed in recognition of the need for a clinical grading system that would reflect the 
vision threatening risk of DR. This describes three stages of low risk non-proliferative 
retinopathy, a fourth stage of severe non-proliferative retinopathy and a fifth grade of 
proliferative retinopathy.  
In the UK there are two classification used: The National Screening Committee (NSC) 
for use in England and Wales (Harding et al., 2003),  and the Scottish Diabetic 
Retinopathy Grading Scheme (Leese et al., 2003). The NSC classification adopts a 
simplified approach to grading retinopathy based on features which a non-
ophthalmologist / accredited photographic grader might be faced with in a population of 
diabetic patients (table 1.2).  
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Table 1.2: (continued over two pages) National Screening Committee retinopathy 
grading standard  
NSC International 
Term 
Symptoms Features Action 
R0 No DR Asymptomatic  Normal retina Annual 
rescreen 
R1 Mild non-
proliferative (mild 
pre-proliferative) 
None Haemorrhages & 
microaneurysms only 
Annual 
rescreen 
R2 Moderate non-
proliferative 
None Extensive microaneurysm, 
intraretinal haemorrhage, and 
hard exudates. 
Refer 
HES 
R2 Severe non-
proliferative 
None Previously termed pre-
proliferative. Venous 
abnormalities, large blot 
haemorrhages, cotton wool 
spots (small infarcts), venous 
beading, venous loop, venous 
reduplication, IRMA. 
Urgent 
refer 
HES 
R3 Proliferative 
retinopathy 
Floaters, 
sudden visual 
loss or 
asymptomatic 
New vessel formation either 
at the disc (NVD) or 
elsewhere (NVE). Extensive 
fibrovascular proliferation, 
retinal detachment, pre-
retinal or vitreous 
haemorrhage.  
Urgent 
refer 
HES 
M0   No maculopathy Annual 
rescreen 
M1 
 
 
 
 
 
Diabetic 
maculopathy 
 
 
 
 
 
Blurred 
central vision 
 
 
 
 
 
The macula is defined as a 
circle centred on the fovea, 
with a radius of the distance 
to the disc margin (section 
2.3.3).  If the leakage 
involves or is near the fovea 
the condition is termed 
clinically significant macular 
oedema (CSMO). 
Exudative maculopathy 
presents with leakage , retinal 
thickening, microaneurysms, 
hard exudates at the macula. 
Ischaemic form can have a 
featureless macular with 
Refer 
HES 
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NSC International 
Term 
Symptoms Features Action 
NVE and poor vision. 
Milder Forms 
exudate < or = 1DD (Disc 
diameter) of centre of fovea 
circinate or group of exudates 
within macula 
any microaneurysm or 
haemorrhage < or = 1DD of 
centre of fovea only is 
associated with a best 
Snellen’s visual acuity (VA) 
of < or = 6/12 
retinal thickening < or = 1DD 
of centre of fovea (if stereos 
available) 
P Photocoagulation Reduced night 
vision, glare 
Small retinal scars 
throughout the peripheral 
retina. 
 
OL Other lesion / Un-
gradable 
 Un-gradable is usually due to 
cataract, other lesions usually 
referred for assessment 
 
CSMO: Clinically Significant Macular Oedema, DD: Disc Diameter, HES: Hospital 
Eye Service, NVD: New vessel on disc, NVE: New vessel elsewhere on retina  
 
1.4.3 Methodology of image capture in the screening programmes in UK 
(Harding et al., 2003) 
Each eye is dilated with a mydriatic agent such as guttae tropicamide (0.5% or 1% v/v) 
and guttae phenylephrine (2.5% or 10% v/v) 
Photographers capture 2 x nominal 45º fields per eye (Figure 1.5a and 1.5b), 1 fovea 
centred and 1 disc centred. 
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Macular image (1.5a)  
 
 
AND 
Disc image (1.5b) 
centre of fovea ≤1DD from centre of 
image 
vessels clearly visible within 1DD of 
centre of fovea 
vessels visible across >90% of image 
centre of disc ≤1DD from centre of 
image 
fine vessels clearly visible on 
surface of disc 
 vessels visible across >90% of 
image 
  
Figure 1.5 (a & b): Showing definition of fovea and disc centred images. Adapted 
from National Screening Committee guideline for diabetic retinopathy 
 
Definitions 
Fovea: The fovea lies at the centre of the image and is marked by a ‘+’ symbol 
represented by big circle figure 1.6.  
1DD: 1DD is defined as the horizontal diameter of the optic disc. 
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Figure 1.6: Representing fovea and 1DD shown in 2.x magnification. Adapted from 
National Screening Committee guideline for diabetic retinopathy 
 
1.4.4 Prevalence of diabetic retinopathy 
The purpose of this review is to address the regional and ethnic variations in DR and to 
review risk factors that may explain the differences.  
1.4.4.a Diabetic retinopathy in type 1 diabetes  
There are more epidemiological studies on T1D related DR in Caucasian population 
from the European countries compared to other parts of the world reflecting the disease 
predilection and historically better healthcare systems (Table 1.3). The prevalence rates 
of DR range from 10-50% depending on the methods used to screen for DR, the type of 
population screened, the age of the patients, and the duration of diabetes. The 
prevalence rates are usually lower in population-based studies compared to hospital-
based populations. 
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Table 1.3: (continued over two pages) Studies on the rates of diabetic retinopathy 
in TID in Caucasians in North America and Europe  
Reference  
and year 
Methods  of 
Examination 
Ph, O 
Participants 
and mean age 
of cohort 
Prevalence 
of DR in 
study 
Population 
study or 
clinic 
based. 
(Klein et al., 1984b) Ph 996 
< 30 years 
54% Any DR            
27% PDR 
Population  
(Arfken et al., 1994) Ph 142 
17.2±8.7 years 
39% Any DR             Hospital 
based 
(Danielsen et al., 
1982) 
O 212 
NA 
34% Any DR 
6.1% PDR 
Hospital 
based 
(Sjolie, 1985) 
 
Ph 718 
3-76 
30% Any DR            
9% PDR 
Population  
(Burger et al., 1986) O 231 
17.6± 4.0 
47% Any DR            
4% PDR 
Hospital 
based 
 (McCance et al., 
1989) 
O 216 
26.6 
56% Any DR            
4% PDR 
Hospital 
based 
(Pinto-Figueiredo et 
al., 1992) 
O 1302 
24.14±12.47 
42% Any DR            
7% PDR 
Population 
(Joner et al., 1992)
 
 
Ph 369  
18.3±4.9 
33% Any DR             Population 
(Falck et al., 1993)
 
 
Ph 194 
11.8 
11% Any DR             Hospital 
based 
(Stephenson et al., 
1995) 
Ph 2479 
32.7±10.2 
46% Any DR            
10% PDR 
Population  
(Kristinsson et al., 
1994b)
 
 
Ph+O 205 
32.9±0.91 
52% Any DR            
13% PDR                    
9%  MO 
Population 
(Kokkonen et al., 
1994) 
Ph 80 
21.6 
70% any DR 
10% PDR 
Population 
(Johansen et al., 
1994) 
Ph 138 
25-34 
59% Any DR            
17% PDR 
Hospital 
based 
(Ebeling and 
Koivisto, 1997) 
Ph 140 55% Any DR            
21% PDR 
Hospital 
based 
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Reference  
and year 
Methods  of 
Examination 
Ph, O 
Participants 
and mean age 
of cohort 
Prevalence 
of DR in 
study 
Population 
study or 
clinic 
based. 
33.0±0.8 
(Kuiv et al., 1997)
 
 
Ph 149 
34-71 
(median 40 
years) 
77% Any DR            
17% PDR 
Population  
(Kernell et al., 1997)
 
 
Ph+O  557 
14.6 
15% Any DR            
2% PDR 
Population  
(Olsen et al., 1999) 
 
Ph 339 
(median 21.1 
years) 
57.6% Any 
DR 
Population 
(Larsson et al., 1999) 
 
Ph 285 
33.1±9.6 
75% Any DR            
22% PDR 
Population  
(Nordwall et al., 
2006) 
Ph 80 
(7-22) 
27% Any DR Population 
O-ophthalmoscopy, Ph-photography  
The earliest signs of DR in T1D usually occur after 5-10 years of diabetes duration and 
the prevalence of DR is strongly correlated to duration of disease. Nearly all subjects 
with T1D will develop some degree of retinopathy within twenty years of diagnosis but 
this may change with better control of risk factors (Klein et al., 1984c, Klein et al., 
2008a). So the current guidelines recommend annual screening for all patients from the 
age of 12 years in UK or 10 years in US (American Academy of Pediatrics, 1998, NSC, 
2010).  
There are limited studies on prevalence of DR in T1D from non-Caucasian dominated 
countries probably because T1D is more prevalent in people of European ancestry (table 
1.4). Moreover, information on other ethnic groups is more recent perhaps due to better 
case ascertainment and improvement in the healthcare systems (Arfken et al., 1994, 
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Elbagir et al., 1995, Esteves et al., 2009, Gomes et al., 2000, Motala et al., 2001, Roy, 
2000, Majaliwa et al., 2007, Ko et al., 1999).  
Table 1.4: Prevalence rates of DR in T1D in non-Caucasian population 
Author and 
year 
Ethnic 
group 
Methods of 
Examination  
Ph, O 
Number of 
participant
s with 
mean 
age(years) 
Prevalence 
rates 
Type of 
study 
(Arfken et al., 
1994) 
African 
American 
 
Ph 58 
20.7±10.0 
 
36% Any 
DR 
 
Hospital 
based  
(Elbagir et al., 
1995) 
Sudan O 91  
15-75 
43% Any 
DR            
10% PDR 
Hospital 
based 
(Fairchild et 
al., 1994) 
Australia Ph 255 
11.0-19.9  
42% Any 
DR 
Populati
on 
(Ramachandra
n et al., 2000) 
Indian Ph 617 
Median 
25(10-50) 
13.4% Any 
DR 
Populati
on 
(Ko et al., 
1999) 
China O 150 
30.7± 0.5 
14% Any 
DR             
Hospital 
based 
(Roy, 2000) 
 
African 
American 
Ph + O  724 64% Any 
DR            
19% PDR  
Hospital 
based 
(Motala et al., 
2001) 
African O 36 
39.9 ± 11.2 
56% Any 
DR            
17% PDR 
Hospital 
based 
(Maguire et al., 
2005) 
Australia Ph 618 
 
34% Any 
DR 
Populati
on 
(Majaliwa et 
al., 2007) 
Tanzania O 99 
12.6 ± 3.5 
23% Any 
DR 
Hospital 
based 
(Scott et al., 
2004)  
 
New 
Zealand 
Ph 237 
16.7 
25% Any 
DR  
Hospital 
 
Inter-regional differences in prevalence rates of DR are best observed in the four 
multinational studies: The DiaMond Substudy of Complications (DiaComp), the WHO 
Multinational Study of Vascular Diseases in diabetes (MSVDD), the EURODIAB 
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Study and the DiabCare Asia 1998 study (DiaMond study group, 2006, EURODIAB, 
1994, Lee et al., 2001b, Nitiyanant et al., 2002, Walsh et al., 2006). 
In the EURODIAB study of patients from 31 clinics in 16 European countries, the rate 
of retinopathy ranged between 25% in Austria to 60% in Portugal (EURODIAB, 1994). 
The DiaComp study also mirrored such variations in prevalence of self-reported 
retinopathy in subjects with short duration of diabetes, with highest rates noted in 
Lithuania (29.9% requiring laser treatment) (Walsh et al., 2006). The prevalence rates 
were more consistent in people with long duration of diabetes. Similarly, the WHO 
MSVDD found the cumulative incidence of any retinopathy to vary at least two-fold 
between centres, with even greater variation in the frequency of PDR. 
The Asian Young Diabetes Research (ASDIAB) Study, reported the prevalence of DR 
in 724 young diabetic subjects of age 12-40 years with duration of diabetes of less than 
12 months in 7 centres of four Asian countries. The fact that the Asian study has very 
few patients with DR again reflects both the low prevalence of T1D and the low rates of 
healthcare utilization. It is interesting to note that DR prevalence was least among 
Indians (5.3%) as compared to other ethnic groups such as Malays (10%) and Chinese 
(15.1%) (Rema and Mohan V, 2002). Higher levels of fasting and glucagon stimulated 
C-peptide among the Indians were postulated to partly explain the lower prevalence of 
DR in this group (Rema and Mohan V, 2002). 
Few single-centred studies from the Indian sub-continent also show a low prevalence. A 
study in Pakistan amongst TID of more than 10 years duration reports a prevalence of 
7.7% (Shera et al., 2007). Similarly, a study from South India in a cohort of T1D 
followed up over 15 years showed that despite an earlier age of onset of the disease 
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there was lower prevalence rates of 13.4%  and 1.9% of any DR and PDR   respectively 
(Ramachandran et al., 2000) implying despite the earlier age of onset and poorer 
glycaemic control, there may be other clinical and genetic factors that may determine 
the rate of complications in various ethnic groups (Borchers et al., 2010). The study also 
showed that the prevalence of T1D is increasing in India (10.5/10,000 per year) 
probably due to better case ascertainment and improved survival rates. These rates are 
similar to the incidence reported in Asian children in the UK (Ramachandran et al., 
2000). 
In a study comparing South African Black and Indian subjects with T1D of over 10 year 
duration, no ethnic differences in prevalence of DR (Blacks 55.6%, Indians 45.5%), was 
reported despite the fact that the prevalence of hypertension was higher in the Blacks. 
However, the onset of retinopathy from time of diagnosis occurred earlier in Blacks 
(13.0 +/- 4.6 years versus 18.0 +/- 4.6 years) (Motala et al., 2001). 
Similarly, Arfken et al compared the risk of development of PDR between African-
Americans and whites with T1D and showed that 17.5% of the African-Americans 
developed PDR compared to 10.2% in the whites but ethnicity was not a risk factor 
after adjusting for glycaemic control and duration of the disease (Arfken et al., 1994).   
A cross-sectional study from Brazil showed comparable prevalence to European studies 
(Esteves et al., 2009, Gomes et al., 2000).  
The prevalence of macular oedema and clinically significant macular oedema (CSMO) 
is also related to the duration of the disease with very low rates within five years of 
diagnosis to 29% showing evidence of MO at 20 years (Klein et al., 1984b, Klein et al., 
1984b, Klein et al., 1984a, Klein et al., 1989d, Klein et al., 1995b, Klein et al., 2009a, 
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Williams et al., 2004b). However, it is crucial to note that the prevalence of MO varies 
depending on the period of study within the same region due to the improved healthcare 
experienced by the T1D subjects. Incidence studies will provide a better insight into 
these temporal changes. 
The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) is the largest 
study with data on incidence of DR in a predominantly Caucasian population in the 
United States (Klein et al., 1984b, Klein et al., 1985a, Klein et al., 1985c, Klein et al., 
1985b, Klein et al., 1989b, Klein et al., 1989d, Klein et al., 1990, Klein et al., 1994b, 
Klein et al., 1995b, Klein et al., 1998, Klein et al., 2008a, Klein et al., 2009a). Table 1.5 
gives the incidence data of DR and visual impairment at different time-points. Studies 
in Europe at similar time-points also reveal that approximately 50% with no retinopathy 
develop any retinopathy by 5-7 years (Agardh et al., 1997, Burger et al., 1986) while 
9% with background retinopathy develop PDR by 5 years. Higher prevalence was noted 
in subjects with poorer control of blood pressure and glycaemic status as confirmed by 
the Diabetes Control and Complications Trial (DCCT). This study involving volunteers 
with TID of less than 5 years duration from 29 medical centres in Canada and the USA 
and showed that 54.2% of patients had DR at baseline and 67.1% had DR within 5 years 
of diabetes duration and the rate of progression of DR decreased significantly and 
exponentially with better control of hyperglycaemia (DCCT, 2000). The Berlin 
Retinopathy study also stressed that a threshold of HbA1C of at least 9% is required to 
reduce the risk of progression (Danne et al., 1994).  
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Table 1.5: Incidence of DR at different time points in WESDR  
US 
WESDR 
N No DR 
to any 
DR 
DR to 
PDR 
MO CSMO Blindness VI 
4 years 
(Klein et al., 
1989b) 
891 59% 10.5% 8.2% 4.3% 1.5% 1.5% 
10 years 
(Klein et al., 
1994b) 
765 89.3% 29.8% 20.1% NA 1.8% 9.4% 
14 years 
(Klein et al., 
1998) 
634 86% 37% 26% 17% 2.4% 12.7% 
25 years 
(Klein et al., 
2008a) 
567 83% 42% 29% 17% 3% 13% 
N: Number 
Incidence studies on other ethnic groups are limited (Arfken et al., 1994, Gomes et al., 
2000, Kalter-Leibovici et al., 1997). The risk of conversion to PDR was higher in non-
Ashkenazi Jewish origin versus Ashkenazi independent of the glycaemic and blood 
pressure parameters (Kalter-Leibovici et al., 1997).  On the contrary, African-
Americans have higher incidence of PDR compared to whites that is explained by 
poorer control of the conventional risk factors (Arfken et al., 1994). In the WHO 
MSVDD study complicating T1D in different ethnic groups, American Indians had a 
higher incidence of any retinopathy compared to the European and Asian cohorts (Lee 
et al., 2001b). 
Incidence studies from the Scandinavian countries have observed a decline in incidence 
rates of nephropathy earlier than the decrease in incidence rates of severe retinopathy 
over the last 25 years (Bojestig et al., 1998b, Hovind et al., 2003, Nordwall et al., 2006). 
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This decrease in the cumulative incidence of both retinopathy and nephropathy is 
attributed to better control of the risk factors. A similar decline in incidence of visual 
impairment due to diabetes has also been reported from the same region (Hovind et al., 
2003, Backlund et al., 1997).  Comparatively, in the US, a similar decline in rates of 
PDR was not noted in the Pittsburgh Epidemiology of Diabetic Complications Study 
over a 25-year period of follow-up (Pambianco et al., 2007). However, annualized 
estimates of the 25 year WESDR study have also shown a decline in rates of PDR in the 
latter half of the study compared to the first 12 years (Klein et al., 2008a).  The 25 year 
incidence study of MO in the WESDR study also observed a decrease in rates of MO 
from 2.3% in the first four years of the study compared to 0.9% at 25 years follow-up.  
The reduction in incidence rates of MO and PDR is also reflected in the lower 
prevalence of visual impairment (VI) in more recent period of diagnoses of T1D (Klein 
et al., 2009a, Klein et al., 2008a).   
A similar decline in DR prevalence is also observed in children and adolescents in both 
European and other ethnic groups (Sano et al., 2009, Massin et al., 2007). Several 
authors have attributed this to advances in insulin therapy preventing or decreasing 
glucose excursions (Maguire et al., 2005, Massin et al., 2007, Mohsin et al., 2005).  
Studies from around the world have identified a variety of predictors for the 
microvascular complications of T1D with disease duration and glycaemic control being 
the strongest risk factors. The geographic and ethnic variations in DR are largely 
accounted for by significantly worse glycaemic control in the minor ethnic groups 
(Arfken et al., 1994, Moreira, Jr. et al., 2010, Mendes et al., 2010, Svensson et al., 2009, 
Povlsen et al., 2005b, Povlsen et al., 2005a).  
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The DCCT and Epidemiology of Diabetes Interventions and Complications (EDIC) 
study results suggest that the risk of DR progression is higher in adolescents than in 
older-onset T1D subjects (Massin et al., 2007, White et al., 2010, Morales, 2009). The 
cumulative incidences of a progression of 3 steps or more in the ETDRS retinopathy 
level, from DCCT baseline to EDIC Year 4, were 65% and 32%, respectively, in the 
conventional and intensive groups of the original adolescent cohorts, compared to 49% 
and 18%, respectively, for the entire cohort of T1D. This may be due in part to globally 
worse glycaemic control in the original adolescent cohort than in older T1D subjects 
during both the DCCT and EDIC studies, but still underlines the higher risk of DR 
progression in these young patients.  
Comparison of prevalence studies on DR in T1D between different regions should be 
done with caution. The approach of different healthcare systems on the management of 
T1D varies significantly. The DCCT demonstrated that intensive therapy was more 
effective when initiated during the first 5 years of diabetes as primary prevention than 
when introduced as secondary intervention after complications had begun to develop. 
Moreover, the beneficial effects of intensive therapy on the onset and progression of 
retinopathy were not evident until after three or four years of therapy. So the risks of 
DR are determined more by the ‘metabolic memory’ of hyperglycaemia than to the 
prevailing level of hyperglycaemia (The Diabetes Control and Complications Trial 
Research Group, 2002). This was confirmed by data from the Fulminant T1D 
Committee that suggested that HbA1C up to 5 years earlier made a greater contribution 
to progression of retinopathy than the present level (Lind et al., 2010).  
It is also known that, despite adequate glycaemic and blood pressure control, DR can 
progress and once the disease process reaches a certain stage, its effects become 
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irreversible. This phenomenon of 'retinopathic momentum' was defined in the DCCT 
and suggests that once DR progresses far enough down the line, then the momentum 
carries it forward, and that any form of intervention would not affect its relentless 
progress.  Given that glycaemic control is the one of the strongest risk factor for DR, the 
early implementation of intensive treatment of diabetes determines the prevalence and 
incidence of DR in T1D in any region in the world.   
Another important risk factor in T1D is hypertension especially high systolic blood 
pressure (Arfken et al., 1994, Walsh et al., 2006) and high nocturnal blood pressure 
(Rodrigues et al., 2010). Inhibition of angiotensin converting enzyme (ACE) and 
angiotensin receptor blockade reduces the risk of progression of DR in normotensive 
T1D (Chaturvedi et al., 1998, Chaturvedi et al., 2008, Jandeleit-Dahm and Cooper, 
2006) independent of the effect on hypertension. The effect of changes in clinical 
practice brought about by these trials are shown in the Steno Diabetes Centre Study and 
have contributed partly both to the recent decline in DR prevalence rates (Hovind et al., 
2003, Klein and Klein, 2010) and will influence the prevalence rates of DR in future. 
There are no studies on other ethnic groups on the effect of these drugs on the 
prevalence of retinopathy.  
High caloric and sodium intakes are significant and independent risk factors for 
progression of DR in African American patients with T1D (Roy and Janal, 2010).  Risk 
modelling of a Thai cohort showed that serum creatinine of >2mg/dl is an added risk 
factor in that population (Chetthakul et al., 2006b). 
Other contributing factors include high body mass index (BMI) (Ko et al., 1999, De 
Block et al., 2005), lack of physical activity, dyslipidemia (plasma triglycerides) in 
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CSMO (Miljanovic et al., 2004), microalbuminuria, smoking  and socio-economic 
factors (Pedro et al., 2010). High haemoglobin levels predicts the incidence of PDR in 
T1D (Conway et al., 2010) while moderate alcohol consumption reduced the risk of 
PDR (Beulens et al., 2008).  
Age at onset significantly modifies the long-term risk of proliferative retinopathy. The 
highest risk is in age-at-onset group 5-14 years, whereas the lowest risk is in age-at-
onset group 15-40 years (Hietala et al., 2010). Hormonal changes induced by puberty 
including increased growth hormone and insulin-like growth factor and the effect of 
prepubertal diabetes duration in the development of DR remain controversial (Flack et 
al., 1996, Donaghue et al., 2003).  
In a Caucasian study, increment of carotid intima-media thickness in T1D was 
associated with diabetic microangiopathy (Gul et al., 2010) but a similar association 
was not observed in a Japanese cohort (Ogawa et al., 2009). 
 The current evidence supports a multifactorial and polygenic aetiology. It is also 
possible that genetic differences contribute to the higher risk of DR in certain ethnic 
groups (Borchers et al., 2010, Abhary et al., 2009, Roy et al., 2009).  Whether the 
effects of ethnicity are independent of socioeconomic status remains the matter of 
considerable controversy. While a few studies showed a positive association of low 
socioeconomic control and poor metabolic control (Bachmann et al., 2003), other 
studies failed to show such effects (Carter et al., 2008). Other social, cultural and 
behavioural factors including access to health care may also contribute to the ethnic 
variations in DR.  
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In conclusion, there is geographic and ethnic variability in the rate of retinopathy in 
T1D that cannot be explained by the variations in study methodologies only. Although 
it may be thought to parallel the prevalence of T1D, other factors may play important 
roles including differences in genetic risk factors, ecological differences such as socio-
economic inequalities, differential distribution of known risk factors between ethnic 
groups and differences in healthcare systems and availability of more intensive medical 
care around the world to keep T1D related complications low for these people.  
1.4.4.b Diabetic retinopathy in type 2 diabetes: There has been a surge in the reports 
on T2D related DR in the last 2 decades, especially from Asia. More multi-ethnic 
comparative studies are also available to better understand the variations in DR between 
racial groups. A breakdown of the prevalence rates of races per continent provides us 
with a vision on future needs per region.  
Europe 
Most of Europe is historically predominantly populated by Caucasians. However, in the 
past 20 years, migrations of other ethnic groups have converted some European cities to 
multiracial population. These ethnic groups are mainly Asians and Afro-Caribbeans. As 
diabetes and its complications are far more prevalent in these ethnic groups, data on 
ethnicity-specific prevalence rates are crucial to assess health needs. Table 1.6 shows 
the prevalence rates of predominantly Caucasian population in Europe at different time 
points (clinic-based studies have been included in areas where no population based 
studies are available). Comparison of data between regions is difficult because of 
different study entry criteria and methodology used. Studies employing retinal 
photography consistently suggest that the prevalence of DR is close to 40%, whereas 
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STDR account for 6-8% of all diagnosed cases in Caucasians. However, some regions 
in Europe report low rates, suggesting that DR is still under diagnosed in these areas 
(Beynat et al., 2009).Various longitudinal studies indicate an annual incidence of DR of 
2-6% in the Caucasian population.   
Table 1.6: (continued over two pages) Prevalence rates of diabetic retinopathy in 
predominantly Caucasian population with T2D in Europe 
Author  
and year 
Region Sample 
size 
Methods of 
examination 
Ph, O 
Prevalence  
rate 
(Kalm et al., 1989) 
 
Sweden 185 O + Ph 39% Any DR   
4% PDR  
21% Macular 
Oedema 
(Sparrow et al., 
1993) 
 
UK 148 O 52% Any DR 
4% PDR 
10% CSMO 
(Leese et al., 1993) 
 
Rural versus 
Urban  
UK 
961 rural 
versus 
1225 
urban 
Ph Any DR  
13% rural, 
7% urban  
(Kristinsson et al., 
1994a) 
 
Iceland 243 
Hospital 
based 
Ph 41% Any DR  
7% PDR 
10% Macular 
Oedema 
(Stolk et al., 1995) Netherland 
Rotterdam 
Study 
7129 Ph 4.8% Any DR 
(Hirvela and 
Laatikainen, 1997) 
Finland 113 aged  
> 70 years  
O + Ph 21% Any DR 
2% PDR                       
(Cahill et al., 1997) 
 
Ireland 150 
Hospital 
based 
O+ Ph 14% Any DR 
3% PDR                       
(Kohner et al., 
1998) 
UKPDS 2964 
Newly 
diagnosed 
Ph 37% Any DR 
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Author  
and year 
Region Sample 
size 
Methods of 
examination 
Ph, O 
Prevalence  
rate 
T2D 
(Delcourt et al., 
1998) 
 
France 428 
Hospital 
based 
Ph 32%  Any DR 
3%  PDR 
5% Macular 
Oedema 
(Rajala et al., 1998) Finland 790 Ph 4% Any DR             
(Younis et al., 
2003) 
 
Liverpool, 
UK 
 
7615 Ph 34% Any DR       
1% PDR                  
9% Macular 
Oedema     
6% STDR 
(Olivarius et al., 
2001) 
 
Denmark 1251 O + Ph 5% Any DR                                  
1% Macular 
Oedema 
(Ling et al., 2002)  
 
UK 775 O + Ph 30% Any DR  
 3% PDR 
6% Macular 
Oedema 
(Giuffre et al., 
2004)  
Italy 1588 O + Ph 34% Any DR 
5% PDR                       
(Hove et al., 2004) 
 
Denmark 378 Ph 31% Any DR 
3% PDR                       
(Beynat et al., 
2009) 
Rural France 1718 Ph 5% Any DR                                 
1% Macular 
Oedema 
UKPDS: UK Prospective Diabetes Study 
Comparative studies between ethnic groups in Europe shows that sight-threatening 
complications of diabetes mellitus affect racial and ethnic minority populations 
disproportionately (table 1.7). Earlier studies on the ethnic variations in the prevalence 
rates of DR are conflicting. As early as 1987, Cruickshank et al reported no difference 
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in prevalence of mild DR between West Indians and Caucasians in UK and between 
West Indians in UK and Jamaica based on undilated fundus examination. However, 
since then the reports have been conflicting. In the U.K., blacks had an equal risk of 
retinopathy after adjustment for age (Cruickshank and Alleyne, 1987), and Asians had a 
lower risk after adjustment for risk factors like smoking or treatment.  
Table 1.7: Inter-ethnic comparison of prevalence of DR in Europe 
Author  
Year 
Ethnic 
groups 
N Methods of 
examination  
Ph, O 
Prevalen
ce of DR 
Prevalence  
of MO 
Prevalence 
of STDR 
(Chaturve
di et al., 
1996a) 
Caucasian 
Afro-
Caribbean 
889 
583 
Ph 37% 
33% 
 4% PDR 
1% PDR 
(Das et 
al., 1994) 
 
Caucasian 
South 
Asia 
2241 
73 
O 17% 
23% 
- 
- 
- 
- 
(Raymon
d et al., 
2009) 
Caucasian 
South 
Asia 
614 
421 
Ph 
 
37% 
45% 
8% 
13% 
16% 
12% 
 
The prevalence of T2D is three to five times as prevalent in the South Asians and 
African-Caribbeans in UK compared to the Caucasians (Riste et al., 2001). Table 1.7 
highlights the increased prevalence of DR and CSMO in South Asians in UK compared 
to the Caucasians. The reports on the African-Caribbean are conflicting. However, 
African-Caribbean people with diabetes have wider retinal arterioles that may contribute 
to enhanced microvascular damage in this ethnic group (Mahal et al., 2009). The 
maximal hyperaemic response of the microvascular to heat and post ischemic response 
is also significantly attenuated in African-Caribbeans compared to the Caucasians 
(Strain et al., 2005).  
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United States 
Epidemiologic studies from the US over the past 25 years have provided the most data 
on the prevalence, natural history and its associated risk factors for diabetic retinopathy. 
The prevalence of DR in Non-Hispanic whites in the US is similar to the rates reported 
in the whites in Europe. Approximately 40% have evidence of retinopathy, and 8% have 
sight-threatening disease at any time (Kempen et al., 2004).  In persons without 
retinopathy, studies suggest that the risk or incidence of new retinopathy is between 5% 
and 10% per year. One of the landmark epidemiologic studies WESDR identified the 
key risk factors for diabetic retinopathy in the 1980s: longer duration of diabetes, 
hyperglycaemia, and hypertension. These observations led to the major clinical trials 
that have conclusively proven the importance of adequate control for glycaemia and 
blood pressure levels to prevent visual loss from diabetic retinopathy (UKPDS, 1998b, 
UKPDS, 1998a). Findings from WESDR and subsequent epidemiologic studies have 
been used widely to develop guidelines for patient care around the world. The WESDR, 
a population-based cohort study of diabetes in which participants were first examined in 
1980-82, showed that in persons with T2D, the prevalence of diabetic retinopathy 
ranged from 29% in those with diabetes for less than 5 years to 78% in those with 
diabetes for over 15 years (Klein et al., 1984c).  The few studies conducted in more 
contemporary populations suggest significantly lower prevalence of diabetic retinopathy 
compared to WESDR, although differences in study design, population characteristics, 
and definitions of diabetes and retinopathy between earlier and newer studies make it 
difficult to draw definitive conclusions.
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The main population groups in the US are non-Hispanic Whites, Hispanics, African-
Americans and Asian Americans. Data on Native American Indian population is also 
available.  
In the US, the most common non-Caucasian ethnic groups include Hispanics Latinos, 
African-Americans, Chinese and Pacific Islanders and Native Indians. 
A comparative study between ethnic groups (table 1.8 and 1.9) shows that the Hispanic 
and the African-American have a higher risk of clinical significant macular oedema. 
Table 1.8: shows the studies in different ethnic groups in the US 
Author  
and year 
Ethnic group Sample 
size 
 
Methods of 
examination 
Ph, O 
Prevalence  
rate 
(Kahn and Milton, 
1980) 
Predominantly 
Caucasian 
2477 Ph+O 3.1% Any DR             
(Klein et al., 
1984c) 
Predominantly 
Caucasian 
1370 Ph 54% Any DR  
9% PDR         
(Klein et al., 1992) Predominantly 
Caucasian 
416 Ph 68% Any DR  
11%PDR                      
11% Macular 
Oedema 
(Nagi et al., 1997) Pima Indian  991 Ph 38% Any DR             
(Schulz et al., 
1997) 
Oneida Indian 345 O 9% Any DR             
(Smith et al., 2007) Vanuatu 83 Ph 52.9% Any DR 
1% PDR 
 
The Hispanic/Latinos comprise 15.1% of the population of the United States. The 
prevalence of DR and MO in Latinos ranges from 30 to 50%. The prevalence of DR in 
Hispanics has not changed significantly over time. The prevalence of DR in Hispanics 
was 41.8% compared to 54.1% in non-Hispanic whites in the San Luis Valley Study 
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conducted from 1984-1992 (Hamman et al., 1989). Data from the recent Los Angeles 
Latino Eye Study (LALES), which comprised of only Latinos ≥ 40 years, showed an 
overall prevalence of 46% (Varma et al., 2004). Although there are noted ethnic 
differences in the phenotype of DR, large scale population based studies are needed to 
confirm this observation. Several studies show a prevalence of hard exudates in the 
Black population and a prevalence of intra-retinal haemorrhages in the Latino 
population (Klein et al., 1992, Lim et al., 2008a, Varma et al., 2004). It is also 
interesting to note that the severity of DR aggregates in families rather than the presence 
of DR itself in a study on Mexican- American T2D siblings of probands with DR 
(Hallman et al., 2005). 
The meta-analysis of eight major US epidemiological studies conducted by the Eye 
Diseases Prevalence Research Group (Kempen et al., 2004) also revealed a significant 
prevalence of MO in the ethnic minority populations of the studies in comparison to the 
non-Hispanic whites. The prevalence of MO ranged from 1.2% to 5.1% in studies 
composed of non-Hispanic whites to 8.9% in a study composed of Hispanics (no risk 
factor adjustment made) (Kempen et al., 2004). 
One of the major studies exploring the issue of MO was the Multi-Ethnic Study of 
Atherosclerosis (MESA) (Wong et al., 2006). Little or no cardiovascular disease was 
found in this diabetic population and the study revealed the prevalence of DR in this 
cohort to be 33.2%, with CSMO accounting for 5.6% and sight-threatening retinopathy 
accounting for 7.9%. However, ethnicity was not a risk factor when adjusted for other 
predictive variables, such as blood sugar and blood pressure. This indicates that a 
differential susceptibility to risk factors does not exist between ethnic groups in a 
relatively healthy T2D population. 
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In contrast, the Veterans Affairs Diabetes Trial (VADT) study where cardiovascular 
disease was found in 40% of their populace at baseline revealed an increased prevalence 
of sight threatening DR in Hispanics compared to non-Hispanic whites. This difference 
was unaccounted for by inter-ethnic differences of the established risk factors, for 
example, duration of diabetes, age, glycaemic control and blood pressure. There was 
also an ethnic variation in the increased prevalence of CSMO in Hispanics (3 times) and 
the Blacks (2.5 times) in comparison to the non-Hispanic white population. The 
presence of CSMO was also independently associated with the severity of DR, diastolic 
blood pressure and a history of amputation (Emanuele et al., 2009).  
The annual incidence of retinopathy for the Latino study (LALES) (Varma et al., 2004) 
(7.1%) was similar to the rates found in the WESDR (8.6%) (Klein et al., 1989c), the 
black Barbados Incidence Study of Eye Diseases (Leske et al., 2003) (7.5%) but higher 
than the rates found in the non-Hispanic white Blue Mountains Eye Study (BMES) 
(Cugati et al., 2006) (4.4%), the non-Hispanic white Australian Diabetes Obesity and 
Lifestyle (AusDiab) (2.78%) (Tapp et al., 2003) and the Liverpool eye study (0.8%) 
(Broadbent et al., 1999). The LALES study also reported that the 4 year incidence of 
DR was 34%, MO was 5.4% and CSMO was 7.2% (Varma et al., 2004). A higher 
incidence of DR was associated with the younger age group and longer duration of 
diabetes. However, a higher incidence of MO was only associated with longer duration 
of diabetes (p=0.004) (Varma et al., 2010a). 
For presenting binocular visual impairment (VI) and blindness, the 4 year incidence was 
2.9% and 0.3% respectively. Also with respect to best corrected VI and blindness, the 4 
year incidence was 1.2% and 0.3% respectively (Varma et al., 2010b). Cultural and 
socio-economic disparities may have a role to play in this finding. Appiah et al in 1991 
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suggested that late diagnosis of diabetes in the Latino and Black population may 
account for the increased severity of DR at presentation (Appiah et al., 1991). In the 
USA, Latinos account for one of the highest rates of visual impairment secondary to eye 
disease. The prevalence and risk of undetected eye disease is unquantifiable. This 
population access to health care is at best inconsistent and unequal and this may 
influence disease statistics. For example, in the Proyecto VER (Vision Evaluation and 
Research) study, there was a higher prevalence of PDR in the low income group which 
may have reflected use of healthcare (West et al., 2001). In contrast, no association was 
found between socio-economic status and DR in a cohort of Mexican-Americans and 
Caucasians with adult onset diabetes in Texas (Haffner et al., 1989).  
African-American (Blacks) 
Approximately 13% African-American have diabetes (Chin et al., 1998) with the 
prevalence and incidence of diabetes being at least twice as high as the white Americans 
(Centers for Disease Control and Prevention (CDC)., 2010, Harjo et al., 2010).   
Earlier prevalence studies on DR in this group are limited by methodological flaws 
(Baker et al., 1998).  The Barbados Eye Study (BES) reported a prevalence of 25.8% in 
the black Caribbean population (Leske et al., 1999a) while the National Health and 
Nutrition Examination Survey (NHANES) III reported a prevalence of 26.5% for 
African-Americans compared to 18.2% in non-Hispanic white Americans aged 40 or 
older (Zhang et al., 2008b).  Nevertheless, reliable estimates based on contemporary 
studies on inter-ethnic comparisons also reveal significantly higher rates of DR in 
African-Americans. Data from the Atherosclerosis Risk in Communities Study (ARIC) 
indicate a prevalence of diabetic retinopathy of 27.7% in African-Americans as 
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compared with 16.7% in white Americans (Klein et al., 2002b) while the 
Cardiovascular Health Study (CHS) in adults aged 65 years and older in US reported a 
prevalence of 35.4% for African-Americans compared to 16.0% for white Americans 
(Klein et al., 2002a). The Veterans Affairs Diabetes Trial (VADT) noted that both the 
prevalence and severity of DR were more frequent in African Americans compared to 
non-Hispanic whites (29% versus 22%) and these differences could not be accounted 
for by an imbalance in traditional risk factors such as age, duration of diagnosed 
diabetes, hyperglycaemia, and blood pressure (Emanuele et al., 2005).  The MESA also 
showed that the prevalence of any DR was higher in the African-American compared to 
the non-Hispanic whites (36.7% versus 24.8%) but observed that race was not an 
independent predictor of retinopathy (Wong et al., 2006).  Recently, a 2-field non-
mydriatic screening programme noted a prevalence of DR to be 15.7% with no 
difference between ethnic groups in an urban multi-racial population (Lim et al., 
2008a). These prevalence rates may be an underestimate due to poorer ascertainment 
levels and higher mortality rates in African-Americans compared to their white 
counterparts (Baker et al., 1998).  
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Table 1.9: (continued over two pages) Diabetic retinopathy in Hispanics and 
African Americans 
Author  
Year 
Ethnic 
 Groups 
N Methods of 
examination 
Ph, O 
Prevalence 
of DR 
Prevalence 
of MO 
Prevalence 
 of STDR 
(Harris 
et al., 
1998)  
 
Non 
Hispanic 
Blacks 
Mexican 
America
ns 
Non-
Hispanic 
whites 
261 
 
 
308 
 
345 
Ph 27% 
 
 
33% 
 
18% 
- 
 
 
- 
 
- 
2% PDR 
 
 
6% PDR 
 
1% PDR 
(Harris 
et al., 
1999)  
 
African 
America
n 
Non-
Hispanic 
whites 
57 
 
49 
Ph 50% 
 
19% 
- 
- 
- 
- 
(Hamma
n et al., 
1989) 
Hispanic
s 
Non-
Hispanic 
whites 
166 
 
85 
Ph 43% 
 
48% 
- 
- 
7% PDR 
 
5% PDR 
(West et 
al.,2001) 
Mexican
- 
America
n 
1044 Ph 48% 2% 6% PDR 
(Emanue
le et al., 
2005) 
African 
America
n 
Hispanic 
Non 
Hispanic
s Whites 
2402 
 
36 
779 
Ph 20% 
 
35% 
47% 
 29%* 
 
36%* 
22%* 
(*ETDRS 
score > 40) 
(Varma 
et al., 
2004)  
Hispanic
s 
1217 Ph 47% 10% 12% PDR 
6% CSMO 
(Wong 
et al., 
Whites 
African-
153 
289 
Ph 24.8% 
37.4% 
3% 
11% 
3% PDR 
4% PDR 
59 
 
Author  
Year 
Ethnic 
 Groups 
N Methods of 
examination 
Ph, O 
Prevalence 
of DR 
Prevalence 
of MO 
Prevalence 
 of STDR 
2006) America
n 
Hispanic
s 
Chinese 
America
ns 
 
235 
101 
 
37.4% 
25.7% 
 
11% 
9% 
 
4% PDR 
5% PDR 
(Lim et 
al., 
2008a) 
African 
America
n 
Hispanic 
Non 
Hispanic
s Whites 
216 
 
229 
127 
Ph 14% 
 
17% 
14% 
  
 
More importantly, the prevalence of CSMO was 8.63% in the BES, twice higher than 
reported in the white population reported at the same time points (Klein et al., 1992, 
Klein et al., 1995b, Leske et al., 1999a). Similarly, 15.6% African-Americans were 
noted to have CSMO compared to 6.3% non-Hispanic whites in the Veterans Affairs 
Diabetes Trial (VADT) (Emanuele et al., 2005) while the Multi-Ethnic Study of 
Atherosclerosis (MESA) showed that the risk of CSMO is approximately 5 times in 
African-American than whites (11.1% versus 2.7%) (Wong et al., 2006). 
There is paucity of data on incidence of DR in this group. Harris et al observed DR in 
50% of African-American compared to non-Hispanic white participants (19%) after 4 
years follow-up but these differences could not be explained by differences in risk 
factor profile (Harris et al., 1999). The BES showed that the 9-year DR incidence was 
39.6% (38.0% for minimum, 9.0% for moderate, and 2.6% for severe/proliferative DR). 
Incidence tended to increase with diabetes duration and treatment. Of persons with pre-
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existing DR at baseline, 8.2% progressed to proliferative DR. The CSMO incidence was 
8.7%, and it increased with diabetes duration, accounting for most of the overall 
incidence of sight-threatening DR (Leske et al., 2006).  
On the whole, African-Americans have higher rates of macro- and micro-vascular 
complications of diabetes (Harris et al., 1993) and are more susceptible to the known 
risk factors of DR (Harris et al., 1999, Harris et al., 1998, Wong et al., 2006). So other 
gene-environmental interactions have to be explored.  In addition, familial clustering 
evidenced by increased risk of severe diabetic retinopathy among family members with 
diabetes (Looker et al., 2007), in siblings of affected individuals (approximately 3-fold 
increased risk) and the moderate heritability of diabetic retinopathy risk (0.52) have to 
be further investigated (Arar et al., 2008).  
Native American-Indians 
There are more than 2 million native Americans comprising more than 500 tribal 
organizations (Carter et al., 2000). A comprehensive review of complications of T2D in 
indigenous population revealed that high prevalence rates of diabetic retinopathy were 
seen for all populations with available data (Naqshbandi et al., 2008). A high rate of 
40% for DR was observed in the Alberta First Nations of Canada (Oster et al., 2009) 
and 37.8% in Pima Indians in Arizona (Nagi et al., 1997). In the James Bay Cree in 
Canada, the prevalence of DR was 34% with the prevalence of NPDR and PDR being 
28.5% and 2.5% respectively (Maberley et al., 2002). In Manitoba, Canada, the 
prevalence of diabetic retinopathy in First Nations and Métis was 17.0% (Oster and 
Toth, 2009). One study found a retinopathy prevalence of 24% of Carolinians and 
Chamorros in the Commonwealth of the Northern Mariana Islands (Zimmet et al., 
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1984). The Cherokee Indians in the United States were reported to have a rate of 24.6% 
(Farrell et al., 1993). Two studies were carried out with the Oklahoma Indians and 
indicated prevalence rates of PDR and NPDR of 1.1% and 11.5%, respectively, while a 
follow-up later that year showed PDR and NPDR rates of 3.6% and 21.1% (Lee et al., 
1992, West et al., 1982), respectively. The Strong Heart study showed that the Dakota 
Sioux Indians also had a high prevalence of DR (45.3%) (Berinstein et al., 1997). 
Elevated serum and urinary sialic acid and microalbumin concentrations have been 
strongly linked to the presence of microvascular complications in this ethnic group 
(Nayak and Bhaktha, 2005). Limited access to healthcare is also observed to be an 
important cause of undiagnosed and increased prevalence of microvascular and 
macrovascular complications in Alberta First Nations individuals with diabetes living 
on reserves (Oster et al., 2009).   
Asian-American and Pacific Islanders 
The Asian Americans are a diverse community of partial or full Asian heritage. They 
have the highest educational attainment level and median household income of any 
racial demographic in the US and they are heavily urbanized.  It is projected that by 
2070, the Asian population will reach 11% of the total population of the US.  
The Pacific Islanders are the indigenous population of the three regions known as 
Melanesia, Micronesia and Polynesia. More than 50% of the population is overweight 
and over 40% suffered from diabetes, cardiovascular disease and hypertension resulting 
in high premature mortality rates.   
Analyses of data from the Behavioural Risk Factor Surveillance System comparing 
Asian Americans/Pacific Islanders  with Whites and diabetes showed that the rates of 
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DR in this diverse community is 2.2 times the rates reported in Whites despite 
comprehensive adjustment of risk factors including socio-economic status.  Reports as 
early as 1991 indicate a high prevalence of DR among the Polynesian Western Samoans 
indicating that urbanization may not be the driving force for the high prevalence in this 
group (Collins et al., 1995). Similarly, Fijian and Indians living in the Fiji islands had 
more severe and more prevalent DR than Australian Indians. Differences in healthcare 
systems may be an important factor implicated in this difference as delay in the 
diagnosis of diabetes as well as poor glycaemic control are possible factors in Fiji 
(Brooks et al., 1999). 
The overall prevalence of DR has been increasing since 1990 and the current prevalence 
rate is 21.9%. An increase in public awareness and improved healthcare facilities may 
have led to the increased diagnosis of retinopathy in subjects with either known or 
unknown diabetes.  
ASIA 
The remarkable economic achievement in Asia in the last 30 years has resulted in a 
great improvement in living standards and prolongation of life expectancy. The 
alarming prevalence of T2D in Asia is a public health and economic threat. The highest 
numbers of estimated cases of diabetes in 2000 and 2030 are in India and China. Most 
of the studies on the prevalence of DR are from India and China with a recent surge of 
reports from China, South East Asia and the Arab countries. 
Indian Subcontinent 
It is estimated that nearly 80 million people in India will have diabetes by the year 2030 
(Wild et al., 2004). Several reports have suggested that T2D in Indians may differ from 
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their European counterpart in several aspects including younger age of onset, obesity, 
insulin resistance and genetic predisposition (Rema et al., 1996, Rema et al., 2000, 
Rema and Mohan V, 2002).  Moreover, the demographic right shift of the population, 
urbanization and the disparity in access to healthcare may all have implications on the 
prevalence of diabetes and its complications in this region. Although cataract and 
uncorrected refractive errors remain the major causes of blindness in this region 
(Dandona et al., 1999), the impending diabetic epidemic in the subcontinent pose a 
significant public health concern (Namperumalsamy et al., 2009).    
There are several clinic-based and population derived studies on DR in South Asia 
particularly focused on the urban-rural disparities and risk factors. Table 1.10 shows the 
population based studies from India.  
Table 1.10: Prevalence of diabetic retinopathy in India 
Author 
/Year 
Diagnosis of 
diabetes 
N Methods of 
examination 
Ph, O 
Age  
(years) 
Prevalence 
 of DR (%) 
(Dandona et al., 
1999) 
OGTT 2522 O 31-86 22.4 
(Ramachandran et 
al., 1999) 
Self-reported 3010 O 52±9.7 23.7 
(Narendran et al., 
2002) 
RBS>120mg
/dl 
5212 O 61.70 ± 
8.0 
26%                           
(Rema et al., 2005) OGTT 1529 Ph 52±11 17.6 
(Raman et al., 
2009) 
FBS>126mg
/dl 
1414 Ph 56.3±1
0 
18 
(Namperumalsamy 
et al., 2009) 
FBS>126mg
/dl 
2802 O 47.0±1
2.7 
12% 
 
As undiagnosed diabetes remains a major challenge in this region, clinic-based studies 
are referral-biased and are not always an accurate reflection of the prevalence in this 
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population (Rema et al., 2005). Clinic-based detection of DR show higher prevalence 
rates compared to targeted screening (Agarwal et al., 2006). However, it is interesting to 
note that no significant difference in prevalence was noted between clinic-based and 
population-based screening programmes in the Hoorn Screening Study reiterating the 
differences in the healthcare systems (Spijkerman et al., 2003). The diagnostic criteria 
for diabetes also differ between studies and reports are based on self-reported diabetes, 
fasting blood sugar and/or oral glucose tolerance test. Similarly, only recent studies 
have utilized retinal photography as screening tools (Raman et al., 2009, Rema et al., 
2005).   
The prevalence of DR in known diabetes appears to be lower than that reported among 
Europeans. In contrast to the studies from Europe and US, studies that used retinal 
photography reveal a lower prevalence rate of DR of 18% (Raman et al., 2009, Rema et 
al., 2005). 
Similarly, the prevalence of DR among newly diagnosed diabetes in India is low (5-7% 
compared to studies from neighbouring areas such as Nepal (19.3%) (Paudyal et al., 
2008), Sri Lanka (15%) (Weerasuriya et al., 1998)  and Pakistan (15%) (Wahab et al., 
2008). In the United
 
Kingdom Prospective Diabetes Study (UKPDS, 1994, Kohner et 
al., 1998) done two decades ago show that the prevalence of
 
DR at the time of diagnosis 
was higher in South Asians (17.5%) compared to the Europeans (7.9%). Most of the 
other population based Western studies report a prevalence rate of 7%-11%. This may 
again reflect the differences in management of diabetes between regions. It has been 
observed that the actual onset of diabetes occurs much earlier (could be 9 to 12 years) 
before it is clinically presented and diagnosed (Harris et al., 1998). So earlier diagnosis 
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and optimal treatment of diabetes will potentially reduce the prevalence of DR 
(UKPDS, 1998a).  
However, the rate of CSMO is high. The Sankara Nethralaya-Diabetic Retinopathy 
Epidemiology and Molecular Genetic Study (SN-DREAMS) study on 1414 T2D 
reported that one third of the patients had any MO while 6. 27% had CSMO (Raman et 
al., 2010b). In the Chennai Urban Rural Epidemiology Study (CURES), the prevalence 
of MO among the known diabetic subjects was 6.3% and 1.1%  among the newly 
diagnosed diabetic subjects (Rema et al., 2005).  Maculopathy was noted to be as high 
as 17.6% in a study from Pakistan (Jamal-u-Din et al., 2006) on predominantly T2D.    
The two major known risk factors, the length of exposure to hyperglycaemia and the 
degree of glycaemic control for DR, are also observed in the studies from South Asia, 
consistent with findings
 
in the Caucasian counterparts. The CURES study revealed
 
that 
for every 5-year increase in duration of diabetes, the
 
risk for DR increases by 1.89-fold, 
whereas a 2% increase
 
in HbA1c results in a 1.7-fold increase in risk for DR (Rema et 
al., 2005).
 
 
In the UKPDS, the risk reduction in eye complications for every 1 per cent decrease in 
HbA1c was 40% for DR, 25% for STDR and 15% for blindness (UKPDS, 1998a).
 
Since microvascular complications are directly related to the duration of diabetes and 
the age of onset of diabetes is earlier in South Asians, it is intriguing that the DR rates 
are lower than the South Asian counterparts in the western world. Although 
underestimation and survival bias may be important reasons for these differences, 
genetic susceptibility indicated by familial clustering (Radha et al., 2002) and the 
interaction/balance of susceptibility and protective genes (Uthra et al., 2010) with the 
66 
 
environment may also be important parameters that need to be investigated. 
Environmental factors including the characteristic dietary ingredients in South Indian 
diet such as curcumin has been postulated to decrease the oxidative stress in diabetes 
(Premanand et al., 2006). 
Urbanisation, obesity and adaptation to Western diet may also influence the rates of DR 
in urban population and the emigrant Indian population in the West. Studies in India 
have focused on urban-rural differences in DR because approximately ¾ of the area of 
India is rural (Namperumalsamy et al., 2009) and westernization is more localised to the 
urban area. The prevalence of DR in South Asians is more prevalent in those who live 
outside the Indian sub-continent (Raymond et al., 2009) and in urban cities (Raman et 
al., 2009) compared to rural population (Namperumalsamy et al., 2009).  
Another important observation is that the prevalence of STDR is also higher in the 
South Asians who live in the developed countries (Raymond et al., 2009) compared to 
their counterparts in India. The AdREM study also noted a higher rates of DR in Asians 
compared to Caucasians (Stolk et al., 1995). These findings may correlate to their 
changes in life-style characteristics and consequent susceptibility to the risk factors for 
DR or merely relate to better case ascertainment and different classifications used.  
Although diabetes is more likely to develop in people with higher socioeconomic status, 
this was not a risk factor for DR in the SN-DREAMS study that used sampling of socio-
economic status based on multiple indices. However, studies that defined socio-
economic status based on annual income found that the low-income group subjects 
showed a trend to lower prevalence of diabetes and DR (Ramachandran et al., 2002)  in 
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contrast to the western population studies where diabetes is reported to be higher among 
the lower economic group (Connolly et al., 2000).  
The age specific prevalence of DR show a similar trend to Western counterparts with an 
increased prevalence in the sixth decade compared to the previous decade with an 
ensuing decline in rates following that. Similar trends are also observed by the Eye 
Diseases Prevalence Research Group's report on the prevalence of DR in the United 
States, the Barbados Eye Study, the Beaver Dam Study, and the Wisconsin 
Epidemiologic Study of Diabetic Retinopathy and this pattern may be partly explained 
by survival bias (Kempen et al., 2004, Klein et al., 1984c, Klein et al., 1992, Leske et 
al., 1999a, Zhang et al., 2010). The prevalence of DR is almost twice more in those 
subjects who develop diabetes before the age of 40 years than those who develop it later 
(33.3% versus 16.5%) (Raman et al., 2011).  
A male preponderance of DR has been reported in reports from India (Raman et al., 
2009, Rema et al., 2005, Dandona et al., 1999). This observation is in agreement with 
other studies (Kohner et al., 1998, Nagi et al., 1997).
 
A gender effect has also been 
reported in the prevalence of diabetes with UK Asian males up to the age of 60 years 
showing a higher prevalence of diabetes than females (Sharp et al., 1964). In older 
patients, the prevalence rates in males and females are similar, possibly as a result of an 
increase in mortality in Asian men from cardiovascular disease (Balarajan, 1998). 
However, contemporary data on this aspect is required to merit further investigation.
  
The prevalence of DR among subjects with diabetes was higher in those receiving 
insulin treatment in studies from India (Raman et al., 2009, Rema et al., 2005) again 
similar to the findings observed in the Western studies (Klein et al., 1992, Kohner et al., 
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1998). This is probably because of more severe diabetes with poor glycaemic control. 
Similar findings were reported in the study of Pima Indians, and in the Beaver Dam 
study (Raman et al., 2009, Klein et al., 1992, Nagi et al., 1997). In contrast, in the 
WESDR, it was shown that among
 
the older diabetic subjects, after adjustment for 
HbA1c level,
 
there was no association of insulin treatment with either the
 
incidence or 
progression of retinopathy. 
Other reported risk factors for the prevalence of DR in the South Asian studies included 
anaemia (Ranil et al., 2010), isolated abdominal obesity and increased waist-hip ratio in 
women (Raman et al., 2010a). Hyperlipidemia (elevated serum cholesterol, serum 
triglycerides and low density lipoprotein (LDL) is observed as a risk factor for MO in 
two population based studies (Raman et al., 2010b, Rema et al., 2006). The UKPDS 
showed that the incidence of retinopathy was associated with systolic blood pressure but 
hypertension did not play a major role in the CURES study (Pradeepa et al., 2008). 
Akin to other western studies, prevalence of PDR was higher in patients with 
proteinuria compared to microproteinuria (Mohan et al., 2000). The CURES study also 
demonstrated that intima media thickness and arterial stiffness are significantly 
associated with DR (Rema et al., 2006).   
Lastly, genetic susceptibility and familial clustering of DR have also been reported in 
South Indian population. Siblings of the probands with DR had 3.5 times higher risk of 
developing retinopathy (Rema et al., 2002).   
CHINA 
The World Health Organization estimates that over 40 million Chinese will have 
diabetes by 2030 (Wild et al., 2004). Studies in different Chinese populations with 
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similar genetic characteristics have shown substantial variations in the prevalence rates 
of diabetes (Chang et al., 2000). The prevalence rates of diabetes are consistently higher 
in Hong Kong and Taiwan than Mainland China regardless of diagnostic criteria or 
study periods. Moreover, the percentage of undiagnosed diabetes is 68.6% in Mainland 
China as compared to 52.6% in their counterparts in Hong Kong and Taiwan. Chinese 
in Hong Kong and Taiwan generally live in an urbanised environment (Wong and 
Wang, 2006) while over 800 million (64%) live in economically deprived rural regions 
in China (Wang et al., 2009). So as in the Indian subcontinent, it is important to note the 
regional variations of DR in China.  
Data on DR in the Chinese population in Asia are mainly from Hong Kong, Taiwan, 
Mainland China and comparative studies are available on Singapore Chinese, Chinese 
Mauritians and Chinese Americans.  In Taiwan, the prevalence of DR was reported as 
35.0% while the prevalence of DM for newly diagnosed diabetics was 28.3% (Chen et 
al., 1992). The two studies on incidence of DR in Hong Kong Chinese patients show the 
prevalence of DR to be 28.4% and 39.2% baseline respectively (Tam et al., 2005, Tam 
et al., 2009, Wang et al., 1998). The recent Beijing Eye Study that covered both rural 
and urban population reported the prevalence of DR among Chinese patients aged 40+ 
years with a self-reported diagnosis of diabetes to be about 37% and  vision-threatening 
retinopathy in 5% of the subjects (Xie et al., 2009).  Both DR and MO in subjects with 
known diabetes mellitus were significantly more common in the rural group. The 
Handon Eye Study in rural China reported the highest prevalence rate (43.1%) (Wang et 
al., 2009). Although better case ascertainment should be taken into account, prolonged 
exposure to poor glycaemic control, undiagnosed diabetes and high rates of 
hypertension (74%) in rural China are possible explanatory factors.  
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In a multiethnic study in Mauritius, the Chinese Mauritians with known diabetes had 
similar rates to the Indians and Creoles in Mauritius. However, the prevalence rates of 
DR (43.8%) were similar to rural Chinese population in Mainland China (Dowse et al., 
1998, Wang et al., 2009).  
The MESA study provided the data for the Chinese Americans. The prevalence among 
the Chinese sample (25.7%) was similar to whites (24.8%) in the MESA. So there is a 
significant regional variation in the prevalence of DR among the Chinese population 
which may be partly explained by differences in health care access. However, gene-
environmental interactions may also provide important clues to these variations. 
The prevalence rate in the newly diagnosed subjects in Taiwan was 21%, which was 
similar to those found in newly diagnosed Hong Kong Chinese (21.9%). These rates are 
lower than rates in rural China (33.5%) (Chang et al., 1990, Chen et al., 1992). It is 
striking to note that the prevalence rate of DR in newly diagnosed patients were higher 
within 12 months of diagnoses than when routinely screened for DR at point of 
diagnoses of diabetes. Both the Chinese subjects in the Beijing study (Liu et al., 2002) 
and the Hong Kong study (Wang et al., 1998) showed a prevalence rate of 21% at 12 
months from diagnoses. In contrast, the Da Qing study in which 110 660 individuals 
were screened for diabetes by glucose tolerance tests and amongst 423 newly diagnosed 
diabetic patients, retinopathy was found in 15.4% (Hu et al., 1991) . These studies 
suggest that the prevalence of DR increases within the first year of diagnoses. However, 
Dowse et al (Dowse et al., 1998) noted that there is a significant association between 
current age and retinopathy in the newly diagnosed study and suggested that current age 
might behave as a surrogate marker of diabetes duration in these newly diagnosed 
patients. Liu DP et al (Liu et al., 2002) showed that the age of onset of hyperglycaemia 
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is much younger in the Beijing Chinese (36 years) compared to the Fijian Indians (37 
years) while the age of onset of hyperglycaemia in the Anglo-Celtic patients in 
Australia was much older at 54 years. This may partly explain the ethnic differences in 
prevalence and severity of DR (Harris et al., 1998, Liu et al., 2002).  
Females and lower socioeconomic groups were more common in the newly diagnosed 
group. More females are undiagnosed than males indicating social, hormonal or genetic 
basis.  
Similar to the studies in South Asia, the Beijing eye study on the survey of visual 
impairment in the Chinese population reported diabetic retinopathy as a minor cause of 
blindness (low vision 0%/ blindness 7.7%) (Jonas et al., 2009).  
The incidence and progression of DR are not significantly different between Chinese 
and Caucasian populations. Progression to sight-threatening retinopathy was more 
common (7.9% versus 0.7%), and occurred more rapidly (mean 1.5 years versus 2 
years) in eyes with baseline retinopathy than that without. High baseline glycosylated 
haemoglobin is observed as a predictor for disease onset and progression (Chen et al., 
1995, Tam et al., 2005, Tam et al., 2009).  
Despite different study procedures and populations, the prevalence of DR mirror the 
regional prevalence rates of diabetes with higher rates of diabetes in Hong Kong and 
Taiwan compared to Mainland China. Nevertheless, there is an upward trend within 
Mainland China too. The risk factors for DR are similar to those demonstrated in the 
Caucasian population and include duration of diabetes, age at onset of diabetes, age at 
examination, type of diabetes treatment, control of diabetes hypertension, proteinuria, 
serum creatinine level, serum cholesterol level and BMI (Xie et al., 2009). Subclinical 
72 
 
hypothyroidism in the Chinese population has been associated with sight threatening 
DR (Yang et al., 2010). 
The increasing prevalence and the urban-rural differences are often attributed to 
urbanization especially increasing obesity, sedentary lifestyle and dietary transition 
towards a high-fat, high-energy-density and low-fibre diet.   
South East Asia 
Asian Malays are the third largest ethnic group in Asia, including 300 to 400 million 
people. The overall prevalence of DR was 35% and approximately 10% have sight 
threatening DR. The presence of DR was also associated with longer diabetes duration, 
poorer glycaemic and blood pressure control, and lower levels of total and LDL 
cholesterol. Systemic vascular diseases, including stroke and chronic kidney disease 
were associated with sight threatening DR (Wong et al., 2008a).  
A similar rate was reported in Thailand diabetes registry project.  The authors found the 
factors associated with DR were duration of diabetes, HbA1c level, systolic BP and 
diabetic nephropathy (Chetthakul et al., 2006a).  
Middle-East 
The number of people with diabetes mellitus in the Middle East is expected to grow 
three times from the 2000 to 2030 with approximately 60 million estimated to have the 
disease by 2030 (WHO, 2005). Numerous studies on DR in Middle East inhabitants 
have been published in recent years. They mainly underscore the great disease 
heterogeneity in North African and Asian Arab countries, probably reflecting the 
genetic and socioeconomic heterogeneity of the populations in these regions as well as 
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environmental differences. While direct comparisons with other ethnic groups are 
lacking, the existing data provide some indications that Arabs frequently have high rates 
of DR. The cross-sectional survey of DR in the United Arab Emirates has reported 
variable prevalence rates from a low of 19.0% (Al-Maskari and El-Sadig, 2007) to high 
of 54% (Saadi et al., 2007).  Other studies in the region have reported variable rates of 
DR:  Qatar (23.5%) (Elshafei et al., 2010), Saudi Arabia (16.7%- 31%) (Alwakeel et al., 
2008a, Khan et al., 2010, El-Asrar et al., 1998), Oman (14.39% - 42%) (Khandekar and 
Mohammed, 2009, el Haddad and Saad, 1998), Egypt (42%) (Herman et al., 1998), Iran 
(39.3%) (Golbahar J.Rahimi M.Tabei M.B., 2008, Manaviat et al., 2008, Manaviat et 
al., 2004, Javadi et al., 2009), Turkey: (45.5%) (Sehnaz Karadeniz Z., 2007), and 
Lebanon (35%) (Salti et al., 2009). A systematic review of studies from Iran showed a 
prevalence of DR in known diabetics and newly diagnosed diabetes to be 30-40% and 
9-11% (Amini and Parvaresh, 2009).  
Visual impairment due to DR in this region highlights the need for resource allocation 
for systematic screening and timely treatment of this potentially avoidable complication 
(Chiang et al., 2010). Although the prevalence of sight threatening DR is high in this 
region, public awareness of eye complications remain limited (Bamashmus et al., 2009, 
Salti et al., 2009, Javadi et al., 2009). Gender inequality for eye care is also an issue in 
this region although the disparity has lessened in the last decade (Khandekar and 
Mohammed, 2009).  
The prevalence of DR in newly diagnosed diabetes in Kuwait was 8%.  The substantial 
heterogeneity in reported prevalence of retinopathy may partly be real, for example due 
to differences in the age structure of different population, but may again be due to 
differences in study methodology and population sample. The presence of 
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microalbuminuria was highly significantly associated with DR in the UAE study 
population. 
SUB-SAHARAN AFRICA 
African people with diabetes have a high complication burden, which are both difficult 
to treat and prevent (Gill et al., 2009). Ophthalmoscopy based studies reveal a 
prevalence rate of DR to be about 15-17% (Erasmus et al., 1989, Rotimi et al., 2003). 
However, a South African multi-ethnic photography based study showed a higher 
prevalence rate with no differences between ethnic groups (Black African 37%; 
Europeans 41%; Indians 37%). However, severe retinopathy was more frequent in 
African and Indians (Kalk et al., 1997). In another study that compared the rates 
between black African and Indians, the rates of DR were 68.8% in blacks versus 59.2% 
in Indians. The mean age of onset was earlier in Indians but the blacks had an earlier 
onset of retinopathy from time of diagnosis. Duration of diabetes and systolic 
hypertension were significantly associated with DR with Blacks being more prone to 
hypertension than Indians (Motala et al., 2001).  
AUSTRALASIA 
Studies from Australia dates back more than 3 decades and provides encouraging 
evidence of the impact of health education and resultant better glycaemic control on the 
prevalence and incident DR (Cugati et al., 2006, McCarty et al., 2001, Muller et al., 
2007). The earliest clinic-based study of DR in Australia was the Newcastle Diabetic 
Retinopathy Study (1977 to 1988). The prevalence rate of DR was 35%. Since then 
population based studies have reported lower rates (Mitchell, 1985). The Australian 
Diabetes, Obesity and Lifestyle Study was a nationally representative population-based 
75 
 
study of 11,247 people aged ≥25 years, from 42 randomly selected urban and rural areas 
of Australia that reported a prevalence rate of DR of 21.9% in those with known 
diabetes and 6.2% in those with newly diagnosed diabetes (Tapp et al., 2003). The Blue 
Mountain Eye Study (BMES) is an urban based population study that was carried out in 
residents aged 49 years or older in Sydney in 1992–1994. The prevalence rate of DR 
was 35.5 %. The 5 year cumulative incident data of DR was 22.2%, lower than the 4 
year cumulative incidence of 32.7% reported for non-insulin-treated predominantly 
Caucasian subjects with diabetes in the WESDR cohort and a clinic based Swedish 
study (Cugati et al., 2006, Mitchell et al., 1998). This may be a true difference due to 
better public awareness and better glycaemic control in Australia as elucidated in the 
Melbourne Visual Impairment Project in 2003 that reported the 5-year incidence of DR 
to be 11% with most patients with sight threatening disease receiving treatment 
(McCarty et al., 2001).  However, similar lower incidence rates have also been reported 
in other ethnic groups from Japan, Korea, Taiwan, Mauritians and non-Hispanics (Chen 
et al., 1992, Kim et al., 1998, Tapp et al., 2003, Tudor et al., 1998, Morisaki et al., 
1994) where suboptimal glycaemic control remains an issue.  
The Australian Aborigines has the highest reported incidence of vision-threatening 
retinopathy in Australia and one of the highest ever reported incidences of CSMO in the 
world (Jaross et al., 2003). The Katherine Region Diabetic Retinopathy Study  on the 
Australian Aborigines in the northern territory of Australia highlighted that data on this 
indigenous population is hampered with small sample size and short follow-up (Jaross 
et al., 2003). Access to treatment for DR is a problem for the inhabitants of  Fiji, Samoa 
and Tonga (Brian et al., 2010). However, it is interesting to note that the Darwin Region 
Urban Indigenous Diabetes Study observed no difference in prevalence rates of DR in 
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T2D in urban Indigenous Australians and the general Australian population despite 
poorer glycaemic control (Maple-Brown et al., 2008).  
On the contrary, the Greek-born migrants in Australia have low rates of DR that cannot 
be explained by the effect of established risk factors for DR (Brazionis et al., 2010).  
In the New Zealand population, the ethnic composition is predominantly European, the 
Polynesian population, consisting of indigenous New Zealand Maori and immigrants 
from the other Pacific Islands. The prevalence of diabetes and obesity in these 
Polynesians are 2-4 times higher than Europeans, with younger age of onset of diabetes, 
a genetic susceptibility to nephropathy and inadequate access to healthcare (Simmons et 
al., 1989, Moore and Lunt, 2000). A household survey showed that the overall 
prevalence rates of DR did not vary between the ethnic groups but the prevalence of 
moderate or severe retinopathy was significantly higher in the Polynesians (4.0% in 
Europeans, 12.9% in Maori and 15.8% in Pacific people) (Simmons et al., 1991). 
Recent data indicate that the Wellington regional retinal screening programme for DR 
has a good coverage of the people with diabetes with low rates of DR and sight 
threatening disease. However, the Maoris were under-represented (Frederikson and 
Jacobs, 2008).  Nevertheless Te Wai o Rona: Diabetes Prevention Strategy recently 
reported that the rate of retinopathy in newly diagnosed diabetes is also low suggesting 
that case detection for diabetes in the community is improving, but that other strategies 
among those at risk of diabetes, including those promoting smoking cessation, will be 
needed to reduce the risk of renal disease among Maori with diabetes (Lim et al., 
2008b). 
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1.5 Systemic risk factors for diabetic retinopathy 
1.5.1 HbA1C and glycaemia control 
Long term observational studies demonstrate that improved glycaemic control reduces 
the development and progression of existent retinopathy (DCCT, 1993). Both the 
Stockholm Diabetes Interventional Study (Reichard et al., 1991) (n= 102) and Diabetic 
control and complication trial  (DCCT, 1993) (n= 1441) have demonstrated beneficial 
effects in delaying the progression of diabetic retinopathy with intensive diabetic 
control in type I disease: There was a fivefold reduction in the DCCT study at the end of 
5 years, and a 25% reduction in the Stockholm study at the end of 7.5 years.  
A similar trend of 8% reduction in progression of DR was observed in the UKPDS (n= 
3867) study with intensive tight control for T2D over 10 years and in a more recent 
study the Action to Control Cardiovascular Risk in Diabetes (ACCORD) when HbA1c 
was less than 6% versus 7.0-7.9% at the end of 4 years (Chew EY et al, 2010) . There is 
paradoxical worsening of DR seen with intensive tight control in first few years but 
these acute lesions resolve with time and in the long term are better off with tight 
diabetic control (DCCT, 1993).  
1.5.2 Hypertension 
Diabetes and hypertension commonly co-exist in both T1D and T2D. In WESDR 17% 
of T1D had hypertension at baseline and 25% incidence at 10 years (Klein et al., 
1996a). Similarly in T2D this is exceedingly common with a prevalence of 80 – 85% in 
cohort studies (O'Connell et al., 2010, Vijayakumar et al., 2009). 
Studies have shown that angiotension converting enzyme inhibitors (ACE-I) such as 
lisinopril or the angiotensin II type 1receptor blocker: losartan, candersartan have 
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significant anti-angiogenic effect, independent of their effects on systemic BP (UKPDS, 
1998b, Chaturvedi et al., 1998, Chaturvedi et al., 2008, Estacio et al., 2000). In T1D 
patients, antihypertensive treatment with angiotensin converting enzyme (ACE) 
inhibitors resulted in 23% reduction in the progression of retinopathy and progression to 
proliferative DR by 80% in type 1 normotensive diabetes (Chaturvedi et al., 1998).  
However, similar effects were not mirrored in the UKPDS and the ABCD study 
(UKPDS, 1998b, Estacio et al., 2000). 
In T2D, in the UKPDS study, tight control of blood pressure (< 150/80) versus ‘less’ 
tight control (<180/105) resulted in a 34% and 47% reduction in significant 
deterioration of retinopathy and visual acuity at the end of 7.5 years respectively. This 
reduction was seen independent of glycaemic control and the drugs used to control 
hypertension mainly ACE inhibitors or β blockers. However there was no difference in 
the progression of DR between the groups assigned to a policy of tight BP (diastolic BP 
goal of 75 mmHg) control versus less tight BP control (diastolic BP goal of 80-89 
mmHg) in Appropriate Blood Pressure Control in Diabetes (ABCD) Trial (n =470) over 
a period of 5.3 years (Estacio et al., 2000).  
The Diabetic Retinopathy Candesartan Trials (DIRECT) which was placebo-controlled 
randomised controlled trial (RCT) studied the effect of candesartan in reducing the 
incidence and progression of DR in both T1D and T2D (Chaturvedi et al.,2008, Sjolie et 
al.,2008). The trial looked at role of candesartan in prevention (Prevent 1 & 2) and 
progression (Protection 1& 2) of DR in T1D and T2D respectively.     
In DIRECT-Prevent 1 (n= 1421), the incidence of retinopathy was 25% in patients from 
no retinopathy in the candesartan group compared to (31%) in the placebo group of 
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T1D. In the DIRECT-Protect 1 study (n=1905) progression of retinopathy occurred in 
13% in both the candesartan and placebo groups. Thus candesartan reduced incidence of 
retinopathy in T1D with no significant benefit on retinopathy progression.  
The DIRECT-Protect 2 (n=1905) 17% of patients with T2D in the candesartan group  
had progression of DR compared to 19% in the placebo group, with  regression of 
retinopathy  of 19% in the candesartan group compared to 14%  in the control group 
after a median follow up 4.7 years .  
ACCORD eye study found no significant difference in progression of retinopathy in 
patients with intensive SBP (<120mmHg) versus less these intensive SBP (<140mmHg) 
at the end of 4 years (Chew EY et al, 2010). In summary uncontrolled and sustained 
high SBP (>140mmHg) in T2D and higher DBP (>80mmHg) in T1D are significant risk 
factors associated with both development and progression of diabetic microvascular 
complication but they cease to have significant impact after adequate control. British 
Hypertension Society recommends in diabetic patients initiation of antihypertensive 
drug therapy if systolic blood pressure (SBP) is sustained at ≥140mmHg and/or diastolic 
blood pressure (DBP) is sustained ≥90mmHg and optimal BP goals of  SBP 
<130mmHg and DBP of <80mmHg (Williams et al., 2004a). 
1.5.3 Age 
Older patients with diabetes have a greater risk of visual impairment (Hayward et al., 
2002). Diabetic Retinopathy is the 3
rd
 leading cause of severe (5.9%) and partial sight 
impairment (7.4%) in England and Wales after age-related macular degeneration and 
glaucoma (Bunce and Wormald, 2008). 
1.5.4 Pregnancy 
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Most pregnant patients with background retinopathy will not experience a worsening of 
their retinopathy during pregnancy. A small and unpredictable group of patients will 
progress rapidly to PDR;  in addition, they remain at risk for a year post-partum (DCCT, 
2000). The NSC has formulated the following guidelines for screening during 
pregnancy (National Screening Commitee, 2008) 
Annual screening is offered to women for diabetic retinopathy in the preconception 
period using two-field mydriatic digital photography using guttae tropicamide only for 
dilation. Women with T1D and T2D are offered two-field mydriatic digital photography 
to national standards at (or soon after) their first antenatal clinic visit and again at 28 
weeks’ gestation. If background diabetic retinopathy is found to be present, an 
additional screen is performed at 16-20 weeks gestation and post partum. 
1.5.5 Renal disease 
There is an association between retinopathy and all levels of abnormal renal function, 
from albuminuria to frank proteinuria, independent of duration of diabetes and level of 
glycaemic control, in both types 1 and 2 diabetes, especially in some ethnic groups 
(Collins et al., 1995). However this relation between renal and retinal angiopathy is 
complex as they share common confounding and predisposing factors mainly chronic 
hyperglycaemia, high HbA1c levels, duration of diabetes, and elevated BP. A recent 
meta-analysis has shown that all patients with T1D should receive ACE inhibitors to 
reduce incidence of macroalbuminuria, though this effect is not mediated by reduction 
in BP or structural changes associated with diabetic nephropathy (ACE Inhibitors in 
Diabetic Nephropathy Trialist Group, 2001).  
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Large cross-sectional and longitudinal population studies have demonstrated that the 
severity of diabetic retinopathy is indicator of risk of severe proteinuria. Elevated 
albumin excretion has also been found as a risk factor for retinopathy in many ethnic 
groups (Kofoed-Enevoldsen et al., 1987) and presence of gross proteinuria at baseline 
was associated with 95% increased risk of developing macular oedema among T1D 
patients (Klein et al., 1995a).   
1.5.6 Hyperlipidemia   
In the WESDR and Hoorn (Van Leiden et al., 2002) studies there was a correlation 
between high cholesterol blood levels and risk of retinopathy in the diabetic population. 
Lipid lowering drugs like Simvastatin and Atorvastatin have long demonstrated 
beneficial effect in reducing the hard exudates and progression of DR in clinical trials 
(Cullen et al., 1974, Harrold et al., 1969).  Similar results were seen in the Fenofibrate 
Intervention and Lowering Intervention in Diabetes (FIELD) study, which was a double 
blind placebo controlled RCT (Keech et al., 2007). The results showed that, in the 
fenofibrate treatment arm (n = 4895) of the study, the need for first laser treatment for 
retinopathy was significantly lower (p = 0.0002) than in the placebo arm (n = 4900) 
[3.4% versus 4.9%]. 
1.5.7 BMI 
There has been a global increase in obesity with changing life style. This has nearly 
doubled the prevalence of diabetes in last decade (Narayan et al., 2007). It is however 
unclear if increased BMI is independent risk factor for the development and progression 
of DR. 
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1.5.8 Smoking 
The relationship between cigarette smoking and microvascular complications of 
diabetes is complex. However, it appears that cigarette smoking is not a risk factor for 
the development or progression of retinopathy in observational studies (Moss et al., 
1996).   
1.5.9 Alcohol 
There is no clear data available about the effects of alcohol consumption and the 
development or progression of diabetic retinopathy (Xu et al., 2009).  
1.5.10 Effect of ethnicity on risk factors 
1. Haemoglobin A1c (HbA1c) is widely used as an index of mean glycaemia, a 
measure of risk for the development of diabetes complications, and a measure of 
the quality of diabetes care. HbA1c levels are significantly higher in African 
Americans, Hispanics, Asians, and other races and ethnicities compared to whites 
before and after adjusting for age, gender, BMI, duration of diabetes, oral 
medication use, mean fasting plasma glucose, mean postprandial glucose, insulin 
resistance, and β-cell function (Herman et al., 2009). So this aspect should be taken 
into account when comparing glycaemic control between ethnic groups. 
2. Black patients have a higher prevalence and earlier onset of hypertension than other 
ethnic groups, with poorer prognosis than white patients. Blacks are more likely to 
be salt-sensitive, and to have a low plasma renin activity than are whites. They are 
at much greater risk of developing cardiovascular and renal complications (Kola et 
al., 2009). 
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3. The increase in diabetes in Asia differs from that reported in other parts of the 
world: it has developed in a shorter time, in a younger age group, and in people 
with lower BMI. Studies reported that for the same BMI, Asians have a higher body 
fat percentage, a prominent abdominal obesity, a higher intramyocellular lipid 
and/or a higher liver fat content compared to Caucasians. These characteristics may 
contribute to a higher predisposition to insulin resistance at a lesser degree of 
obesity than Caucasians. The differences in body composition are more pronounced 
depending on the region. For the same BMI, among three major ethnic groups in 
Asia, Asian Indians have the highest body fat, followed by Malay and Chinese. 
Lower insulin sensitivity is already observed in Asian Indian adolescents with a 
higher body fat and abdominal obesity compared to Caucasian adolescents. In 
general, Asian adolescents share the same feature of body composition such as 
higher body subcutaneous fat, lower appendicular skeletal muscle and lower gynoid 
fat compared to Caucasian adolescents. This unfavourable body composition may 
predispose to the development of insulin resistance at later age. Genetics may play 
a role and the interaction with environmental factors (changes in lifestyle) could 
increase the risk of developing the metabolic syndrome (Wulan et al., 2010). 
4. Some ethnic groups including the tribal population are 2-4 times more susceptible 
to diabetes so the rates of DR may reflect the rates of diabetes. 
5. Inequality to access to healthcare is an important issue in minor ethnic groups and 
in socially and economically deprived areas.   A recent systematic review reported 
ethnic differences in quality and intermediate outcomes of diabetes care to late 
2004. Intermediate clinical outcomes were worse in Blacks and inclined to be worse 
in Hispanics (Lanting et al., 2008, Soljak et al., 2007). 
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6. Ethnic differences in dietary habit may also be influential factors for the ethnic    
difference (Premanand et al., 2006, Takeuchi et al., 2008). Culture is
 
a major 
determinant of lifestyles and corresponding health outcomes (Perez-Escamilla and 
Putnik, 2007). 
7. Retinal arteriolar dilatation measured from retinal photographs is an important risk 
factor of incident diabetic retinopathy in both T1D and T2D in Caucasians and has 
been confirmed in both the Ausdiab and WESDR cohorts. This risk is 
i
ndependent 
of the known risk factor of hyperglycaemia and hypertension (Klein et al., 2004, 
Rogers et al., 2008). However, venular dilatation is a more significant risk factor for 
the Hispanics, Chinese and African-Americans suggesting ethnicity dependent 
variations in retinal calibre patterns in diabetes (Nguyen et al., 2008, Rogers et al., 
2008). 
1.6 Diabetic retinopathy is a public health problem 
 
DR is the most common cause of visual impairment in the working age group (Klein et 
al., 1984c, Klein et al., 1984b).  Exact numbers are difficult to report as 20-30% of 
population have undiagnosed diabetes. According to the National Health and Nutrition 
Examination Survey in the USA (NHANES 1999-2004), 3.8% of subjects with diabetes 
had visual impairment (Vision of < 20/40 in the better eye) (Zhang et al., 2008b).    
Similarly  DR accounted for 17.7%  of all people registered as visual impaired  in the 
age group of 16-64 years in England and Wales (Bunce and Wormald, 2008), 2.8%  
(Vision < 20/63 in the better eye) (Huang et al., 2009) of all  adult population in China, 
13.3% in India (Herse and Gothwal, 1997) and 8.7% in Barbados (Hennis et al., 2009).   
85 
 
There has been a global increase in the prevalence of DR and it is no longer a burden 
restricted to developed countries. In fact, the steepest gradient of increase in prevalence 
is projected to be in India and China (Klein et al., 1992, Leske et al., 1999a, 
Namperumalsamy et al., 2009, Raman et al., 2009, Rema et al., 2005, Simmons et al., 
1989, Wang et al., 2009, Xie et al., 2009). The increased prevalence may be a true 
increase, or may be the result of better detection rates of DR due to the availability of 
more sophisticated cameras for identification of the disease. It is important to identify 
the rate of increase in prevalence in different regions in the world to enable appropriate 
resource allocation. It is also crucial for us to understand why there are significant 
regional differences in the prevalence rates and whether the increased prevalence of the 
disease equates to increasing rate of visual impairment due to DR. The most common 
causes of visual impairment in DR are macular oedema, non-resolving vitreous 
haemorrhage and tractional retinal detachment.  
1.7 Treatment of diabetic retinopathy 
 
Major population studies (DCCT, 1993; UKPDS, 1998) have highlighted that intensive 
control of diabetes and lifestyle modification can reduce the risk of long term 
microvascular complication like DR. However, this is offset by the increase in the 
prevalence of diabetes overall and the frequency of risk factors in different ethnic 
groups. 
Two large multicentre randomised trials: the Diabetic Retinopathy Study (DRS, 1981) 
and Early Treatment for Diabetic Retinopathy Study (Diabetic retinopathy study, 1978, 
Early Treatment Diabetic Retinopathy Study Research Group, 1985) independently 
identified the beneficial effect of laser treatment in reducing the risk of moderate and 
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severe visual loss respectively. Xenon Arc or argon laser reduced the risk of severe 
visual loss (VA <5/200) by 50-60% in eyes with PDR or severe NPDR in DRS. 
Similarly in ETDRS chances of loss of 15 ETDRS letters was 12% in immediate 
treatment group compared to 24% in the deferred group for macular oedema at end of 
three years. The  2 year randomised control trial, Diabetic Retinopathy Vitrectomy 
Study (DRVS) showed that recovery of good vision (10/20 or better) was more frequent 
in the eyes assigned to early vitrectomy for dense recurrent vitreous haemorrhage (25% 
compared to 15%) in the eyes assigned to conventional observation group (The Diabetic 
Retinopathy Vitrectomy Study Research Group, 1985). 
Laser remains the gold standard treatment for both diabetic maculopathy and PDR. 
However recently there has been surge in the use of steroid and anti-vascular 
endothelial growth factor (VEGF), either as primary treatment or in combination with 
laser to improve potency and efficacy or expedite its action. In a multi-centre 
randomised trial evaluating intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone 
combined with focal/grid laser compared with focal/grid laser alone for treatment of 
MO, eyes treated with 0.5 mg ranibizumab and prompt laser had better visual results 
than laser or steroid with laser at the end of 2 years (Elman MJ et al., 2011). In another 
study by the same group addition of 1 intravitreal triamcinolone injection or 2 
intravitreal ranibizumab injections in eyes receiving focal/grid laser for MO and PRP 
was associated with better visual acuity and decreased MO (Googe J et al., 2011). 
1.8 Cost of Diabetic Retinopathy and Blindness 
 
Data on the costs of key chronic disease like diabetes and its complication allows 
providing estimate of the current size of economic burden and planning future 
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estimates. There were approximately 2.8 million people with diagnosis of diabetes in 
UK in 2009 and it is likely to increase to 4 million by 2025 (www.diabetes.org.uk). In 
UK nearly £9 billion pounds is spent annually on treating diabetes and its complications 
which equates to £16,666 being spent on diabetes every minute (www.diabetes.org.uk). 
A report by the NHS titled Prescribing for Diabetes in England reported that the cost of 
drugs and treatments alone in order to treat people with diabetes had risen by 40% from 
£458.6 million in 2004/5 to £649.2 million in 2009/10 (www.diabetes.org.uk) in last 5 
years.  
There is a substantial expenditure associated with the management of any form of DR 
and a significant increase in cost incurred with increasing severity of DR due to 
increased inpatient, outpatient episode and cost of treatment. Delaying progression by 
better control of risk factors is both cost effective and improves quality of life. In a 
study by Schmier et al, looking at Medicare claims in US in patients with DR, average 
payment was 35% higher in patients with PDR versus patients with no retinopathy. Also 
among diabetic patients with no DR inpatient and outpatient claim was 0.05%, 38% 
respectively that increased to 0.39% and 94% in patients with PDR. Similarly total 
payments were significantly higher for cases with NPDR (>63%), PDR (>4 fold) 
compared to no patients with no retinopathy (Schmier JK et al., 2009) 
There are an estimated 166,325 people in UK with diabetic MO in one or both eyes, and 
of these, 64,725 individuals had CSMO (Minassian DC et al., 2011). Patients with MO 
consume significantly more healthcare resources, incur higher costs compared to 
diabetic patients without retinal complications and have negative impact patients’ health 
related quality of life (Chen E et al., 2010). In a study by Shea et that analysed 
administrative claims from a sample of US Medicare beneficiaries from 2000 to 2004 in 
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people with diabetic MO costs were more than 30% higher than for diabetic patients 
without retinal disease at 1 and 3 years after diagnosis. Inpatient costs constituted 
almost half of the total costs. Total costs incurred in the year of diabetic MO diagnosis 
were 27% higher than the previous year. After adjustment for age, sex, race/ethnicity, 
geographic region, and baseline comorbid conditions, MO was a significant 
independent predictor of total medical costs – associated with 25% higher 1-year costs 
and 27% higher 3-year cost (Shea AM et al, 2008). In UK the estimated cost for overall 
health and social care costs in 2010, on the pathway from screening to rehabilitation and 
care in the home in people with MO, was  £116 296 038 (Minassian DC et al, 2011). 
In a study commissioned by Royal National Institute of Blind (RNIB) there were 
approximately 1.8 million people with partial sight and blindness in UK in 2008 
(Access Economics Pty Limited, 2011) and 62,000 (3.5%) of these are due to diabetic 
retinopathy.  Of all the people with diabetic retinopathy nearly 19,000 (8.7%) were 
blind with a vision of < 6/60 in the better eye. There is projected 46% increase to 93,000 
people with partial sight and blindness in UK by 2050 due to diabetic retinopathy and 
majority (> 65%) of it will be  in working population (age < 65 years). In the same 
study estimated annual expenditure due to blindness or partially sighted in UK in 2008 
was £6.4 billion which is projected to rise to in £7.9 billion by 2013. According to other 
study commissioned by Diabetes, UK (Diabetes.org.uk) lifetime costs to the UK 
government for a person with diabetic retinopathy can be £314,512 per person assuming 
productivity loss to 65 years of age. So if early detection or screening could potentially 
avoid 1000 cases it could save up to £314 million to the UK government. 
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1.9 Conclusion 
  
Race- and ethnicity-related differences in prevalence of DR, CSMO and visual 
impairment remain an important public health issue. Understanding the epidemiology of 
DR in different ethnic groups is essential for more effective screening and treatment of 
DR. Several studies have highlighted the inter-ethnic variations in the susceptibility to 
known risk factors of complications of diabetes.  In particular, the prevalence of 
metabolic syndrome illustrates the continuum of inter-ethnic variations. The studies on 
prevalence rates of diabetes indicates that obesity, urbanization, changes in diet and 
increasing sedentary life-style, the declining rate of communicable diseases and 
associated mortality will inevitably lead to increased health burden due to diabetes and 
its related complications. Although a concerted approach on prevention of these risk 
factors exists in several countries around the world, it is important to understand that a 
directed ethnic-specific approach is required to reduce the burden especially in multi-
racial populated cities. Policy makers and clinicians should focus on the development of 
guidelines that are ethnic specific so that more effective control of risk factors is 
feasible. It is also important to highlight that further research on other genetic and 
environmental risk factors are necessary to better understand these differences. 
However, direct comparison of studies from individual countries are seriously hampered 
by differences in the definitions for the individual clinical complications and the 
methods used in their assessment, in addition to enormous variations in the ages of 
subjects at diagnosis and study entry. Educational programs aimed at the physician to 
facilitate cultural competence and at the patient to increase level of knowledge about 
their disease are appropriate and enthusiastically endorsed (Wilson and Eezzuduemhoi, 
2005). In the UK, the NSC has provided guidelines on screening techniques and grading 
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criteria that guide all DR screening programmes. This allows for uniform grading 
outcome and comparative data between established programmes. In addition it is the 
national requirement for all screening programs to provide 95-100% coverage of 
screening to all patients with diabetes. There are several regions globally where 
screening programmes do not exist or are still in their infancy. So the regional variations 
in diabetic retinopathy and the differences in frequency of DR in various ethnic groups 
are important for different types of stakeholders. Data is difficult to obtain from some 
areas in the world and therefore we believe that outcomes of studies such as this may be 
translated to policy makers and clinicians in areas where no local data is obtainable.  
Very little is known about inter-ethnic global differences in severity of DR in UK. DR 
is a final pathway of a complex interplay of systemic biochemical and metabolic 
abnormalities and local tissue effects on all cells of the retina. Established risk factors 
for the two types of disease are very similar. However T1D is more prevalent in Whites 
than Afro-Caribbeans indicating some race specific differences in risks. Risk factors for 
T2D can be broadly divided into modifiable and non modifiable. Non modifiable risk 
factors include: increasing age (Centers for Disease Control and Prevention (CDC)., 
2010), ethnicity (Egede and Dagogo-Jack, 2005), genetic predisposition, history of 
gestational diabetes, and low birth weight. Modifiable factors include increased body 
mass index(BMI) (Hu et al., 2001), physical inactivity (Jeon et al., 2007), hypertension 
and smoking (Will et al., 2001) and psychosocial factors such as depression, increased 
stress, lower social support, and poor mental health status (Grandinetti et al., 2000, 
Strodl and Kenardy, 2006). The severity of the disease is related to the duration of 
diabetes (Klein et al., 2008b, Klein et al., 2009b). As mentioned previously there are 
differences in risk factors and access to healthcare between ethnic groups. It is also 
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important to focus on the prevalence and risk factors of subjects with end stage disease 
(PDR). Identification of risk stratification models for end-stage disease is as important 
as early disease. Prevention of end-stage may potentially reduce severe visual 
impairment more significantly than early prevention.  
 
1.10 Aim of the study 
 
1. There is paucity of prevalence data on diabetic retinopathy amongst ethnic minority 
population in UK especially Afro-Caribbeans and in people with T1D. This study 
aims to determine the prevalence of DR and visual impairment in three main ethnic 
groups. The cohorts identified for the study include one region from the North of 
the country (Yorkshire) and London from the South of England. South East London 
has a multi-racial population with a majority of the ethnic minority consisting of 
Afro-Caribbeans (24%). Other than London, there is a high proportion of Asians in 
Yorkshire and the Humber and the West Midlands. South Asian population makes 
up 17% of the population of North Kirklees, while Wakefield has a predominantly 
Caucasian population.  
2. A regional difference in frequency of DR and VI will be determined from this 
study. 
3. The differences of risk factors between ethnic groups will also be determined to 
assess whether ethnicity is an independent risk factor or is it the differential 
susceptibility to risk factors that explain any ethnic specific differences in VI and 
DR. 
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4. In addition, further investigations will include detailed analyses of subjects with 
end-stage diabetic retinopathy to understand inter-ethnic differences and identify 
any risk factors to explain any differences. The clinical details and risk factors to be 
collected from General Practitioners will include: age at onset of diabetes, age of 
patient, sex, history of hypertension, HbA1C, microalbuminuria, serum lipids, BMI 
(body mass index), smoking, use of statins, peripheral neuropathy, peripheral 
vascular disease, myocardial infarction or coronary arterial bypass and stroke 
(Section 2.6 & 2.7). 
5. The role of renal function in the ethnic groups will also be compared and correlated 
to the retinopathy levels in each ethnic group. This includes subgroup of subjects 
with end-stage renal disease from the London cohort to determine the retinopathy 
grades and the relation to different ethnic groups.  
This study on the prevalence of all grades of retinopathy and the associated risk factors 
in various ethnic groups will hopefully inform policy makers and clinicians on the need 
to reinforce ethnicity based screening and treatment threshold in diabetic retinopathy. 
Within its overall aim the following objectives were defined: 
1) To discover the prevalence of diabetic retinopathy (DR) in various ethnic 
groups, ethnic group as defined by Census of 2001, United Kingdom (Section 
2.3) and presence of DR as National Screening Committee (NSC) UK (Sections 
1.4.3 and 2.2). 
2) To assess the prevalence of visual impairment in various ethnic groups as 
defined by NSC (Sections 2.2 and 2.4). 
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3) To elucidate the systemic risk factors for diabetic retinopathy in people with 
T1D a case control study will be done for sight threatening diabetic retinopathy 
(severe NPDR and proliferative diabetic retinopathy) in London cohort only. 
These will be matched by age, and type of diabetes to patients with no diabetic 
retinopathy in ratio of 1: 2.  
4)  To elucidate the systemic risk factors for diabetic retinopathy in people with 
T2D, similar data will be collected in the London cohort. 
5) To determine the outcome following vitrectomy (Surgical outcome for end stage 
DR) including inter-ethnic differences in outcome.  This part of the study will 
relate to the London cohort only. 
6) To determine the temporal relation between end stages retinal and renal disease 
(diabetic population on renal dialysis) with reference to the different ethnic 
groups. This part of the study will relate to the London cohort only. 
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CHAPTER II 
MATERIALS AND METHODS 
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2.1 Methods  
2.1.1 Ethics approval  
The Research Ethics Committee of King’s College Hospital, London School of Hygiene 
and Tropical Medicine and the Clinical Effectiveness Department of the hospital also 
approved the study (CASS AP0861-01) (Appendix 1, 2 & 3).  
2.1.2 Study population  
The comprehensive population based Diabetes Register keeps an up to date count of the 
people with diabetes in South East London and West Yorkshire. These patients are 
screened annually for diabetic eye disease by the regional diabetic retinopathy screening 
programs: in South East London, by the Diabetic Eye Complications Screening (DECS) 
program and in Yorkshire, the by Wakefield and North Kirklees diabetic retinopathy 
screening program. Both the screening programs are well established and quality-
assured.  
2.1.3 Digital photography-Retinal photographs 
Fundus photography was performed at each site following a standardized protocol 
recommended by the NSC (For detailed methodology see section 1.4.3).  
In short, both eyes of each participant were photographed after mydriasis. Standard 
software was used for image acquisition and archiving. Images were then graded for 
first full disease grade and second full disease grade by experienced screeners and 
graders.  Arbitration was performed by medical retina consultants at both sites. Five 
percent of the patients were not fit for digital photography and were examined for 
retinopathy using slit-lamp biomicroscopy.  
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2.1.4 Grading of diabetic retinopathy 
Retinopathy was considered to be present if any characteristic lesion as defined by the 
ETDRS severity scale were present: microaneurysms, hemorrhages, cotton wool spots, 
intraretinal microvascular abnormalities, hard exudates, venous beading, or new vessels. 
For each eye, a retinopathy severity score is assigned as recommended by the NSC (See 
section 1.4.2).  
Presence of macular oedema (M1) is characterized by presence of any of signs vascular 
leakage within macular area like retinal thickening, microaneurysms, hard exudates or 
may be featureless as in ischemic maculopathy (section 1.4.1).  
P1 signifies the presence of laser treatment. This is further classified into macular laser 
or pan retinal photocoagulation (PRP). In cases where macular laser was performed for 
macular edema, the category was termed as M1P1 to give the life-time prevalence of 
treated maculopathy. 
2.1.5 Screen positive patients 
Screen positive patients with sight-threatening retinopathy were referred to the 
Ophthalmology department for management. Patients requiring photocoagulation 
therapy were treated according to the guidelines from the ETDRS (Early Treatment 
Diabetic Retinopathy Study Research Group, 1985) and the DRS (Diabetic retinopathy 
study, 1978). 
A small proportion of diabetic patients (<2%) were permanently excluded from 
screening because they are severely visually impaired or refused screening. These 
patients were not included in the analyses.  
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2.1.6 Visual acuity testing  
The protocols for recording visual acuity in both screening programmes are similar (as 
recommended by the National Screening Committee). Presenting visual acuity is 
recorded. This is measured with
 
the participant wearing their "walk-in" optical 
correction (i.e.
 
spectacles or contact lenses) using ETDRS charts. If
 
no letters are read at 
2 metres, visual acuity is assessed as counting fingers, hand movements,
 
perception of 
light, or no perception of light. 
2.2 Data collection 
2.2.1 Baseline demographics, vision and retinopathy status of population affected 
with diabetes form screening program 
The diabetes register is the nearest true representation of the population with diabetes. 
The screening programs maintain and update their databases from the diabetes register. 
The screening database and computer software of the digital photography at both sites 
provided details on the visual acuity and grade of retinopathy of those who were 
screened between 1
st
 September 2008 and 30 September 2009. The data collected from 
these registers included baseline demographics: date of birth, gender, ethnicity, type of 
diabetes, and best corrected Snellen visual acuity in both eyes, retinopathy grades in 
both eyes, maculopathy grades in both eyes and any photocoagulation treatment 
administered (Appendix 4).  The number of patients that refused screening was noted. 
2.2.2 Data collection from hospital eye services 
The retinopathy grades obtained by slit lamp biomicroscopy or indirect ophthalmoscopy 
were recorded for subjects for whom it was technically difficult to acquire retinal 
photographs. Also the records of subjects who were exempted from the screening 
programme because they were under the care of the specified hospital eye service was 
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collected using specialist feedback forms circulated in the diabetic clinic (appendix 5) or 
are blind were collated from hospital records and the registers for visually impaired.  
The number of subjects for which no records were obtainable was noted. In addition, 
there were subjects with very recently diagnosed diabetes (less than 12 weeks from 
referral as newly diagnosed diabetes) or who were only recently registered with family 
practices in the area, were excluded. The ETDRS diabetic retinopathy grades in 
feedback forms were converted to the NSC equivalent (section 1.4.3) Patients that are 
already registered severely visually impaired were also examined and their data was 
included. 
2.3 Ethnicity data 
 
The target population for this study includes Caucasians, and those of Afro-Caribbean 
and South Asian descent /origin. The study did not separately identify duration of stay, 
food habits and role of micronutrients in UK of ethnic minority population to analyze 
their impact on generations living in UK.  The allocation of ethnicity for this study was 
defined as per the 2001 Census as follows:  
A White: British; Irish or any other White background. 
B Mixed: White and Black Caribbean; White and Black African; White and Asian or 
any other mixed background. 
C Asian or Asian British: Indian; Pakistani; Bangladeshi; any other Asian background. 
D Black or Black British: Caribbean; African; any other Black background. 
E Chinese or other ethnic group: Chinese; any other. 
The project focused on groups A, C and D. The people who are in groups B and E were 
excluded due to small numbers.  
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2.4 Definition of visual impairment 
 
Blindness as defined by the WHO standard is the best-corrected visual acuity of <6/120 
in the better-seeing eye; 6/60 or worse by the US definition and 6/60 or worse by 
National Screening Criteria (NSC).  Low vision is defined as  <6/18 to 3/60 by WHO 
standard, <6/12 is visual impairment by US definitions and 6/18 or worse by NSC 
definition {(NSC, 2010, US, 2010 WHO, 2010) (Table 2.1)}. 
Table 2.1: Equivalence of visual impairment according to NSC, US and WHO 
criteria 
<6/12 is visual impairment by US definitions. Equal to ≤ 6/18 which is “Sight 
impairment” according to National Screening Committee programme criteria  
2.5 Data Collection and statistical analysis on prevalence of DR and visual 
impairment 
 
The data analysis was performed using Stata version 11.0 (Stata Corp., College Station, 
TX, USA). Data were analysed at the individual subject level. The eye with the worse 
grade was used in the analyses. Descriptive analyses include reporting the age-specific 
prevalence and of the different DR and visual impairment in diabetic people in the three 
ethnic groups. The estimates from the two areas were similar, and hence data was 
pooled to provide national prevalence data that can be used for resource allocation. The 
 WHO  National 
Screening 
Committee  
US  
 
Visual 
Impairment  
<6/18  6/18 or worse < 6/12  
Low Vision  Low vision: <6/18 
to 3/60 
6/60 or worse < 6/60 Severe 
visual impairment 
Blindness  Blindness: <3/60   
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association between DR and the various clinical risk factors was explored using logistic 
regression models. 
2.6 Random sampling 
 
A case control study was performed in London to assess clinical risk factors for sight 
threatening diabetic retinopathy (severe NPDR and PDR). A random sample of 3,346 
people from the patients with completed ethnicity, demographics and retinopathy data 
from London was generated and this included all patients with severe NPDR and PDR 
in patients with T1D and T2D disease. These were matched by age, and type of diabetes 
to patients with no diabetic retinopathy in ratio of 1: 2.  
2.7 Clinical risk factors 
  
The clinical details and risk factors that  collected from General Practitioners included: 
age at onset of diabetes, age of patient, sex, history of hypertension, HbA1C, 
microalbuminuria, serum lipids, BMI, smoking, use of statins, peripheral neuropathy, 
peripheral vascular disease,  myocardial infarction or coronary arterial bypass and 
stroke (appendix 6) . 
2.8 Risk factors for end stage DR 
  
The study also looked at the ethnic variations in people with PDR  who underwent 
vitrectomy secondary to PDR between January 2007 to December 2009 at King’s 
College Hospital, London and St Thomas’s Hospital, London. A dedicated vitreo-retinal 
electronic patient software allowed case identification from both centres from 2007-09.  
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This study enabled provision of evidence of anatomical and visual outcome for this 
complex and sight threatening disease due to diabetic retinopathy with particular 
reference to the ethnic differences.  
The patients were divided in three groups 
Group A: Tractional retinal detachment with/without haemorrhage 
Group B: Non clearing vitreous haemorrhage (at least 3 month duration) secondary to 
proliferative diabetic retinopathy (PDR)  
Group C: Others (Tractional diabetic macular oedema, epi-retinal membrane etc.) 
Data collected included age, ethnicity, baseline best corrected visual acuity, indication 
for the procedure, complication, outcome and duration of follow up. Visual acuities 
were converted to LogMAR, and CF, HM and PL and no perception of light (NPL) 
were assigned values of 1.85, 2.3, 2.6 and 2.9 respectively (Holladay, 1997, Schulze-
Bonsel et al., 2006). The primary endpoints of the study were anatomical success and 
eyes with visual acuity ≤ 0.3 LogMAR (20/40) at last follow up with reference to 
different ethnic groups. 
2.9 The relation of retinopathy status to end stage renal disease in various ethnic 
groups 
  
Data on consecutive patients with a diagnosis of diabetes related end stage renal disease 
(ESRD) was extracted from the renal database maintained by the hospital eye service. 
Further demographic and clinical data of these patients was collected as previously 
stated in section 2.7 (appendix 6). The study cohort was divided in two cohorts: 1) PDR 
with ESRD and 2) NPDR with ESRD  
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Diabetic nephropathy (DN) was confirmed if a chart review revealed a diagnosis
 
by 
renal biopsy or the clinical criteria of diabetes duration 5
 
years prior to dialysis with 
proteinuria
 
>500 mg/24 h, or urine dipstick protein >30 mg/dl, in the
 
absence of other 
causes of ESRD. The date of diagnosis of ESRD was defined as the date of initiation of 
renal replacement therapy.  Individuals with diabetes with ESRD due to other causes 
were excluded, typically
 
due to short duration of diabetes prior to ESRD.  Multiple 
logistic regression analyses were performed, in which the effects of potentially 
confounding variables were controlled. The following were used as independent 
variables: age, gender, HbA1c at the time of diagnosis of ESRD, lipid profile, 
hypertension, smoking, peripheral vascular disease, neuropathy, macrovascular 
complications and renal function tests. Comparison of disease severity between ethnic 
groups was done using ANOVA analysis. Kaplan Meier survival analysis was 
performed to assess the time to ESRD in different ethnic groups. 
2.10 Statistical analysis 
 
SPSS 17.0 software was used for statistical analysis for methods described in section 
2.7, 2.8 & 2.9. All significance levels were defined at p<0.05. Logistic regression 
analyses were performed to control for potentially confounding variables. 
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CHAPTER III 
RESULTS 
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3.1 Patient profile in screening program 
 
There were 20,878 registered subjects with known diabetes in the family practices of 
West Yorkshire region and 36,266 in South East London (Table 3.1). The total 
population in these areas are 534,883 and 868,322 respectively (Yorkshire and the 
Humber Quality Observatory (YHQO), 2011). So the prevalence of diagnosed diabetes 
is 4.2%. The average national prevalence of diagnosed diabetes is 4%. The Association 
of Public Health Observatories  model indicates that the prevalence of diabetes (defined 
as a total of undiagnosed and known diabetes) is significantly higher in the minor ethnic 
groups with estimated rates in Caucasians - 6.9%, African-Caribbean – 9.8% and 
Asians- 14% (Yorkshire and the Humber Quality Observatory (YHQO), 2011). The 
number of eligible study population with T2D were 17,332 and 29,630 and with T1D 
were 1211 and 2112 respectively in West Yorkshire and South East London 
respectively.  Data on DR was available in 50,285 subjects (Table 3.1). 
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Table 3.1: Baseline diabetic population profile in two screening program 
 
West 
Yorkshire 
South East 
London 
Total 
Total diabetic population 20,878 36,262 57,140 
Total eligible  population for this 
study 
18,552 31,733 50,285 
Eligible Type 1 diabetes 1,211 2112 3323 
Eligible Type 2 diabetes 17341 29621 46962 
Information on retinopathy or 
ethnicity not available* 
836 2412 3248 
Moved out of area* ** 242 242 
Attend other screening program* ** 634 634 
Patients refused screening* 83 244 327 
Deceased during study period* 35 767 802 
Medically unfit for screening* 161 230 391 
* Population not included for further analysis. ** No information available 
Overall 93.3% of the study population had T2D with a mean age of 63.6 SD13.3 years. 
There were more males (52.86%) in the whole population cohort and Afro-Caribbeans 
amongst the ethnic minority population. In all 76.9% of the population with T1D and 
37% with T2D were in working age group (20-59) (Table 3.2). The age- distribution of 
T1D is in keeping with the disease onset before the age of 30 years and the increasing 
longevity associated with this disease. The fact that 80% of people with T1D are 
Caucasian suggests that T1D is not associated with ethnic group.   
In contrast, approximately 63% of T2D is observed in persons aged 60 years and over. 
A greater proportion of people with T2D are of non-Caucasian origin compared to T1D 
in keeping with the higher prevalence of T2D in the minority ethnic groups. 
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Table 3.2: Characteristics of the screened population 
 
Type 1 diabetes 
N= 3,323 
Type 2 diabetes 
N= 46,962 
Mean age in years (SD) 39.4 (16.3) 63.6 (13.3) 
 N (%) N (%) 
Age <20 326 (9.8) 23 (0.1) 
Age 20-29 748 (22.5) 134 (0.3) 
Age 30-39 755 (22.3) 1634 (3.5) 
Age 40-49 680 (20.5) 5779 (12.3) 
Age 50-59 382 (11.5) 9802 (20.8) 
Age 60-69 235 (7.1) 12352 (26.3) 
Age 70-79 152 (4.6) 11843 (25.2) 
Age 80+ 44 (1.3) 5366 (11.4) 
Male 1764 (53.1) 24842 (52.9) 
Caucasian 2682 (79.2) 30352 (64.7) 
African-Caribbean 344 (10.4) 8023 (17.1) 
South Asian 120 (3.6) 3397 (7.2) 
Mixed race 105 (3.2) 2577 (5.5) 
Other 123 (3.7) 2587 (5.5) 
 
3.2 Prevalence of diabetic retinopathy 
 
In people with T1D the prevalence rates of any diabetic retinopathy was 53.1%, STDR 
was 5.9% and these were not significantly different between ethnic groups. In T1D, the 
prevalence of DR was similar in the three ethnic groups. People of African/Afro-
Caribbean origin had a lower prevalence of “any retinopathy” compared to Caucasian 
people. The numbers of people in the non-Caucasian ethnic groups with T1D were 
relatively small which meant the study had low power to detect differences between the 
ethnic groups with respect to retinopathy in T1D.  
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The prevalence of any DR among people with T2D in South East London and in 
Yorkshire was 39.52% and 39.57% respectively (table 3.3). This was not significantly 
different and hence the data was collated to provide overall prevalence rate and across 
each ethnic group.  
Table 3.3: Prevalence of retinopathy 
 South 
Asia 
Caucasian Afro-
Caribbean 
Total 
South East London 37.89       36.78       51.49 39.52 
Yorkshire 41.22       39.36 - 39.57 
Combined 39.70 38.0 51.30 39.50 
 
In T2D, the prevalence of any DR was significantly higher in the African-Caribbean 
group compared to both Caucasians and South Asians. Diabetic retinopathy was 
detected on the fundus photographs in 18,565 (39.5%) of people, diabetic maculopathy 
in 3953 (8.4%), clinically significant macular oedema in 2,220 (4.7%), and sight 
threatening retinopathy in 1,865 (4.0%) people. Sight threatening diabetic retinopathy 
was significantly more prevalent in the South Asians (4.0%) and Afro-Caribbeans 
(3.7%) compared to Caucasians (2.5%) with diabetic maculopathy being twice as 
prevalent in South Asians (11.7%) and Afro-Caribbeans (12.9%) compared to 
Caucasians (6%) (Table 3.4, 3.5 and Figure 3.1 (a-d).   
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Table 3.4: Prevalence of diabetic retinopathy by ethnic group 
 Caucasians Afro-
Caribbean 
South Asian Whole 
population 
N (%) N (%) N (%) N (%) 
Type 1 diabetes 2628 (100) 344 (100) 120 (100) 3323 (100) 
R1, R2 or R3 1446 (55.0) 154 (44.8) 64(53.3) 1766 (53.1) 
R1 only 1177 (44.8) 116 (33.7) 51 (42.5) 1438 (43.3) 
R2 only 80 (3.0) 4 (1.2) 6 (5.0) 92 (2.8) 
R3 only 189 (7.2) 34 (9.9) 7 (5.8) 236 (7.1) 
R2 or R3 269 (10.2) 38 (11.1) 13 (10.8) 328 (9.9) 
M1 371 (14.1) 47 (13.7) 17 (14.2) 449 (13.5) 
M1 and P1 171 (7.3) 35 (11.1) 12 (11.0) 225 (6.8) 
(R2 or R3) 
 and M1 
164 (6.2) 20 (5.8) 7 (5.8) 196 (5.9) 
Type 2 diabetes 30350 (100) 8023 (100) 3397 (100) 46959 (100) 
R1, R2 or R3 11538 (38.0) 4117 (51.3) 1350(39.7) 18565 (39.5) 
R1 only 10378 (34.2) 3718 (46.3) 1146 (33.7) 16700 (35.6) 
R2 only 445 (1.5) 70 (0.9) 88 (2.6) 637 (1.4) 
R3 only 715 (2.4) 329 (4.1) 116 (3.4) 1228 (2.6) 
R2 or R3 1160 (3.8) 399 (5.0) 204 (6.0) 1865 (4.0) 
M1 2249 (7.4) 1037 (12.9) 396 (11.7) 3953 (8.4) 
M1 and P1 1127 (3.7) 720 (9.0) 211 (6.2) 2220 (4.7) 
(R2 or R3) and 
M1 
770 (2.5) 299 (3.7) 136 (4.0) 1274 (2.7) 
 
Logistic regression analyses (Table 3.5) showed that the risk of DR, STDR and CSMO 
increased with increasing age and male gender. People with T1D had twice the risk of 
all grades of retinopathy compared to people with T2D.  Minority ethnic groups (both 
South Asians and Afro-Caribbeans) were twice as likely to have CSMO and STDR 
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compared to their white counterparts. There were no consistent regional variations in 
the severity of DR 
Table 3.5: Odds ratio (OR) and confidence interval for overall prevalence of 
diabetic retinopathy  
Odds ratio* 
(95% CI) 
Any 
retinopathy 
R1, R2 or R3 
(n=20,344) 
Any  
proliferative 
diabetic 
retinopathy 
R2or R3 
(n= 2,195) 
CSMO 
M1P1 
(n=2,446) 
STDR 
R2 or R3 or 
M1P1 
(n=3,426) 
Age 
(per year age) 
1.007 
(1.006, 1.008) 
1.005 
(1.002, 1.009) 
1.019 
(1.016,1.022) 
1.012 
(1.099,1.015) 
Men 1 1 1 1 
Women 0.93 
 (0.90,0.97) 
0.77 
 (0.71,0.84) 
0.91 
(0.84,0.99) 
0.84 
(0.78,0.90) 
DECS 1 1 1 1 
Wakefield 0.91 
(0.87, 0.94) 
0.69 
(0.63, 0.77) 
1.79 
(1.61, 1.99) 
1.04 
(0.96,1.13) 
T1D 1 1 1 1 
T2D 0.47 
(0.43, 0.51) 
0.32 
(0.27, 0.37) 
0.42 
(0.35, 0.49) 
0.35 
(0.31, 0.40) 
Caucasians 1 1 1 1 
Afro-
Caribbeans 
1.79 
(1.70, 1.89) 
1.61 
(1.42, 1.82) 
2.12 
(1.91, 2.35) 
1.99 
(1.81,2.18) 
South Asians 1.10 
(1.02, 1.18) 
1.52 
(1.31, 1.77) 
1.98 
(1.71, 2.30) 
1.82 
(1.61, 2.06) 
Other 0.75 
(0.70, 0.80) 
0.59 
(0.48, 0.72) 
0.68 
(0.57, 0.81) 
0.68 
(0.58, 0.79) 
*Adjusted for all factors on the table 
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Figure 3.1a: Retinopathy in type 2 diabetes 
There were 49,659 people at risk of developing retinopathy and it was present in 39.5 % 
of the population at given time. Afro-Caribbean had significantly high prevalence rate 
of retinopathy (51.3%) compared to Caucasian (38.0%) or South Asians (39.7%).  The 
age specific prevalence was similar in South Asians to other ethnic groups. The upward 
trend reflects fewer people in elderly age group in South Asians   
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Figure 3.1b: Non proliferative retinopathy in type 2 diabetes 
Overall prevalence rate was 35.6% with Afro-Caribbeans (43.6%) showing significantly 
highest prevalence compared to Caucasian or South Asians. In South Asians increasing 
prevalence was seen with increasing age where in Afro-Caribbeans and Caucasians 
early peak was seen in 3
rd
 decade of life and the rates were constant thereafter. The 
disparity observed in South Asians is due to reasons explained previously. 
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Figure 3.1c: Pre proliferative and proliferative retinopathy (R2 or R3) in type 2 
diabetes  
South Asians with 6.0% and Afro-Caribbean with 5.0% had higher prevalence rates of 
either R2 or R3 compared to Caucasians. However Afro-Caribbean had higher (4.1%) 
prevalence rate of proliferative (R3) compared to South Asians (3.4%) and Caucasians 
(2.4%). Also Afro-Caribbeans had risk of 1.79 compared to Caucasian to develop any 
retinopathy.    
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Figure 3.1d: Life time risk of maculopathy in patient with type 2 diabetes 
Life time prevalence for maculopathy was 4.7% and it was significantly greater in Afro- 
Caribbeans (9.0%), South Asians (6.2%) than Caucasians (3.7%). Maculopathy rates 
did not differ with gender in any ethnic groups but a high rate in 7th decade was seen in 
Afro- Caribbeans compared to other population.   
 
 
 
 
 
0
2
0
4
0
6
0
8
0
P
re
v
a
le
n
c
e
%
<20 20- 30- 40- 50- 60- 70- 80+
Age group
males females
Whole population
0
2
0
4
0
6
0
8
0
P
re
v
a
le
n
c
e
%
<20 20- 30- 40- 50- 60- 70- 80+
Age group
males females
Caucasians
0
2
0
4
0
6
0
8
0
P
re
v
a
le
n
c
e
%
<20 20- 30- 40- 50- 60- 70- 80+
Age group
males females
African/Afro-Carribbeans
0
2
0
4
0
6
0
8
0
P
re
v
a
le
n
c
e
%
<20 20- 30- 40- 50- 60- 70- 80+
Age group
males females
South Asians
M1P1: type 2 diabetes
114 
 
3.3 Prevalence of visual impairment 
3.3.1 Visual acuity in the screened population 
Overall, 88.9 % of the population in West Yorkshire and 94% in South East London had 
a visual acuity of 6/12 better in the best seeing eye. Overall prevalence of severe visual 
impairment (SVI) was similar accounting for 0.6% of patients in the two population 
cohorts Overall, 3787 (7.5%, 95% confidence intervals 7.3, 7.8) of the people with 
diabetes attending screening were not eligible for driving based on their presenting 
visual acuity and 1699 (3.4%, 95% CI 3.2, 3.5) were visually impaired (<6/12) and 195 
(0.4%, 95% CI 0.33, 0.44) severely visually impaired. (Table 3.6) 
Table 3.6: Vision in the screened population   
 Vision in 
best eye 
Wakefield DECS 
N % Cumulative 
%* 
N % Cumulative 
%* 
18557* 100 100 31773 100 100 
1 >=6/6  13529 72.9 100 23123 72.8 100.0 
2 6/7.5 0 0.0 27.1 6737 21.2 27.2 
3 6/9 3154 17.0 27.1 0 0.0 6.0 
4 6/12 1052 5.7 10.1 1036 3.3 6.0 
5 6/18 461 2.5 4.4 412 1.3 2.8 
6 6/24 140 0.8 1.9 130 0.4 1.5 
7 6/36 101 0.5 1.2 142 0.4 1.1 
8 6/60 48 0.3 0.6 70 0.2 0.6 
9 <6/60 72 0.4 0.4 123 0.4 0.4 
*1 person had no data on vision 
3.3.2 Visual acuity by ethnic group and type of diabetes 
In the London cohort, visual impairment (VI) and severe visual impairment (SVI) in 
T2D was 9.07% and 0.63% in South Asians, 4.47% and 0.37% in Caucasians, 7.54% 
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and 0.53% in Afro-Caribbean respectively. The overall VI and SVI in T1D was 8.89%, 
0.00% in South Asians, 3.70% and 0.13% in Caucasian, 6.15% and 0.59% in Afro-
Caribbean (Table 3.7 and 3.8). 
Table 3.7: Visual impairment by ethnic group 
Vision in best eye South Asian 
N (%) 
Caucasian 
N (%) 
Afro-Caribbean 
N (%) 
Other 
N(%) 
6/9 or better 3153 (89.6) 30575 (92.6) 7702 (92.0) 
5088 
(94.3) 
<6/9 – 6/12   196 (5.6) 1345 (4.1) 364 (4.4) 180 (3.3) 
<6/12-6/18  88 (2.5) 568 (1.7) 151 (1.8) 66 (1.2) 
<6/18-6/60  65 (1.9) 401 (1.2) 114 (1.4) 50 (0.9) 
<6/60††† 16 (0.5) 120 (0.4) 45 (0.5) 14 (0.3) 
Specific cut-points     
<6/9 *  365 (10.4) 2,434 (7.4) 674 (8.1) 310 (5.7) 
<6/12 or ≤ 6/18**  169 (4.8) 1,089 (3.3) 310 (3.7) 130 (2.4) 
<6/18† 81 (2.3) 521 (1.6) 159 (1.9) 64 (1.2) 
≤ 6/60††   27 (0.8) 194 (0.6) 67 (0.8) 25 (0.5) 
*Vision required for driving 
** <6/12 is visual impairment by US definitions. 
† Visual impairment World Health Organisation (WHO) based on International 
Classification of Diseases (ICD) 10 classification 
†† “Severe sight impairment” National Screening programme criteria 
††† Severe visual impairment US criteria 
Overall 2.0% of the population with T1D and 3.5% with T2D had VI and 0.3% with 
T1D and 0.7% with T2D had SVI (Table 3.7). Approximately 4% people with T1D are 
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not eligible for driving based on the presenting visual acuity and this figure nearly 
doubles (7.8%) in T2D.  
Table 3.8: Visual impairment by type of diabetes 
Vision in best eye Type 1 diabetes 
 N (%) 
Type 2 diabetes 
N (%) 
 3,323 (100) 46,962 (100) 
6/9 or better 3183 (95.8) 43,317 (92.2) 
<6/9 – 6/12   75 (2.3) 2,012 (4.3) 
<6/12-6/18  34 (1.0) 838 (1.8) 
<6/18-6/60  26 (0.8) 604 (1.3) 
<6/60††† 5 (0.2) 190 (0.4) 
Specific cut-points   
<6/9 *  140 (4.2) 3,644 (7.8) 
<6/12 or ≤ 6/18**  65 (2.0) 1,632 (3.5) 
<6/18† 31 (0.9) 794 (1.7) 
≤ 6/60††   9 (0.3) 304 (0.7) 
*Vision required for driving 
** <6/12 is visual impairment by US definitions.  
† Visual impairment World Health Organisation (WHO) based on ICD10 classification 
†† “Severe sight impairment” National Screening programme criteria 
††† Severe visual impairment US criteria 
3.3.3. Visual acuity by severity of diabetic retinopathy 
Presence of sight threatening diabetic retinopathy (STDR) severely impacted the visual 
outcome.  Only 65.3% of patients with STDR had visual acuity of ≥ 6/9 in the better 
eye, 5.5% had VI and 2.8% with SVI respectively (Table 3.9). When considering the 
grades of DR, proliferative diabetic retinopathy remains the commonest cause of visual 
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impairment among the grades of retinopathy. Half of the patients with PDR are not 
legally eligible for driving, and a quarter of them have low vision. Approximately 6% 
are severely visually impaired. Treated but persistent maculopathy (a surrogate marker 
of clinically significant macular oedema) is also an equally important cause for all 
categories of visual impairment.  Approximately 40 per cent of patients in this group 
have visual acuity below the driving standards, 20% have low vision while 3% are 
severely visually impaired. 
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Table 3.9: Visual impairment by severity of diabetic retinopathy  
Vision in 
 best eye 
R1 R2 R3 M1 M1P1 
 18,149 (100) 730 (100) 
1,465 
(100) 
4,403 (100) 2,446 (100) 
6/9 or better 16,717 (92.1) 606 (83.0) 686 (46.8) 3,194 (72.5) 1,421 (58.1) 
<6/9 – 6/12 850 (4.7) 68 (9.3) 402 (27.4) 649 (14.7) 538 (22.0) 
<6/12-6/18 357 (2.0) 28 (3.8) 95 (6.5) 211 (4.8) 165 (6.8) 
<6/18-6/60 193 (1.1) 26 (3.6) 199 (13.6) 261 (5.9) 237 (9.7) 
<6/60††† 32 (0.2) 2 (0.3) 83 (5.7) 88 (2.0) 85 (3.5) 
Specific cut-
points 
     
<6/9 * 1,432 (7.9) 124 (17.0) 779 (53.2) 1,209 (27.5) 1,025 (41.9) 
<6/12 or ≤ 
6/18** 
582 (3.2) 56 (7.7) 377 (25.7) 560 (12.7) 487 (19.9) 
<6/18† 225 (1.2) 28 (3.8) 282 (19.3) 349 (7.9) 322 (13.1) 
≤ 6/60†† 63 (0.4) 5 (0.7) 126 (8.6) 142 (3.2) 135 (5.5) 
*Vision required for driving 
** <6/12 is visual impairment by US definitions.  
† Visual impairment World Health Organisation (WHO) based on ICD10 classification 
†† “Severe sight impairment” National Screening programme criteria 
††† Severe visual impairment US criteria 
3.3.4. Prevalence of Uniocular blindness  
Unilateral visual impairment was present in 11.5% of the population with diabetes and 
3.1% had severe unilateral visual impairment. Uniocular blindness was present in 3.2% 
of diabetics in London and 2.8% in West Yorkshire with greater prevalence of VI and 
SVI in London than Wakefield (Table 3.10). 
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Table 3.10: Unilateral visual impairment i.e. vision in the worst eye for people who 
have good vision (6/9 or better) in one eye 
   Wakefield DECS (London) Total 
Total number of people 
with vision 6/9 or better 
in one eye 
16,683 (100) 29,821 (100) 46,504 (100) 
<6/9 *  2,651 (15.9) 6.908 (23.2) 9,559 (20.6) 
<6/12 or ≤ 6/18**  1,443 (8.7) 3,913 (13.1) 5,536 (11.5) 
<6/18† 862 (5.2) 2,077 (7.0) 2,939 (6.3) 
≤ 6/60††   462 (2.8) 957 (3.2) 1,419 (3.1) 
<6/60††† 310 (1.6) 599 (2.0) 909 (2.0) 
*Vision required for driving 
** <6/12 is visual impairment by US definitions.  
† Visual impairment World Health Organisation (WHO) based on ICD10 classification 
†† “Severe sight impairment” National Screening programme criteria 
††† Severe visual impairment US criteria 
3.4 Risk factors for diabetic retinopathy 
3.4.1 Characteristics of responders of the random sample from London 
A total of 2348 responses were collected from a possible of 3336 people on the random 
sample from DECS, London giving a 70% response rate (See section 2.6 and 2.7).  A 
series of Chi-Square and analysis of variance (ANOVA) were performed on a 
subsample of diabetes patients with no retinopathy (R0) to determine whether there 
were any differences in characteristics by ethnicity. The Chi-Square for type of diabetes 
was significant; Afro-Caribbean (89.1%) and South Asian (87.3%) were likely to have 
T2D than were Caucasians (79.8%), as opposed to T1D.    
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The Chi-Square for medication was also significant - Caucasians were more likely to be 
on just insulin (25.4) than either Afro-Caribbean (15.4) and South Asians (15.4) and 
less likely to be on both insulin and oral medication (10.7 for Whites compared to 13.3 
for Afro Caribbeans, 14.1 for South Asians).  
Diabetes duration was significant, with Whites having had diabetes longer than Afro-
Caribbean or South Asian patients. Afro-Caribbeans also had higher systolic BP than 
Caucasians or South Asians. The same was true for diastolic BP. Afro-Caribbeans had 
higher LDL than Caucasians or South Asians, but there was no difference in HDL. 
South Asians had a lower BMI than Afro-Caribbeans or Caucasians (Table 3.11). No 
differences were found in smoking patterns.  
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Table 3.11: (continued over two pages) Characteristic of study people with no 
retinopathy (R0 in both eyes) 
Characteristic Total White 
Britis
h 
Afro-
Caribbean 
South 
Asian 
Others *F= 
/X2= 
P 
Total 1355 
(100.0) 
797 
(58.8) 
338  
(24.9) 
158 
(11.7) 
62  
(4.6) 
  
Type of 
diabetes 
*     X2(3)
=20.4
2 
.000 
T1D, n (%) 223 
(16.5) 
161 
(20.2) 
37  
(10.9) 
20 
(12.7) 
5  
(8.1) 
  
T2D, n (%) 1132 
(83.5) 
636 
(79.8) 
301  
(89.1) 
138 
(87.3) 
57 
(91.9) 
  
Medication for 
Hyperglycaemia 
*     X2(6)
=27.8
6 
.000 
On tablets, n 
(%) 
777 
(57.3) 
430 
(54.4) 
206  
(62.2) 
96 
(61.5) 
45 
(73.8) 
  
On insulin, n 
(%) 
284 
(21.0) 
201 
(25.4) 
51  
(15.4) 
24 
(15.4) 
8  
(13.1) 
  
On both, n (%) 153 
(11.3) 
85 
(10.7) 
44  
(13.3) 
22 
(14.1) 
2  
(3.3) 
  
Diabetes 
duration, years, 
mean ± SD 
7.71 ± 
7.00* 
8.15 ± 
7.59 
6.92 ±  
6.33 
7.50 ± 
5.19 
6.87 ± 
6.31 
F(3, 
1351)
=2.83 
.037 
On treatment 
for 
hypertension,  
n (%) 
826 
(61.0) 
476 
(59.7) 
206  
(60.9) 
99 
(62.7) 
45 
(72.6) 
  
Systolic BP 
mean ± SD 
131.37 
± 
16.30* 
130.0
2 ± 
16.58 
134.51  
± 16.50 
130.24 
± 14.43 
135.21 
± 13.31 
F(3, 
1311)
=7.20 
.000 
Diastolic BP 
mean ± SD 
75.92 ± 
9.83* 
74.58 
± 9.73 
78.47 ± 
9.89 
75.65 ± 
8.78 
80.47 ± 
9.43 
F(3, 
1311)
=17.0
1 
.000 
LDL 
 mean ± SD 
2.20 ± 
0.90* 
2.13 ± 
0.87 
2.46 ± 0.83 1.92 ± 
1.01 
2.50 ± 
0.93 
F(3, 
1225)
=17.3
6 
.000 
HDL, mean ± 
SD 
1.39 ± 
0.75 
1.37 ± 
0.66 
1.43 ± 0.97 1.44 ± 
0.64 
1.44 ± 
0.83 
F(3, 
1233)
=0.80 
.494 
BMI, mean ± 
SD 
29.16 ± 
7.59* 
28.95 
± 8.23 
30.21 ± 
6.29 
26.93 ± 
6.31 
32.11 ± 
6.27 
F(3, 
1295)
=9.93 
.000 
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Characteristic Total White 
Britis
h 
Afro-
Caribbean 
South 
Asian 
Others *F= 
/X2= 
P 
eGFR, mean ± 
SD 
78.13 ± 
54.16 
78.03 
± 
48.48 
74.28 ± 
48.5 
88.26 ± 
91.18 
75.09 ± 
26.64 
F(3, 
1164)
=2.02 
.110 
Albumin Ratio, 
mean ± SD 
8.22 ± 
35.89 
6.71 ± 
34.85 
13.04 ± 
41.41 
7.03 ± 
34.63 
5.05 ± 
11.10 
F(3, 
943)=
1.89 
.130 
Smoker      X2(6)
=50.4
3 
.000 
No, n (%) 619 
(53.9) 
319 
(46.4) 
203 
(69.0) 
67 
(58.8) 
30 
(55.6) 
  
Ex-smoker, n 
(%) 
301 
(26.2) 
212 
(30.9) 
51 
(17.3) 
20 
(17.5) 
18 
(33.3) 
  
Current, n (%) 229 
(19.9) 
156 
(22.7) 
40 
(13.6) 
27 
(23.7) 
6 
(11.1) 
  
* F = ANOVA, X 2= chi-square 
 
In people with sight threatening diabetic retinopathy (R2 & R3), Chi-Square for Type of 
diabetes was significant; there were more Afro-Caribbean (88.9%) and South Asian 
(89.6) than Caucasians (63.3) with T2D and STDR as opposed to T1D which was more 
in Caucasians.   
The Chi-Square for medication was also significant – more Caucasians were on just 
insulin (46.8) than either Afro-Caribbean (27.8) and South Asians (23.6) and less likely 
to be on both insulin and oral medication (26.5 for Caucasians compared to 43.3 for 
Afro-Caribbeans and 85.3 for South Asians).  
Diabetes duration was significant, with Caucasians having had diabetes longer than 
Afro-Caribbeans or South Asian patients. Whites also had lower systolic BP than Afro-
Caribbeans or South Asians but there was no difference in diastolic BP. Whites had 
lower LDL, but there was no difference in HDL. South Asians had a lower BMI than 
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Afro-Caribbeans or Caucasians. Caucasians were more likely to have ever been a 
smoker, but the rates of current smokers are the same across ethnicities (Table 3.12). So 
the differences in risk factors between ethnic groups in R0 & R2+R3 were similar and 
risk factor differences seem to be determined by ethnicity and not by severity of DR. 
Table 3.12: (continued over two pages) Characteristic of study people with pre-
proliferative and proliferative retinopathy (R2 and R3) 
Characteristic Total White 
Britis
h 
Afro-
Caribbean 
South 
Asian 
Others F/X2 P 
Total 991 
(100.0) 
528 
(53.3) 
342  
(34.5) 
106 
(10.7) 
15  
(1.4) 
  
Type of diabetes *     X2(3)
=90.1
3 
.000 
T1D, n (%) 250 
(25.2) 
194 
(36.7) 
38  
(11.1) 
11 
(10.4) 
7  
(50.0) 
  
T2D, n (%) 741 
(74.8) 
334 
(63.3) 
304  
(88.9) 
95 
(89.6) 
7  
(50.0) 
  
Medication for 
Hyperglycaemia 
*     X2(6)
=49.6
4 
.000 
On tablets, n (%) 257 
(25.9) 
125 
(23.7) 
96  
(28.1) 
32 
(30.2) 
3  
(21.4) 
  
On insulin, n 
(%) 
373 
(37.6) 
247 
(46.8) 
95  
(27.8) 
25 
(23.6) 
6  
(42.8) 
  
On both, n (%) 338 
(34.1) 
140 
(26.5) 
147  
(43.0) 
48 
(45.3) 
3  
(21.4) 
  
Diabetes 
duration, years, 
mean ± SD 
19.82 ± 
10.836
* 
21.55 
± 
11.86 
18.48 ± 
9.37 
15.77 ± 
7.94 
17.60 ± 
10.40 
F(3, 
986)=
11.63 
.000 
On treatment for 
hypertension, n 
(%) 
820 
(82.7) 
428 
(81.1) 
286  
(83.6) 
93 
(87.7) 
13 
(86.7) 
X2(3)
=3.17 
.366 
Systolic BP, 
mean ± SD 
136.77 
± 
19.57* 
134.0
6 ± 
18.46 
140.10 ± 
20.53 
138.71 
± 19.13 
143.60 
± 25.52 
F(3, 
979)=
7.80 
.000 
Diastolic BP, 
mean ± SD 
74.79 ± 
11.18 
74.12 
± 
10.44 
75.53 ± 
12.28 
75.12 ± 
10.41 
79.80 ± 
14.11 
F(3, 
979)=
2.54 
.055 
LDL, mean ± 
SD 
2.11 ± 
0.95* 
2.03 ± 
0.95 
2.23 ± 0.89 2.12 ± 
1.05 
2.24 ± 
1.11 
F(3, 
939)=
3.00 
.030 
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Characteristic Total White 
Britis
h 
Afro-
Caribbean 
South 
Asian 
Others F/X2 P 
HDL, mean ± 
SD 
1.50 ± 
0.65 
1.52 ± 
0.65 
1.49 ± 0.63 1.46 ± 
0.75 
1.09 ± 
0.33 
F(3, 
940)=
1.92 
.124 
BMI, mean ± 
SD 
29.53 ± 
7.03* 
29.19 
± 7.60 
30.61 ± 
6.34 
27.91 ± 
5.88 
28.38 ± 
4.71 
F(3, 
972)=
5.07 
.002 
eGFR, mean ± 
SD 
63.47 ± 
68.53 
68.22 
± 
76.55 
56.94 ± 
63.86 
60.37 ± 
35.07 
63.50 ± 
28.01 
F(3, 
910)=
1.80 
.145 
Albumin Ratio, 
mean ± SD 
37.50 ± 
113.87 
29.09 
± 
102.9
7 
47.36 ± 
122.93 
40.06 ± 
123.90 
87.19 ± 
159.45 
F(3, 
747) 
= 
2.14 
.094 
Smoker *     X2(6)
=36.4
8 
.000 
No, n (%) 425 
(54.3) 
203 
(47.1) 
167 
(64.7) 
53 
(66.3) 
2 
(14.3) 
  
Ex-smoker, n 
(%) 
211 
(26.9) 
141 
(32.7) 
50 
(19.4) 
14 
(17.5) 
6 
(42.9) 
  
Current, n (%) 147 
(168.8) 
87 
(20.2) 
41 
(15.9) 
13 
(16.3) 
6 
(42.9) 
  
* F = ANOVA, X 2= chi-square 
3.4.2 Risk Factor for pre-proliferative and proliferative retinopathy (R2 and R3) 
Logistic regression analysis was performed to identify the significant risk factors for 
sight threatening diabetic retinopathy (R2 & R3) (Table 3.13). There was no increased 
risk with gender. Among ethnic minority groups Afro-Caribbeans were at more risk to 
develop R2/R3 (OR 1.53) than Caucasians. There was no effect of age. People with 
T2D were only 58% as likely to develop R2R3 versus T1D (table 3.13).   
Treatment with insulin increased risk by 3.97 times more than for oral medication alone, 
and was 6.68 times as great if patients were on both insulin and oral medication 
compared to tablets alone. Both duration of diabetes and diabetic control (HbA1c) 
affected the risk for pre-proliferative and proliferative DR: 2.6 if diabetes duration was 
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3-10 years compared to <3; and 27 times more in people with 10+ years duration of 
diabetes. Increasing HbA1C also increased the risk of sight threatening retinopathy 
R2/R3 2.19 times if HbA1c between 7.1 – 9, 3.23 times for 9.1-11 and 2.87 times if 
HbA1c  >11.1 compared to values of < 7. 
Presence for hypertension, and both systolic BP and diastolic BP also affected the risk 
for retinopathy: on treatment for HT = 3.07 times more than if not. Increased blood 
pressure increased the risk of R2/R3, those in the 4th quartile of systolic BP (>145) had 
high risk (OR 2.20) compared to those in the 1st quartile (<117). Similarly trend was, 
seen with diastolic blood pressure, with odds ratios of 0.59, 0.55 and 0.56 in the 2nd, 
3rd and 4th quartiles respectively.  
People on treatment with cholesterol lowering drugs were 1.71 times as likely to 
develop R2R3. For total cholesterol, those in the 2nd quartile were only 70% as likely 
as those in the 1st, while those in the 4th are 23% more likely (1.23 times as likely). For 
LDL, those in the 2nd, 3rd and 4th quartiles were 0.84, 0.68 and 0.75 times as likely as 
the 1st quartile. For HDL, the 2nd, 3rd and 4th quartiles were 1.34, 2.38 and 1.91 times 
as likely (respectively) than the 1st quartile. 
For BMI, the 2nd, 3rd and 4th quartiles were 1.23, 1.28 and 1.35 times as likely, 
respectively, than the 1
st
 to develop R2R3. Impaired renal function also affected the 
development of R2R3: for eGFR, greater than 90 people were 0.48 times less likely to 
have R2/R3 than those with <90. Albumin ratio over 1 corresponds with a 1.65 times as 
likely as those <1. 
Smoking status did not affect likelihood of R2R3. Presence of both microvascular and 
macrovascular complication severely affected the likelihood of R2R3: amputation  28 
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times,  angioplasty patients 2.16 times, coronary artery bypass graft (CABG) 2.55 times, 
microalbuminuria 3.91 times,  on renal dialysis 15 times, presence of  foot ulcer 6.57 
times,  peripheral neuropathy 4.08 times,  myocardial infarctions 2.46 times and 
cerebro-vascular accident 2.06 times respectively. Those with no symptoms were 0.25 
times as likely to develop R2R3.  
Table 3.13: (continued over three pages) Table showing OR and risk of developing 
sight threatening retinopathy versus no retinopathy  
  Number 
at Risk % OR (95% CI) 
P 
Value 
Gender         
Male 531 41.4 1.00 0.42 
Female 460 43.3 1.08 (0.92-1.27)   
Ethnicity         
Caucasians 528 39.8 1.00 <0.001 
Afro-Caribbean 342 50.3 1.53 (1.27-1.84)   
South Asian  106 40.2 1.01 (0.77-1.33)   
Others 15 19.5 0.37 (0.21-0.65)   
Age, per year     1.00 (0.99-1.01) 0.84 
Type of diabetes         
T1D 250 52.9 1.00 <0.001 
T2D 741 39.6 0.58 (0.48-0.72)   
Medication for Hyperglycaemia         
On tablets 257 24.9 1.00 <0.001 
On insulin 373 56.8 3.97 (3.22-4.89)   
On both 338 68.8 6.68 (5.27-8.47)   
Diabetes duration          
Less than 3 years 24 7.5 1.00 <0.001 
3-10 years 148 17.6 2.62 (1.67-4.13)   
10 years or longer 819 68.9 27.12 (17.57-41.84)   
HbA1c %         
< 7 214 28.8 1.00 <0.001 
7.1-9 474 46.9 2.19 (1.79-2.68)   
 9.1-11 210 56.6 3.23 (2.49-4.19)   
 > 11.1 73 53.7 2.87 (1.98-4.17)   
On treatment for hypertension         
No  171 24.4 1.00 <0.001 
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  Number 
at Risk % OR (95% CI) 
P 
Value 
Yes 820 49.8 3.07 (2.52-3.74)   
Systolic BP         
1
st
 Quartile < 117 134 38.7 1.00 <0.001 
2nd Quartile 117-131 257 34.1 0.82 (0.63-1.07)   
3
rd
 Quartile 131-145 289 42.7 1.18 (0.91-1.53)   
4
th
 Quartile ≥ 145 
304 58.1 2.20 (1.66-2.90)   
Diastolic BP         
1
st
 Quartile < 65 188 54.8 1.00 <0.001 
2nd Quartile 65-72 235 41.7 0.59 (0.45-0.77)   
3
rd
 Quartile 72-79 205 40.2 0.55 (0.42-0.73)   
4
th
 Quartile ≥ 79 
356 40.4 0.56 (0.43-0.72)   
Cholesterol Lowering 
Medication         
No  279 34.4 1.00 <0.001 
Yes 709 47.2 1.71 (1.43-2.04)   
Total cholesterol         
1
st
 Quartile < 3 94 49.5 1.00 0.01 
2nd Quartile 3-5 600 40.5 0.70 (0.51-0.94)   
3
rd
 Quartile 5-7 248 46.7 0.90 (0.64-1.25)   
4
th
 Quartile ≥ 7 
29 54.7 1.23 (0.67-2.27)   
LDL         
1
st
 Quartile < 1.5 260 48.2 1.00 0.02 
2nd Quartile 1.5-2.25 347 44.0 0.84 (0.68-1.05)   
3
rd
 Quartile 2.25-3.00 181 38.8 0.68 (0.53-0.87)   
4
th
 Quartile ≥ 3 
156 41.3 0.75 (0.58-0.98)   
HDL         
1
st
 Quartile < 1.5 547 39.7 1.00 <0.001 
2nd Quartile 1.5-2.25 294 46.9 1.34 (1.11-1.62)   
3
rd
 Quartile 2.25-3.00 75 61.0 2.38 (1.63-3.47)   
4
th
 Quartile ≥ 3 
30 55.6 1.91 (1.10-3.29)   
BMI         
1
st
 Quartile < 26.4 323 39.1 1.00 0.04 
2nd Quartile 26.4-29.8 251 44.1 1.23 (0.99-1.53)   
3
rd
 Quartile 29.8-33.8 200 45.1 1.28 (1.02-1.62)   
4
th
 Quartile ≥ 33.8 
203 46.5 1.35 (1.07-1.71)   
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  Number 
at Risk % OR (95% CI) 
P 
Value 
eGFR         
< 90 799 47.0 1.00 <0.001 
>= 90 116 30.2 0.48 (0.38-0.62)   
Albumin Creatinine Ratio 
(ACR)         
< 1 205 36.2 1.00 <0.001 
>= 1 546 48.3 1.65 (1.34-2.03)   
Smoker         
No 560 43.6 1.00 0.26 
Ex-smoker 211 41.2 0.91 (0.74-1.12)   
Current 147 39.1 0.83 (0.66-1.05)   
Microvascular and 
macrovascular complication         
Amputation         
No  950 42.1 1.00 <0.001 
Yes 41 95.3 28.18 (6.80-116.80)   
Angioplasty         
No  883 41.6 1.00 <0.001 
Yes 108 60.7 2.16 (1.58-2.96)   
CABG         
No  881 41.4 1.00 <0.001 
Yes 110 64.3 2.55 (1.85-3.53)   
Dialysis         
No  816 38.7 1.00 <0.001 
Yes 175 90.7 15.37 (9.38-25.16)   
Foot Ulcer         
No  832 39.6 1.00 <0.001 
Yes 159 81.1 6.57 (4.54-9.49)   
Microalbuminuria         
No  731 37.9 1.00 <0.001 
Yes 260 70.5 3.91 (3.07-4.98)   
Myocardial infarction         
No  834 40.7 1.00 <0.001 
Yes 157 62.8 2.46 (1.88-3.23)   
Stroke         
No  878 41.6 1.00 <0.001 
Yes 113 59.5 2.06 (1.52-2.78)   
Peripheral neuropathy         
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  Number 
at Risk % OR (95% CI) 
P 
Value 
No  749 38.2 1.00 <0.001 
Yes 242 71.6 4.08 (3.17-5.26)   
No complication         
No  728 57.9 1.00 <0.001 
Yes 263 25.2 0.25 (0.21-0.29)   
3.4.3 Risk factor for R2R3 in type 1 diabetes 
South Asians were more likely to be male and were less likely to have low levels of 
HbA1C. Retinopathy, maculopathy and age did not differ by ethnicity. Hypertension 
treatment as a whole did not differ among ethnicities, nor do type of medication to 
control blood pressure although Afro-Caribbeans were more likely to be on calcium 
channel blockers (CCB). Whites had lower systolic BP, whereas Afro-Caribbeans had 
higher diastolic BP. Use of cholesterol lowering medication, total cholesterol, LDL, 
HDL, eGFR, ACR, smoking, amputation, angioplasty, CABG, dialysis, foot ulcer, 
microalbuminia, myocardial infarction, stroke and peripheral neuropathy, did not differ 
among ethnicities. Afro-Caribbeans had higher BMI (Table 3.14). 
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Table 3.14: (continued over four pages) Risk factors for retinopathy in people with 
type 1 diabetes 
All except age 
are n (% within 
ethnicity) 
Total White 
British 
Afro-
Caribbea
n 
South 
Asian 
Other F/X2 P 
Gender *     X2(3)=
10.43 
.015 
Male 247 
(52.2) 
185 
(52.1) 
31 
(41.3) 
22 
(71.0) 
9  
(75.0) 
  
Female 226 
(47.8) 
170 
(47.9) 
44  
(58.7) 
9 
(29.0) 
3 
(25.0) 
  
Retinopathy      X2(3)=
4.50 
.212 
No retinopathy 
(R0) 
223 
(47.1) 
161 
(45.4) 
37  
(49.3) 
20 
(64.5) 
5  
(41.7) 
  
Sight 
threatening 
retinopathy (R2 
and R3) 
250 
(52.9) 
194 
(54.6) 
38  
(50.7) 
11 
(35.5) 
7  
(58.3) 
  
Maculopathy in 
either eye 
     X2(3)=
2.35 
.503 
No maculopathy 
(M0) 
320 
(67.8) 
234 
(65.9) 
54 
(73.0) 
23 
(74.2) 
9  
(75.0) 
  
Any 
maculopathy 
(M1) 
152 
(32.2) 
121 
(34.1) 
20 
(27.0) 
8 
(25.8) 
3  
(25.0) 
  
Age, mean ± SD 43.10 
± 
13.58 
43.22±
13.28 
42.51±13.
96 
45.26±
17.32 
37.58±
7.95 
F(3, 
469)=0.
97 
.403 
Diabetes 
duration 
*     X2(6)=
18.80 
.005 
Less than 3 
years 
31 
(6.6) 
23  
(6.5) 
6  
(8.0) 
1  
(3.2) 
1  
(8.3) 
  
3-10 years 93 
(19.7) 
57 
(16.1) 
20  
(26.7) 
14 
(45.2) 
2  
(16.7) 
  
10 years or 
longer 
349 
(73.8) 
275 
(77.5) 
49  
(65.3) 
16 
(51.6) 
9  
(75.0) 
  
HbA1c %  *     X2(9)=
38.36 
.000 
 < 7 89 
(19.2) 
65 
(18.5) 
18 
(24.7) 
2  
(7.1) 
4  
(33.3) 
  
7.1-9 221 
(47.6) 
182 
(51.9) 
20  
(27.4) 
13 
(46.4) 
6  
(50.0) 
  
9.1-11 115 
(24.8) 
84 
(23.9) 
18  
(24.7) 
11 
(39.3) 
2  
(16.7) 
  
> 11.1 39 
(8.4) 
20  
(5.7) 
17  
(23.3) 
2  
(7.1) 
0  
(0.0) 
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All except age 
are n (% within 
ethnicity) 
Total White 
British 
Afro-
Caribbea
n 
South 
Asian 
Other F/X2 P 
On treatment for 
hypertension 
     X2(3)=
6.64 
.084 
Yes 243 
(51.4) 
192 
(54.1) 
30  
(40.0) 
17 
(54.8) 
4  
(33.3) 
  
No 230 
(48.6) 
163 
(45.9) 
45  
(60.0) 
14 
(45.2) 
8  
(66.7) 
  
Medication for 
hypertension 
       
ACE      X2(3)=
4.14 
.247 
No 316 
(67.4) 
243 
(68.8) 
49  
(65.3) 
19 
(65.5) 
5  
(41.7) 
  
Yes 153 
(32.6) 
110 
(31.2) 
26  
(34.7) 
10 
(34.5) 
7  
(58.3) 
  
ARB      X2(3)=
7.06 
.070 
No 414 
(88.3) 
313 
(88.7) 
61  
(81.3) 
28 
(96.6) 
12 
(100.0) 
  
Yes 55 
(11.7) 
40 
(11.3) 
14  
(18.7) 
1  
(3.4) 
0  
(0.0) 
  
Beta blocker      X2(3)=
2.89 
.409 
No 422 
(90.0) 
322 
(91.2) 
64  
(85.3) 
25 
(86.2) 
11 
(91.7) 
  
Yes 47 
(10.0) 
31  
(8.8) 
11  
(14.7) 
4  
(13.8) 
1  
(8.3) 
  
CCB *     X2(3)=
13.27 
.004 
No 393 
(83.8) 
304 
(86.1) 
53  
(70.7) 
24 
(82.8) 
12 
(100.0) 
  
Yes 76 
(16.2) 
49 
(13.9) 
22  
(29.3) 
5  
(17.2) 
0  
(0.0) 
  
Diurectic      X2(3)=
5.98 
.113 
No 416 
(88.7) 
319 
(90.4) 
62  
(82.7) 
26 
(89.7) 
9  
(75.0) 
  
Yes 53 
(11.3) 
34  
(9.6) 
13  
(17.3) 
3  
(10.3) 
3  
(25.0) 
  
Systolic BP *     X2(9)=
24.74 
.003 
1
st
 Quartile < 
117 
123 
(26.2) 
103 
(29.2) 
14  
(18.9) 
6  
(19.4) 
0  
(0.0) 
  
2nd Quartile 
117-131 
172 
(36.6) 
135 
(38.2) 
21  
(28.4) 
10 
(32.3) 
6  
(50.0) 
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All except age 
are n (% within 
ethnicity) 
Total White 
British 
Afro-
Caribbea
n 
South 
Asian 
Other F/X2 P 
3
rd
 Quartile 131-
145 
116 
(24.7) 
75 
(21.2) 
26  
(35.1) 
13 
(41.9) 
2  
(16.7) 
  
4
th
 Quartile ≥ 
145 
59 
(12.6) 
40 
(11.3) 
13  
(17.6) 
2  
(6.5) 
4  
(33.3) 
  
Diastolic BP *     X2(9)=
26.49 
.002 
1
st
 Quartile < 65 70 
(14.9) 
59 
(16.7) 
6  
(8.1) 
5  
(16.1) 
0  
(0.0) 
  
2nd Quartile 65-
72 
132 
(28.1) 
111 
(31.4) 
13  
(17.6) 
7  
(22.6) 
1  
(8.3) 
  
3
rd
 Quartile 72-
79 
110 
(23.4) 
82 
(23.2) 
15  
(20.3) 
9  
(29.0) 
4  
(33.3) 
  
4
th
 Quartile ≥ 79 158 
(33.6) 
101 
(28.6) 
40  
(54.1) 
10 
(32.3) 
7  
(58.3) 
  
Statin for 
cholesterol 
     X2(3)=
2.05 
.562 
No 255 
(54.4) 
198 
(56.1) 
38  
(50.7) 
14 
(48.3) 
5  
(41.7) 
  
Yes 214 
(45.6) 
155 
(43.9) 
37 
(49.3) 
15 
(51.7) 
7  
(58.3) 
  
Total cholesterol      X2(9)=
5.48 
.791 
1
st
 Quartile < 3 36 
(7.8) 
29  
(8.3) 
4  
(5.6) 
3  
(10.3) 
0  
(0.0) 
  
2nd Quartile 3-5 283 
(61.4) 
216 
(61.7) 
43  
(60.6) 
16 
(55.2) 
8  
(72.7) 
  
3
rd
 Quartile 5-7 125 
(27.1) 
95 
(27.1) 
20  
(28.2) 
8  
(27.6) 
2  
(18.2) 
  
4
th
 Quartile ≥ 7 17 
(3.7) 
10  
(2.9) 
4  
(5.6) 
2  
(6.9) 
1  
(9.1) 
  
LDL       X2(9)=
16.52 
.057 
1
st
 Quartile < 1.5 108 
(24.2) 
84 
(24.7) 
15  
(21.4) 
8  
(32.0) 
1  
(9.1) 
  
2nd Quartile 
1.5-2.25 
161 
(36.1) 
129 
(37.9) 
24  
(34.3) 
7  
(28.0) 
1  
(9.1) 
  
3
rd
 Quartile 
2.25-3.00 
91 
(20.4) 
72 
(21.2) 
12  
(17.1) 
3  
(12.0) 
4  
(36.4) 
  
4
th
 Quartile ≥ 3 86 
(19.3) 
55 
(16.2) 
19  
(27.1) 
7  
(28.0) 
5  
(45.5) 
  
HDL       X2(9)=
8.79 
.457 
1
st
 Quartile < 1.5 210 
(47.1) 
154 
(45.3) 
34  
(48.6) 
17 
(68.0) 
5  
(45.5) 
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All except age 
are n (% within 
ethnicity) 
Total White 
British 
Afro-
Caribbea
n 
South 
Asian 
Other F/X2 P 
2nd Quartile 
1.5-2.25 
171 
(38.3) 
133 
(39.1) 
27  
(38.6) 
5  
(20.0) 
6  
(54.5) 
  
3
rd
 Quartile 
2.25-3.00 
51 
(11.4) 
43 
(12.6) 
6  
(8.6) 
2  
(8.0) 
0  
(0.0) 
  
4
th
 Quartile ≥ 3 14 
(3.1) 
10 
(2.9) 
3  
(4.3) 
1  
(4.0) 
0  
(0.0) 
  
BMI  *     X2(9)=
39.14 
.000 
1
st
 Quartile < 
26.4 
248 
(52.8) 
205 
(58.1) 
22  
(29.7) 
15 
(48.4) 
6  
(50.0) 
  
2nd Quartile 
26.4-29.8 
110 
(23.4) 
81 
(22.9) 
21  
(28.4) 
6  
(19.4) 
2  
(16.7) 
  
3
rd
 Quartile 
29.8-33.8 
63 
(13.4) 
40 
(11.3) 
12  
(16.2) 
9  
(29.0) 
2  
(16.7) 
  
4
th
 Quartile ≥ 
33.8 
49 
(10.4) 
27  
(7.6) 
19  
(25.7) 
1  
(3.2) 
2  
(16.7) 
  
eGFR      X2(3)=
5.25 
.155 
< 90 299 
(71.5) 
223 
(69.7) 
54  
(83.1) 
15 
(68.2) 
7  
(63.6) 
  
> 90 119 
(28.5) 
97 
(30.3) 
 
11  
(16.9) 
7  
(31.8) 
4  
(36.4) 
  
ACR      X2(3)=
5.19 
.158 
< 1 123 
(36.7) 
96 
(39.0) 
16  
(26.2) 
9  
(47.4) 
2  
(22.2) 
  
> 1 212 
(63.3) 
150 
(61.0) 
45  
(73.8) 
10 
(52.6) 
7  
(77.8) 
  
Smoker      X2(6)=
9.21 
.162 
No 287 
(64.9) 
218 
(65.1) 
50  
(73.5) 
14 
(50.0) 
5  
(45.5) 
  
Ex-smoker 76 
(17.2) 
57 
(17.0) 
7  
(10.3) 
9  
(32.1) 
3  
(27.3) 
  
Current 79 
(17.9) 
60 
(17.9) 
11  
(16.2) 
5  
(17.9) 
3  
(27.3) 
  
Amputation      X2(3)=
6.73 
.081 
No 459 
(98.7) 
347 
(99.1) 
72  
(97.3) 
29 
(100.0) 
11 
(.917) 
  
Yes 6 
(1.3) 
3  
(0.9) 
2  
(2.7) 
0  
(0.0) 
1  
(8.3) 
  
Angioplasty      X2(3)= .223 
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All except age 
are n (% within 
ethnicity) 
Total White 
British 
Afro-
Caribbea
n 
South 
Asian 
Other F/X2 P 
4.38 
No 448 
(96.3) 
338 
(96.6) 
72  
(97.3) 
26 
(89.7) 
12 
(100.0) 
  
Yes 17 
(3.7) 
12  
(3.4) 
2  
(2.7) 
3  
(10.3) 
0  
(0.0) 
  
CABG      X2(3)=
3.22 
.359 
No 453 
(97.4) 
343 
(98.0) 
70  
(94.6) 
28 
(96.6) 
12 
(100.0) 
  
Yes 12 
(2.6) 
7  
(2.0) 
4  
(5.4) 
1  
(3.4) 
0  
(0.0) 
  
Dialysis      X2(3)=
2.57 
.463 
No 407 
(87.5) 
311 
(88.9) 
61  
(82.4) 
25 
(86.2) 
10 
(83.3) 
  
Yes 58 
(12.5) 
39 
(11.1) 
13  
(17.6) 
4  
(13.8) 
2  
(16.7) 
  
Foot Ulcer      X2(3)=
3.81 
.283 
No 424 
(91.2) 
318 
(90.9) 
67  
(90.5) 
29 
(100.0) 
10 
(83.3) 
  
Yes 41 
(8.8) 
32  
(9.1) 
7  
(9.5) 
0  
(0.0) 
2  
(16.7) 
  
Micro-
albuminuria 
     X2(3)=
3.08 
.380 
No 382 
(82.2) 
292 
(83.4) 
58  
(78.4) 
24 
(82.8) 
8  
(66.7) 
  
Yes 83 
(17.8) 
58 
(16.6) 
16  
(21.6) 
5  
(17.2) 
4  
(33.3) 
  
Myocardial 
infarction 
     X2(3)=
4.84 
.184 
No 445 
(95.7) 
338 
(96.6) 
69  
(93.2) 
26 
(89.7) 
12 
(100.0) 
  
Yes 20 
(4.3) 
12  
(3.4) 
5  
(6.8) 
3  
(10.3) 
0  
(0.0) 
  
Stroke      X2(3)=
6.86 
.077 
No 445 
(95.7) 
339 
(96.9) 
68  
(91.9) 
26 
(89.7) 
12 
(100.0) 
  
Yes 20 
(4.3) 
11  
(3.1) 
6  
(8.1) 
3  
(10.3) 
0  
(0.0) 
  
Peripheral 
neuropathy 
     X2(3)=
0.27 
.965 
No 395 297 64  24 10   
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All except age 
are n (% within 
ethnicity) 
Total White 
British 
Afro-
Caribbea
n 
South 
Asian 
Other F/X2 P 
(84.9) (84.9) (86.5) (82.8) (83.3) 
Yes 70 
(15.1) 
53 
(15.1) 
10  
(13.5) 
5  
(17.2) 
2  
(16.7) 
  
* F = ANOVA, X 2= chi-square 
3.4.4 Risk factor for type 2 diabetes 
Risk factors in T2D included male gender in South Asians (Table 3.15). Caucasians 
were likely to be on insulin and oral medication for hyperglycemia and had diabetes for 
10 years or longer. South Asians had lower HbA1C. Afro-Caribbeans had poor 
glycaemic control, have high systolic and diastolic blood pressure and have high BMI 
and LDL.    
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Table 3.15: (continued over four pages) Risk factors for retinopathy in people with 
type 2 diabetes 
All except age 
are n (% within 
ethnicity) 
Total White 
British 
Afro-
Caribbean 
South 
Asian 
Other F/X2 P 
Gender *         X2(3)=
8.21 
.042 
Male 1036 
(55.3) 
556 
(57.3) 
306  
(50.6) 
136 
(58.4) 
38 
(58.5) 
  
Female 837 
(44.7) 
414 
(42.7) 
299  
(49.4) 
97 
(41.6) 
27 
(41.5) 
  
Retinopathy *         X2(3)=
59.90 
.000 
No Retinopathy 
(R0) 
1132 
(60.4) 
636 
(65.6) 
301  
(49.8) 
138 
(59.2) 
57 
(87.7) 
  
Sight threatening 
retinopathy (R2 
and R3) 
741 
(39.6) 
334 
(34.4) 
304  
(50.2) 
95 
(40.8) 
8 
(12.3) 
  
Maculopathy in 
either eye 
*         X2(3)=
42.98 
.000 
No maculopathy 
(M0) 
1306 
(69.8) 
714 
(73.6) 
368  
(60.9) 
165 
(71.1) 
59 
(90.8) 
  
Any maculopathy 
(M1) 
565 
(30.2) 
256 
(26.4) 
236  
(39.1) 
67 
(28.9) 
6 
(9.2) 
  
Age, mean ± SD 65.12
±12.1
3 
66.60±
12.05 
63.66± 
12.43 
62.24
±11.0
9 
67.02
±10.8
6 
F(3, 
1869)=
12.86 
.000 
Medication for 
Hyperglycaemia 
*         X2(6)=
34.26 
.000 
On tablets, n (%) 1021 
(54.5) 
551 
(56.8) 
296  
(48.9) 
126 
(54.1) 
48 
(73.8) 
  
On insulin, n (%) 228 
(12.2) 
117 
(12.1) 
84  
(13.9) 
23 
(9.9) 
4 
(6.2) 
  
On both, n (%) 469 
(25.0) 
211 
(21.8) 
185  
(30.6) 
68 
(29.2) 
5 
(7.7) 
  
Diabetes duration *         X2(6)=
31.63 
.000 
Less than 3 years 287 
(15.3) 
162 
(16.7) 
83  
(13.7) 
27 
(11.6) 
15 
(23.1) 
  
3-10 years 746 
(39.8) 
411 
(42.4) 
206  
(34) 
96 
(41.2) 
33 
(50.8) 
  
10 years or longer 840 
(44.8) 
397 
(40.9) 
316  
(52.2) 
110 
(47.2) 
17 
(26.2) 
  
HbA1c %  *         X2(9)=
37.31 
.000 
( 4 quarters : < 7  655 
(36.4) 
360 
(38.1) 
202  
(35.7) 
61 
(27.1) 
32 
(51.6) 
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All except age 
are n (% within 
ethnicity) 
Total White 
British 
Afro-
Caribbean 
South 
Asian 
Other F/X2 P 
7.1-9 789 
(43.9) 
429 
(45.4) 
224  
(39.6) 
111 
(49.3) 
25 
(40.3) 
  
 9.1-11 256 
(14.2) 
110 
(11.7) 
99  
(17.5) 
44 
(19.6) 
3 
(4.8) 
  
 > 11.1 97 
(5.4) 
45 (4.8) 41  
(7.2) 
9 
(4.0) 
2 
(3.2) 
  
On treatment for 
hypertension 
          X2(3)=
1.44 
.697 
Yes 457 
(24.4) 
229 
(23.6) 
158  
(26.1) 
55 
(23.6) 
15 
(23.1) 
  
No  1416 
(75.6) 
741 
(76.4) 
447  
(73.9) 
178 
(76.4) 
50 
(76.9) 
  
Medication for 
hypertension 
            
ACE           X2(3)=
5.79 
.122 
No  1008 
(54.7) 
504 
(52.7) 
351  
(58.7) 
120 
(53.3) 
33 
(51.6) 
  
Yes 835 
(45.3) 
452 
(47.3) 
247  
(41.3) 
105 
(46.7) 
31 
(48.4) 
  
ARB *         X2(3)=
11.98 
.007 
No  1423 
(77.2) 
766 
(80.1) 
436  
(72.9) 
175 
(77.8) 
46 
(71.9) 
  
Yes 420 
(22.8) 
190 
(19.9) 
162  
(27.1) 
50 
(22.2) 
18 
(28.1) 
  
Beta blocker *         X2(3)=
11.52 
.009 
No  1435 
(77.9) 
730 
(76.4) 
488  
(81.6) 
163 
(72.4) 
54 
(84.4) 
  
Yes 408 
(22.1) 
226 
(23.6) 
110  
(18.4) 
62 
(27.6) 
10 
(15.6) 
  
CCB *         X2(3)=
10.85 
.013 
No  1210 
(65.7) 
658 
(68.8) 
363  
(60.7) 
148 
(65.8) 
41 
(64.1) 
  
Yes 633 
(34.3) 
298 
(31.2) 
235  
(39.3) 
77 
(34.2) 
23 
(35.9) 
  
Diuretic           X2(3)=
4.97 
.174 
No  1376 
(74.7) 
720 
(75.3) 
430  
(71.9) 
178 
(79.1) 
48 
(75) 
  
Yes 467 
(25.3) 
236 
(24.7) 
168  
(28.1) 
47 
(20.9) 
16 
(25) 
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All except age 
are n (% within 
ethnicity) 
Total White 
British 
Afro-
Caribbean 
South 
Asian 
Other F/X2 P 
Systolic BP *         X2(9)=
28.34 
.001 
1
st
 Quartile < 117 223 
(12.2) 
134 
(14) 
53  
(9.2) 
32 
(14) 
4 
(6.2) 
  
2nd Quartile 117-
131 
581 
(31.8) 
329 
(34.4) 
160  
(27.6) 
71 
(31) 
21 
(32.3) 
  
3
rd
 Quartile 131-
145 
561 
(30.7) 
275 
(28.8) 
190  
(32.8) 
69 
(30.1) 
27 
(41.5) 
  
4
th
 Quartile ≥ 145 464 
(25.4) 
218 
(22.8) 
176  
(30.4) 
57 
(24.9) 
13 
(20) 
  
Diastolic BP *         X2(9)=
35.42 
.000 
1
st
 Quartile < 65 273 
(14.9) 
147 
(15.4) 
88  
(15.2) 
32 
(14) 
6 
(9.2) 
  
2nd Quartile 65-
72 
432 
(23.6) 
245 
(25.6) 
120  
(20.7) 
56 
(24.5) 
11 
(16.9) 
  
3
rd
 Quartile 72-79 400 
(21.9) 
235 
(24.6) 
102  
(17.6) 
53 
(23.1) 
10 
(15.4) 
  
4
th
 Quartile ≥ 79 724 
(39.6) 
329 
(34.4) 
269  
(46.5) 
88 
(38.4) 
38 
(58.5) 
  
Statin for 
cholesterol 
          X2(3)=
4.91 
.179 
No 556 
(30.2) 
286 
(29.9) 
173  
(28.9) 
81 
(36) 
16 
(25) 
  
Yes 1287 
(69.8) 
670 
(70.1) 
425 
(71.1) 
144 
(64) 
48 
(75) 
  
Total cholesterol           X2(9)=
12.01 
.212 
1
st
 Quartile < 3 154 
(8.6) 
85  
(9) 
43  
(7.6) 
21 
(9.5) 
5 
(7.8) 
  
2nd Quartile 3-5 1198 
(66.8) 
642 
(68.2) 
367  
(64.7) 
150 
(67.9) 
39 
(60.9) 
  
3
rd
 Quartile 5-7 406 
(22.6) 
195 
(20.7) 
149  
(26.3) 
43 
(19.5) 
19 
(29.7) 
  
4
th
 Quartile ≥ 7 36  
(2) 
20  
(2.1) 
8  
(1.4) 
7 
(3.2) 
1 
(1.6) 
  
LDL *         X2(9)=
68.75 
.000 
1
st
 Quartile < 1.5 431 
(25) 
256 
(28.3) 
89  
(16.4) 
78 
(36.1) 
8 
(13.1) 
  
2nd Quartile 1.5-
2.25 
628 
(36.4) 
345 
(38.1) 
186  
(34.2) 
74 
(34.3) 
23 
(37.7) 
  
3
rd
 Quartile 2.25-
3.00 
376 
(21.8) 
166 
(18.3) 
158 (29) 39 
(18.1) 
13 
(21.3) 
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All except age 
are n (% within 
ethnicity) 
Total White 
British 
Afro-
Caribbean 
South 
Asian 
Other F/X2 P 
4
th
 Quartile ≥ 3 292 
(16.9) 
139 
(15.3) 
111  
(20.4) 
25 
(11.6) 
17 
(27.9) 
  
HDL            X2(9)=
15.12 
.088 
1
st
 Quartile < 1.5 1169 
(67.3) 
649 
(71.2) 
347  
(63.4) 
133 
(61) 
40 
(65.6) 
  
2nd Quartile 1.5-
2.25 
456 
(26.3) 
209 
(22.9) 
162  
(29.6) 
68 
(31.2) 
17 
(27.9) 
  
3
rd
 Quartile 2.25-
3.00 
72 
(4.1) 
33 (3.6) 26  
(4.8) 
10 
(4.6) 
3 
(4.9) 
  
4
th
 Quartile ≥ 3 40 
(2.3) 
20 (2.2) 12  
(2.2) 
7 
(3.2) 
1 
(1.6) 
  
Body mass index   *         X2(9)=
79.59 
.000 
1
st
 Quartile < 26.4 579 
(32.1) 
333 
(35.2) 
131  
(23) 
106 
(46.5) 
9 
(14.1) 
  
2nd Quartile 26.4-
29.8 
459 
(25.4) 
222 
(23.5) 
158  
(27.8) 
66 
(28.9) 
13 
(20.3) 
  
3
rd
 Quartile 29.8-
33.8 
380 
(21) 
178 
(18.8) 
147  
(25.8) 
33 
(14.5) 
22 
(34.4) 
  
4
th
 Quartile ≥ 33.8 388 
(21.5) 
212 
(22.4) 
133  
(23.4) 
23 
(10.1) 
20 
(31.3) 
  
eGFR *         X2(3)=
17.49 
.001 
< 90 1400 
(84.1) 
735 
(83.3) 
461  
(88.7) 
161 
(78.5) 
43 
(74.1) 
  
> 90 265 
(15.9) 
147 
(16.7) 
59  
(11.3) 
44 
(21.5) 
15 
(25.9) 
  
ACR  *         X2(3)=
9.21 
.027 
< 1 444 
(32.6) 
229 
(32.6) 
122  
(28.7) 
77 
(41.2) 
16 
(33.3) 
  
> 1 919 
(67.4) 
474 
(67.4) 
303  
(71.3) 
110 
(58.8) 
32 
(66.7) 
  
Smoker *         X2(6)=
102.62 
.000 
No 998 
(57.7) 
432 
(47.4) 
374  
(69.5) 
164 
(73.2) 
28 
(48.3) 
  
Ex-smoker 436 
(25.2) 
296 
(32.5) 
94  
(17.5) 
25 
(11.2) 
21 
(36.2) 
  
Current 297 
(17.2) 
183 
(20.1) 
70  
(13) 
35 
(15.6) 
9 
(15.5) 
  
Amputation           X2(3)=
2.13 
.546 
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All except age 
are n (% within 
ethnicity) 
Total White 
British 
Afro-
Caribbean 
South 
Asian 
Other F/X2 P 
No  1797 
(98) 
929 
(97.9) 
586  
(97.7) 
220 
(98.7) 
62 
(100) 
  
Yes 37  
(2) 
20  
(2.1) 
14  
(2.3) 
3 
(1.3) 
0  
(0) 
  
Angioplasty *         X2(3)=
37.54 
.000 
No  1673 
(91.2) 
860 
(90.6) 
569  
(94.8) 
183 
(82.1) 
61 
(98.4) 
  
Yes 161 
(8.8) 
89  
(9.4) 
31  
(5.2) 
40 
(17.9) 
1 
(1.6) 
  
CABG           X2(3)=
6.21 
.102 
No  1675 
(91.3) 
859 
(90.5) 
561  
(93.5) 
198 
(88.8) 
57 
(91.9) 
  
Yes 159 
(8.7) 
90  
(9.5) 
39  
(6.5) 
25 
(11.2) 
5 
(8.1) 
  
Dialysis           X2(3)=
0.79 
.852 
No  1699 
(92.6) 
884 
(93.2) 
552  
(92) 
206 
(92.4) 
57 
(91.9) 
  
Yes 135 
(7.4) 
65  
(6.8) 
48  
(8) 
17 
(7.6) 
5 
(8.1) 
  
Foot Ulcer           X2(3)=
5.10 
.164 
No  1679 
(91.5) 
856 
(90.2) 
556  
(92.7) 
208 
(93.3) 
59 
(95.2) 
  
Yes 155 
(8.5) 
93  
(9.8) 
44  
(7.3) 
15 
(6.7) 
3 
(4.8) 
  
Microalbuminuria           X2(3)=
2.01 
.570 
No  1548 
(84.4) 
800 
(84.3) 
502  
(83.7) 
190 
(85.2) 
56 
(90.3) 
  
Yes 286 
(15.6) 
149 
(15.7) 
98  
(16.3) 
33 
(14.8) 
6 
(9.7) 
  
Myocardial 
infarction 
*         X2(3)=
11.47 
.009 
No  1604 
(87.5) 
819 
(86.3) 
543  
(90.5) 
185 
(83) 
57 
(91.9) 
  
Yes 230 
(12.5) 
130 
(13.7) 
57  
(9.5) 
38 
(17) 
5 
(8.1) 
  
Stroke           X2(3)=
1.33 
.723 
No  1664 
(90.7) 
855 
(90.1) 
548  
(91.3) 
203 
(91) 
58 
(93.5) 
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All except age 
are n (% within 
ethnicity) 
Total White 
British 
Afro-
Caribbean 
South 
Asian 
Other F/X2 P 
Yes 170 
(9.3) 
94  
(9.9) 
52  
(8.7) 
20  
(9) 
4 
(6.5) 
  
Peripheral 
neuropathy 
          X2(3)=
4.29 
.232 
No  1566 
(85.4) 
810 
(85.4) 
516  
(86) 
183 
(82.1) 
57 
(91.9) 
  
Yes 268 
(14.6) 
139 
(14.6) 
84  
(14) 
40 
(17.9) 
5 
(8.1) 
  
* F = ANOVA, X 2= chi-square 
3.4.5 Independent predictors of diabetic retinopathy and vision-threatening 
retinopathy  
Age was a factor for T1D patients to develop R2R3 - with each year the odds increased 
by 5% (Table 3.16).  However this was not true for T2D. Type 1 females were 43% 
more likely to develop R2R3- no sex differences for T2D. Ethnicity does not affect T1D 
patients' risk of developing R2R3, but for T2D Afro-Caribbeans are nearly twice as 
likely as Caucasians whites and South Asians are1.31% more likely than Caucasians. 
Diabetes duration affects the likelihood of developing R2R3 for both types.  For each 10 
years of diabetes, odds increase fourfold for T1D and six fold for T2D. In people with 
T2D, for each increase of 0.5% in HbA1c results in a 16% increase in risk. There was 
no similar effect noted for T1D. Also for each 10-point increase in systolic BP risks of 
developing R2R3 increase 36% for type 1 and 20% for type 2.  
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Table 3.16: Independent predictors of diabetic retinopathy and vision-threatening 
retinopathy 
 
Overall (N=2346) Type I (N=473) Type II (N=1873) 
Risk Factor OR 
 (95% CI) 
P  
Value 
OR 
 (95% CI) 
P 
Value 
OR  
(95% CI) 
P  
Value 
Age, per 
year 
1.00 
 (0.99-1.01) 0.84 
1.05  
(1.04-1.07) 
<0.00
1 
1.00 
 (0.99-1.01) 0.44 
Gender, 
female 
versus Male 
1.08  
(0.92-1.27) 0.36 
1.43 
 (1.00-2.06) 0.05 
0.99  
(0.82-1.19) 0.91 
Ethnicity             
Caucasians 1.00 <0.001 1.00 0.23 1.00 <0.001 
Afro-
Caribbean 
1.53  
(1.27-1.84)   
0.85  
(0.52-1.40)   
1.92 
 (1.56-2.37)   
South Asian  1.01 
 (0.77-1.33)   
0.46  
(0.21-0.98)   
1.31 
 (0.98-1.76)   
Others 0.37  
(0.21-0.65)   
1.16  
(0.36-3.73)   
0.27 
 (0.13-0.57)   
Duration of 
diabetes, per 
10 years 
4.79 
 (4.19-5.48) <0.001 
3.96  
(3.11-5.06) 
<0.00
1 
6.02 
 (5.07-7.16) <0.001 
HbA1c,  
every 0.5% 
increase 
1.12  
(1.09-1.15) <0.001 
0.99  
(0.95-1.04) 0.81 
1.16 
 (1.12-1.19) <0.001 
Systolic BP, 
per 10 
mmHg 
1.19  
(1.13-1.24) <0.001 
1.36 
 (1.21-1.54) 
<0.00
1 
1.20 
 (1.14-1.27) <0.001 
Use of 
diabetes 
medication, 
yes versus 
No 
5.25 
 (3.21-8.56) <0.001 - - 
7.62 
(4.18-
13.89) <0.001 
 
3.4.6 Microvascular and macrovascular complications in people with sight 
threatening retinopathy 
There was a gradual increase in both microvascular and macrovascular complication 
increased with increase age and duration of diabetes (figure 3.2). Approximately 20% of 
people had both peripheral neuropathy and microalbuminuria whereas risk of 
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cardiovascular complication including angina and myocardial infarction was 
approximately 15%, and risk of stroke was 8%.  
 
Figure 3.2: Microvascular and macrovascular complication in people with diabetes 
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3.5 Anatomical and visual outcome following vitrectomy in 2007-2009 
3.5.1 Patient demographics  
A total of 185 eyes of 158 patients had vitrectomy between January 2007 and December 
2009. So 2 per 1000 diabetic patients per year required vitrectomy for diabetic eye 
disease. There were more Caucasians, males, and patients with T2D (Table 3.17). The 
mean age of the population was 54.08 (SD ± 14.15) years and duration of diabetes was 
23.12 (SD± 8.82) in T1D and 17.1 ± (SD 8.12) years in T2D respectively.   
A total of 110 patients were on treatment to lower blood pressure, 96 on cholesterol 
lowering agents,  13 patients with type I and 29 with T2D had ischemic heart disease 
(IHD); 13 with type I and 10 with type II were on renal dialysis and 4 each with T1D 
and T2D had co-existent cerebrovascular accidents respectively. 
Table 3.17: Baseline Demographics 
Ethnicity ( n= 158) 
Caucasian 
Afro-Caribbean 
South Asian 
Others 
Frequency % 
83 
51 
17 
7 
 
85 
73 
 
 
58 
100 
 
117 
 60 
  8 
52.53 
32.28 
10.75 
0.04 
 
54.1 
45.9 
 
 
36.8 
63.2 
 
63.24 
32.43 
4.32 
Gender ( n= 158) 
Male 
Female 
Type of diabetes ( n= 158) 
T1D 
T2D 
Indication for surgery ( n = 185) 
Group A 
Group B 
Group C 
Group A: Tractional Retinal Detachment (TRD), Group B: Non-Clearing Vitreous 
Haemorrhage (NCVH), Group C: Others 
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3.5.2 Effect of systemic factors 
A logistic regression was performed to explore the baseline systemic factors that were 
significant predictors of visual success of the operation (Table 3.18). Group C was 
ignored in regression model due to very few numbers.  The overall regression was 
significant, Chi-square (28) = 82.57, p<0.001, for a Cox & Snell R
2
=0.506 and 
Nagelkerke R
2
=0.700, meaning that the collective set of predictors were able to predict 
between an estimated 51 and 70% of the variance in the likelihood of an operation to be 
a complete success. 
Duration of diabetes (p=0.01) was a significant predictor for likelihood for visual 
success. For each year the patient has had diabetes, the odds decreased by 0.69 for 
successful outcome.  Likewise, if a patient was on insulin, the odds of visual success 
decreased by 0.04 (p=0.02).  Presence of IHD was also significant negative predictor 
(OR: 0.047, p=0.01).  
Time interval in months from decision to operate by physician as demonstrated by 
progressive TRD involving macular or NCVH to date of operation was also a 
significant negative predictor, with each month delay resulting in a decrease in 
likelihood of success, with an OR of 0.59, p=0.021. 
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Table 3.18: Logistic Regression Analysis showing the effect of various systemic 
variables 
                  
B 
                 
S.E. 
                 
Sig. 
             
Exp (B) 
Group A 
(Tractional retinal detachment) 
-20.46 24651.17 0.99 0.00 
Group B 
(Non-Clearing vitreous haemorrhage) 
-11.93 24651.17 1.00 0.00 
Age -0.05 0.06 0.39 0.95 
Male 0.78 0.86 0.36 2.18 
T1D 1.65 2.09 0.43 5.21 
Duration -.37 0.15 0.01 0.69 
Insulin -3.23 1.40 0.02 0.04 
Duration of insulin 0.06 0.13 0.66 1.06 
HbA1c 0.01 0.24 0.98 1.01 
Hypertension -2.419 1.32 0.07 0.09 
Cerebro-vascular accident -0.31 1.61 0.85 0.74 
Total time interval screening positive 
PDR to first laser PRP (month) 
-0.43 0.44 0.33 0.65 
Interval (months): Clinician surgical 
decision to operations 
-0.51 0.22 0.02 0.60 
Intravitreal bevacizumab  -0.88 0.90 0.33 0.41 
Appointments not attended by patient -0.54 0.19 0.01 0.58 
 Group C was omitted in regression model due to very few numbers  
3.5.3 Visual and anatomic outcome 
Overall 93.2%  eyes in group A, 100% in group B and C had stable vision ( loss of <15 
letters).  29.05% in group A, 65% in group B and 100% in group C had final visual 
acuity of better than ≥ 6/12 (LogMAR ≤0.3). Table 3.19 (a & b) shows the visual 
outcomes for each indication of vitrectomy. There was a mean gain of 18.08 ± 27.08 
ETDRS letters in group A, 42.02 ± 27.17 ETDRS letters in group B and 17.37± 26.13 
ETDRS letters in group C (Table 3.23). Overall 6.4% of the patients had best corrected 
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Snellen visual acuity of ≤6/60 in the better eye and were certified visually impaired as 
defined by National Screening Committee (NSC), UK. 
Table 3.19 a: Visual outcome in patients following vitrectomy 
NCVH: Non-clearing vitreous haemorrhage, TRD: Tractional retinal detachment 
Overall anatomic success in this series was 84.32%. As ethnicity was found to be an 
independent risk factor for visual impairment and severity of diabetic retinopathy in the 
total cohort of people with diabetes in this region we estimated the visual outcome of 
vitrectomy in each ethnic group (Table 3.19b). Ethnic minorities had an average of 5.55 
fewer letters than Caucasians, but minority status did not affect final visual outcome 
after controlling for all other factors. 
 
 
 
 
 
 ≥ 15 letters gain ± 15 letters ≥ 15 letters loss 
 First 
operated 
eye* 
N (%) 
All eyes N 
(%) 
First 
operated 
eye* 
N (%) 
All eyes N 
(%) 
First 
operated 
eye* 
N (%) 
All eyes N 
(%) 
TRD  45(46.4%)  58 
(49.6%) 
46 
(47.4%)  
 51(43.6%) 6 (6.2%)  8 (6.8%) 
NCVH  46 
(88.6%) 
 51 
(85.0%) 
 6 (11.4%) 9 (15.0%)    0 (0.0%)  0 (0.0%) 
Other  3 (42.8%) 3 (37.5%)   4 (57.2%) 5 (62.5%)   0 (0.0%) 0 (0.0%)  
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Table 3.19b: Visual outcome in patients following vitrectomy by ethnicity and 
indication 
 Tractional Retinal 
Detachment (TRD) 
Non Clearing 
Vitreous 
Haemorrhage 
(NCVH) 
Other 
 Baseli
ne VA 
Fin
al 
VA 
Mean 
Chan
ge VA 
Baseli
ne VA 
Fin
al 
VA 
Mean 
Chan
ge VA 
Baseli
ne VA 
Fin
al 
VA 
Mean 
Chan
ge VA 
Afro-
Caribbe
an 
(n=51) 
26.91 ± 
18.34 
35.7
6 ± 
27.2
0 
8.83 ± 
26.91 
14.42 ± 
16.71 
60.5
2 ± 
26.9
4 
46.11 
±  
26.13 
58.0 ± 
2.8 
65.0 
± 
14.1
4 
7.0 ± 
11.3 
Caucasia
n 
(n=83)  
19.71 ± 
18.75 
41.7
3 ± 
27.5
3 
22.03 
± 
27.39 
23.15 ± 
18.52 
66.5
5 ± 
27.3
7 
43.39 
±  
27.41 
44.2 ± 
20.67 
62.8 
± 
29.8
2 
18.6 ± 
28.95 
South 
Asian 
(n=17) 
22.30 ± 
16.09 
53.3
0 ± 
25.1
0 
31.10 
± 
26.05 
17.86 ± 
17.81  
52.4
3 ± 
27.3
2 
34.57 
±  
27.82 
48.0 80.0 32.0 
P value  0.435 0.06
4 
0.045 0.104 0.24
8 
0.167 0.604 0.68
1 
0.294 
VA: Visual Acuity 
3.5.4 Ethnicity and appointments    
The number of failed and attended appointments in the eye clinic from the date of 
decision to operate to last follow up was recorded from the hospital electronic record 
system. The average follow up in group A was 17.53 months, and for each missed 
appointment/cancelled by patient, after controlling for months, there was an estimated 
letter loss of 2.09 letters, significance of p=0.033. The average follow up in group B  
was 17.61 months, and for each missed appointment/cancelled by patient, after 
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controlling for months, there was an estimated letter loss of 2.40 letters, significance of 
p=0.033  
3.5.5 Complications 
a) Re-detachment and final retina status: A total of 36/117 (30.7%) of the eyes in group 
A had redo-vitrectomy out of which 17/36 (47.2%) for re-detachment of the retina, 
14/36 (38.9%) for NCVH and 5/36 (13.9%) for epi-retinal membrane. In group B 6/60 
(10.0%) underwent redo vitrectomy, with 4/6 (66.7%) for NCVH and 2/6 (33.3%) for 
retinal detachment.  In this study, 11.35% (21/185) of the eyes had either detached 
retina or developed into phthisis at time of last follow up.  
b) Cataract: Fewer 51 (27.57%) eyes had prior cataract extraction and 41 (22.62%) eyes 
required cataract operation at a mean of 8.01 months following primary vitrectomy 
while 26 (14.05%) eyes had combined primary vitrectomy and cataract extraction. Two 
eyes had subsequent zonular dialysis, while one eye had dropped nucleus during 
cataract extraction following vitrectomy and one eye had subluxated intra-ocular lens.  
c) Post Vitrectomy Vitreous Haemorrhage and sight impairment: In this study, 43.25 % 
of the eyes had post vitrectomy haemorrhage with majority (31.89%) occurred on the 
first post operative day (Table 3.20). 
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Table 3.20: Frequency of post vitrectomy haemorrhage 
 N (Total =185) % Mean episodes 
Group A  59 31.89 1.23 (range 1-3) 
Group B 15 8.10 1.47 (range1-2)  
Group C 6 3.20 1.1 (range1-2) 
No Haemorrhage 105 56.75  
 
Overall 23.56% of the patients had best corrected Snellen visual acuity of ≤6/18 
(ETDRS of 65 letters) in the better eye and were certified visually impaired (VI). 
3.6 Temporal relation of ESRD and Retinopathy 
3.6.1 Prevalence of ESRD 
There were a total of 167 (0.52%) patients with ESRD including Afro-Caribbean 
(n=59), Caucasian (n=76), South Asians (n= 19), and others (n=13) in a population of 
31,773 patients with diagnosed diabetes living in the region. The prevalence of ESRD in 
each ethnic group was 0.45% in Caucasians, 0.71% in Afro-Caribbeans, 1.28% in South 
Asians. Out of 29,630 T2D, 120 (0.40%) patients were diagnosed with ESRD while 47 
(2.2%) of T1D patients (n=2112) had ESRD. In patients with any form of retinopathy 
(n=12,788), the prevalence of ESRD increased to 1.18%.  
Approximately 50% of the patients with ESRD had PDR while 8.17% of patients with 
PDR had ESRD. The prevalence of ESRD in patients with non –PDR was 0.58% which 
was not significantly different from the prevalence of ESRD in any patient with 
diabetes.  The mean interval between diagnosis of PDR and ESRD was 3.71± 5.26 years 
and the interval was significantly shorter than those patients with non-PDR group with a 
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mean interval of 8.70 ± 5.35 years, the mean difference of 4.99 years being significant, t 
(148)=5.73, p<0.001.  
3.6.2 Characteristics of patients with ESRD 
Table 3.21 represents patient demographics, and associated microvascular and 
macrovascular co-morbidities and risk factors in the current cohort of diabetic patients 
at the time of diagnosis of ESRD.  
Table 3.21: Characteristics of the patient cohort with end stage renal disease 
  N Mean SD Median 
Age (years) 167 61.6 12.38 62 
Duration of diabetes (years) 167 23.1 10.50 23 
Use of insulin (years) 167 13.1 13.23 10 
HbA1c 167 8.1 8.10 7.4 
Interval in years (year of  diagnosis of  
status of DR at time of ESRD- year of 
diagnosis of ESRD) 
150 5.9 5.84 6 
Systolic BP 167 138.9 20.50 140 
Diastolic BP 167 71.1 10.43 70 
Haemoglobin 167 11.4 1.54 11.5 
BMI 165 30.4 6.88 29 
Gender (female) (%) 78 46.7   
Insulin use (yes) (%) 141 84.4   
Hypertension (yes) (%) 164 98.2   
Systolic BP - Group (>141) (%) 72 43.1   
Diastolic BP - Group (y>81) (%) 24 14.4   
BMI - Group (>28) (%) 86 51.5   
Increased Cholesterol (yes) (%) 144 86.2   
Smoker (yes) (%) 15 9.0   
Stroke (yes) (%) 40 24.0   
IHD (yes) (%) 56 33.5   
Angioplasty (yes) (%) 41 24.6   
Neuropathy (yes) (%) 58 34.7   
Diabetic foot (yes) (%) 42 25.1   
 
Ethnicity 
 
SE Asian (%) 19 11.4   
Caucasian (%) 76 45.5   
Afro-Caribbean (%) 59 35.3   
Other (%) 13 7.8   
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  N Mean SD Median 
Type of Diabetes     
T1D (%) 47 28.1   
T2D on tablets for diabetes (%) 27 16.2   
T2D 2 with insulin for diabetes (%) 93 55.7   
Stage of Retinopathy     
No Retinopathy (%) 15 9.6   
NPDR (%) 69 40.7   
PDR (%) 83 49.7   
 
3.6.3 Regression analyses 
Using  regression analysis (Table 3.22) PDR status had a beta coefficient of -6.62, 
p<0.001, if a patient was classified as PDR, he would have an ESRD onset of 6.62 years 
earlier than those who were not classified as PDR, above and beyond the influence of all 
other variables. 
Table 3.22: Multiple regression analysis for all Continuous and binary predictors 
 
 
B 
Standard 
Error 
Standard 
Beta T 
p-
value 
Constant 2.134 8.806  0.242 0.809 
Age 0.051 0.042 0.111 1.218 0.226 
Gender 0.299 0.796 0.027 0.376 0.708 
Duration of diabetes 0.188 0.064 0.355 2.937 0.004 
Insulin Use -0.023 1.254 -0.002 -0.019 0.985 
HbA1C  0.161 0.274 0.048 0.589 0.557 
PDR -6.621 1.088 -0.585 -6.087 0.000 
Maculopathy 2.028 1.205 0.171 1.683 0.095 
HT 7.040 5.279 0.103 1.333 0.185 
Systolic BP – Value -0.023 0.024 -0.077 -0.965 0.337 
Diastolic BP – Value -0.005 0.048 -0.009 -0.108 0.914 
Haemoglobin – Value -0.356 0.269 -0.095 -1.325 0.187 
BMI – Value -0.060 0.057 -0.074 -1.058 0.292 
Increased Cholesterol -0.760 1.271 -0.044 -0.598 0.551 
Smoker 1.118 1.419 0.060 0.788 0.432 
Drusen 0.066 1.395 0.003 0.047 0.962 
Stroke 0.521 0.986 0.040 0.529 0.598 
IHD 0.678 1.292 0.057 0.525 0.601 
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B 
Standard 
Error 
Standard 
Beta T 
p-
value 
Angioplasty 1.791 1.410 0.139 1.270 0.207 
Neuropathy 0.526 0.977 0.045 0.538 0.591 
Diabetic  foot -0.693 1.083 -0.054 -0.640 0.524 
Atrial/Ventricular 
Fibrillation 
-1.284 1.112 -0.088 -1.155 0.250 
 
A gender predisposition was also observed. Women with non-PDR took 7 years to 
develop ESRD compared to women with PDR who develop ESRD in 4 years. However, 
a man with non-PDR took 10 years to develop ESRD but only 3 years to develop ESRD 
if he developed PDR. So PDR men have ESRD 7 years sooner than NPDR men – this 4 
year disparity being significant (Table 3.23). 
Table 3.23: Effect of gender in years on status of development of ESRD 
PDR Gender Mean SD N 
NPDR Male 9.89 6.762 28 
Female 7.85 3.924 39 
Total 8.70 5.349 67 
PDR Male 3.02 4.518 52 
Female 4.87 6.228 31 
Total 3.71 5.263 83 
Total Male 5.43 6.300 80 
Female 6.53 5.249 70 
Total 5.94 5.840 150 
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3.6.4 Ethnicity and ESRD 
The group mean differences for ESRD onset intervals between PDR and non-PDR 
patients was significant, there was no differences by ethnicities, and nor does ethnicity 
moderate the relationship between PDR and ESRD onset.  
3.6.5 Duration of diabetes 
Overall, the beta coefficient was 0.188, p<0.01.  Thus for each one-year increase in 
duration of diabetes, the ESRD latency increased by 0.19 years above and beyond the 
influence of all other variables. 
3.6.6 Maculopathy 
Presence of co-existent maculopathy marginally increased the risk of developing ESRD 
(p=0.095).  Maculopathy patients with ESRD had a latency period 2.03 years shorter 
than non-maculopathy patients.  
3.6.7 Type of diabetes  
Type of diabetes was classified into 3 main groups: T1D: young onset who required 
insulin from the time of diagnosis of diabetes. T2D on tablets: adult onset diabetes that 
required oral agents /± life style modification and T2D on insulin: adult onset diabetes 
that require both oral medication and insulin. 
In patients with PDR type of diabetes did not affect the ESRD latency and it was 
significantly shorter than non-PDR patients. However, in patients with non-PDR T1D 
have significantly longer ESRD latencies than either kind of T2D (Table 3.24). 
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Table 3.24: Effect of diabetes type on ESRD latency 
 
 
 
 
 
 
 
 
3.6.8 Survival analyses by ethnicity  
 A survival analysis was performed upon the latency to develop ESRD, to examine 
differences among ethnicities (figure 3.3). Ethnic minorities have earlier peak 
“proportion terminated” i.e. people who developed ESRD than Caucasians. 
PDR Type Mean SD N 
NPDR T1D 14.75 9.910 8 
T2D on  tablets 6.18 3.340 17 
T2D on insulin 8.57 3.890 42 
Total 8.70 5.349 67 
PDR T1D 4.15 6.584 39 
T2D on  tablets 2.33 2.066 6 
T2D on insulin 3.47 3.964 38 
Total 3.71 5.263 83 
Total T1D 5.96 8.183 47 
T2D on  tablets 5.17 3.473 23 
T2D on insulin 6.15 4.666 80 
Total 5.94 5.840 150 
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Figure 3.3: Survival Function to ESRD 
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CHAPTER IV 
DISCUSSION 
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4.1 Prevalence of DR 
 
This study highlights important differences in the prevalence of DR across all ethnic 
groups with more prevalent sight threatening retinopathy in ethnic minority groups. It is 
the largest cross-sectional study on the prevalence of DR in the various ethnic groups 
with diabetes in the UK. The study shows that the risks of any retinopathy in T2D are 
highest in people with of African descent compared to South Asians or Caucasians. 
Both South Asians and Afro-Caribbeans are twice as likely to have CSMO and STDR 
compared to the Caucasians. No ethnic variations in prevalence of DR were observed in 
T1D although there were proportionately very small numbers of minor ethnic groups 
with T1D.  
The estimated population of UK in 2008 was 51.4 million of which 2.7 million were 
Asians (mainly South Asians) and 1.3 million were of Black ethnic background. Over 
the past decades there has been a significant change in the ethnic composition of the UK 
population. For example, there was increase from just over 6% to 10 % of foreign born 
people between 1981 and 2006 in the UK, with the majority of this increase occurring 
since 2001. Also it is predicted that net migration between 2006 and 2031 will be 
around 4.9 million migrants that represents nearly 69% of the population growth 
(Access Economics Pty Limited). Hence the current estimates on the prevalence of 
diabetic retinopathy and visual impairment from this study will guide health policy 
makers and decision making bodies to allocate adequate resources and target at risk 
ethnic minority population against this sight threatening complication.  
This study comprised of people with diabetes in two community based diabetic 
retinopathy screening programme, one representing the inner city population cohort in 
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UK (South East London) and the other reflecting regions within UK with pockets of 
minor ethnic groups (West Yorkshire). So the study population is a true representation 
of the ethnic minority groups in the UK. Of the 57,144 people diagnosed with diabetes 
in the two regions, data on DR was available in 50,331 (88.1%) which is comparable to 
the response rates of other population-based studies.  
The prevalence of diagnosed diabetes in this study is 4.2% with similar rates of 
diagnosed diabetes between the three ethnic groups.  Based on the associations of health 
professionals in ophthalmology model (Yorkshire and the Humber Quality Observatory 
(YHQO), 2011) that shows a disproportionate burden of diabetes in South Asians and 
Afro-Caribbeans, this study suggests that undiagnosed diabetes and/or uptake of retinal 
screening remain an issue especially in the minor ethnic groups in the UK. So in 
absolute terms, the disparities in prevalence of DR between ethnic groups noted in this 
study are unlikely to be due to the differences in prevalence of the underlying diabetic 
disease.  
In our study ethnic minority (Afro-Caribbean > South Asian> Caucasian), type of 
diabetes (T1D), use of insulin, long duration of  diabetes (>10 years) duration, poor  
glycaemic control (HbA1c >11), high systolic blood pressure (>131), on treatment for 
cholesterol and high total cholesterol were independently related to high risk of sight 
threatening DR (R2 & R3) (Table 4.13). 
Both ethnicity and diabetes have been reported to be risk factors for microvascular and 
macrovascular complication including coronary heart disease, stroke, peripheral 
neuropathy and nephropathy from population based and cross sectional studies. T1D, 
longer duration and poor control of diabetes have been recognised globally as risk 
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factors for diabetic retinopathy. Also the inequality in DR could be complex from 
greater prevalence and insulin resistance in population and poor access to health care 
systems (Bhopal et al., 2002, Aspinall P and Jacobson B, 2004).  A recent health survey 
from England also reported cardiovascular disease more common among South Asians 
with diabetes and also higher prevalence of end stage renal disease, stroke and 
hypertension in Black Caribbean, Indian and Pakistani population (Zaninotto et al., 
2007, Cappuccio et al., 2003). 
4.1.1 Comparative prevalence of diabetic retinopathy in type 1 diabetes and 
systemic risk factors 
The overall prevalence of DR in T1D was 53.1%, CSMO of 8.9% and STDR of 14.4%. 
The rates of DR was similar in both Caucasian (55.0%) and South Asians (53.3%) but 
was significantly lower in Afro-Caribbean’s. However Afro-Caribbeans had 
significantly higher prevalence of R2/R3 (11.1%) compared to other ethnic groups. 
Maculopathy rates of (13.5%) were similar across all ethnic groups: Caucasians 
(14.1%), South Asians (14.2%) and Afro-Caribbeans (13.7%).  
Although there is no historical comparative data in the UK, it is reassuring to note that 
the prevalence in this population is very similar to that observed in the Nordic countries 
(41.8% DR and 12.1% STDR) (Heintz et al., 2010) where there is overwhelming 
evidence of a decline in the incidence of STDR compared to reports published two 
decades ago (Bojestig et al., 1998a, Hovind et al., 2003). Much of the information on 
prevalence of DR in T1D is available from the WESDR in North America that was done 
more than 2 decade ago or multicentre European studies that were clinically based 
(Stephenson et al., 1995). A comparison with such studies runs the risks of comparison 
of different health care system and population that is more dynamic today in terms of 
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length of stay in one place, has a longer life span and better access to health care 
system.  
The prevalence of DR in this study is lower than that noted in the 725 New Jersey study 
on type 1 African Americans that showed that 64% of the cohort have any retinopathy, 
18.9% proliferative diabetic retinopathy and 12% have CSMO (Roy, 2000). Patients in 
New Jersey study were identified through hospital admissions and that could explain 
higher rates than seen in our population based study. Very limited information on DR 
prevalence is available from the native South Asian population. This could partly be due 
to lower prevalence rate of T1D, lack of screening services and health inequalities. The 
Diabetic Care-Asia Study reported 22% prevalence rate for any DR amongst T1D 
population from 230 centres in 12 Asian countries with a mean diabetic duration of 9.4 
(SD7.2) years. In contrast the prevalence of any DR in native South Asians with T1D 
was noted to be much lower at 13.4% (Ramachandran et al., 2000). Caution should be 
exercised when comparing epidemiological studies using different assessment 
techniques and classification. Nevertheless, the observations in this study indicate that 
ethnicity by itself is not an independent risk factor for the prevalence of any categories 
of DR in T1D when the same ascertainment techniques are used.  
In our study risk of sight threatening retinopathy (R2/R3) was related to duration of 
diabetes. For shorter duration of diabetes (3-10) years ethnic minority were at increased 
risk: South Asians (45.2%) > Afro-Caribbeans (26.7%) than Caucasian (16.1%).  Such 
high prevalence rates seen in our study in ethnic minorities with shorter duration 
especially in South Asians could possibly be due to fewer numbers and poor glycaemic 
control. Studies have reported variable prevalence rates across ethnic groups with 
shorter duration of diabetes: 16.8% amongst South Asians with less than < 10 years of 
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diabetes (Ramachandran et al., 2000), 49.5% in African Americans (Roy, 2000) and 
19% among Caucasians in Wisconsin county of North America (Klein et al., 1984b). 
Similarly diabetic control (indicated by HbA1c levels) affected the risk of developing 
R2/R3. A proportionally linear affect was seen for HbA1c (7.1-9.0%) across all ethnic 
groups but not for HbA1c > 9.0%. This could possibly be explained by fact that after a 
certain threshold point hyperglycaemic damage continues irrespective of the absolute 
numeric values. Systemic blood pressure was independent risk factor for STDR in our 
study. Overall 51.4 % of the patients with T1D were on medication to lower the blood 
pressure. This included people purely on either angiotensin converting enzyme (ACE) 
inhibitor or angiotensin receptor blockers (ARB). ACE inhibitors and ARB’s are 
primarily used for reno-protective function but have additional blood pressure lowering 
effect (Jandeleit-Dahm and Cooper, 2006) and are used in isolation or combination with 
other drugs.  The prevalence of hypertension in our study was not statistically different 
across ethnic groups and was similar to previously reported by Maahs DM et al (Maahs 
et al., 2005) but both Afro-Caribbeans and South Asians had high systolic BP and 
diastolic BP (3rd and 4
th
 quartile) than Caucasians. Cross sectional and long term 
longitudinal studies have established that presence of hypertension and elevated 
diastolic blood pressure as significant risk factor for sight threatening retinopathy across 
all ethnic groups with T1D (Klein et al., 2008a, Leske et al., 2005). Both ethnicity and 
presence of diabetes has been endorsed as risk factors for hypertension. Higher 
prevalence of BP and high systolic and diastolic BP readings were reported amongst 
ethnic minorities and African Americans by SEARCH study group (Rodriguez et al., 
2010). A similar trend was seen for total cholesterol and LDL. Afro-Caribbeans had 
higher BMI with 25.7% of the population > 33.8 (BMI) compared to 7.6% of the 
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Caucasians and 3.2% of the South Asians.  Also Afro-Caribbeans had higher prevalence 
of amputation and on renal dialysis for end stage renal disease compared to Caucasians 
and South Asians. There is paucity of data on the actual prevalence and risk factors for 
foot complications including peripheral neuropathy, amputation due to T1D. African- 
American had nearly twice the rate of lower limb amputation compared to Non-
Hispanic Americans possible due to increased prevalence of peripheral vascular disease 
due to diabetes in this cohort of population (Lavery et al., 1996). A similar pattern of 
increased prevalence in African American was seen by Chaturvedi N et al in WHO 
Multinational Study of Vascular Disease in Diabetes. Risk factors identified in the study 
included glycaemic control and increased BMI (Chaturvedi et al., 2001). 
Macroalbuminuria and end stage renal disease are recognised complication of diabetes 
and risk factors for STDR. There is no direct comparison but in a recent estimate by 
National Institute of Health, US it is also more prevalent in ethnic descent of Afro-
American and Asians in comparison to Non-Hispanic Caucasians both due to inherited 
genetic risk factors and greater prevalence of systemic co-morbidities in the ethnic 
minority cohorts (U S Renal Data System, 2010, Gross et al., 2005).  
Long duration of diabetes, higher baseline serum glucose, uncontrolled systolic pressure 
and high serum cholesterol levels have all been implicated as risk factors for sight 
threatening retinopathy (Klein et al., 1996b, Van Leiden et al., 2002, Wong et al., 
2008b).   Two large independent, interventional, multicentre studies have proved the 
beneficial effects of tight blood pressure control and glycaemic on incidence and 
progression of DR. (DCCT, 1993, UKPDS, 1998b, UKPDS, 1998a). DCCT study 
recruited 1,441 patients with T1D who were treated by either conventional therapy 
(defined as 1 or 2 injections per day) or intensive diabetes management (defined as 3 or 
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more daily injections or continuous infusion). Results showed intensive therapy reduced 
the risk for developing retinopathy by 76 % and slowed the progression of the disease 
by 54% in participants with some eye damage at the beginning of the study. Early 
treatment with intensive therapy was most effective; however it had a beneficial effect 
over the entire range of retinopathy. In addition to a beneficial effect on retinopathy it 
slowed development and progression of diabetic kidney disease by 50% and peripheral 
neuropathy by 60%. This improvement was achieved with an average 10% reduction in 
HbA1c from 8 to 7.2%. Studies from Caucasian population mainly WESDR, a 
population-based study in southern Wisconsin, in 1984 of 996 T1D, reported prevalence 
of diabetic retinopathy was 17% with diabetes duration of < 5 years that increased up to 
97.5% with >15 years duration of diabetes. PDR was 67% in persons with diabetes for 
>35 years. In the same study severity of retinopathy with diabetes duration >10 years 
was related to longer duration, high levels of glycosylated haemoglobin, presence of 
proteinuria, higher diastolic BP, and male gender (Klein et al., 1984b). A another study 
funded by WHO, DiaComp, comprised 25 centres in 18 countries from Asia, Africa, 
Australia, Europe, and North and South America. In this study complications were 
assessed by self-report of physician diagnosis and subjects with diabetes diagnosed at 
<15 years of age and had duration of diabetes varied between 5–24 years when 
surveyed. Diabetic retinopathy was related to age, duration of diabetes, hypertension 
and women had a significantly higher prevalence of retinopathy and laser treatment. 
The World Health Organization (WHO) Multinational Study of Vascular Disease in 
Diabetes (MSVDD), examined the prevalence and incidence of microvascular 
complications in individuals with T1D (Lee et al., 2001a). In the UK cohort of 245 
patients, any retinopathy was around 37% with PDR in 6% of the cases. Women had 
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higher systemic blood pressure but lower risk of hypercholesterolemia. EURODIAB a 
clinic based cross sectional study, examined complication prevalence in T1D subjects 
from 16 European countries. There were 172 participants from four centres in England 
with mean age of 33.8 years (SD10.7), mean duration of diabetes of 16.6 years 
(SD10.1) and a mean HbA1c of 7.3 (SD1.7). Any retinopathy was present in 51% of the 
subjects, background retinopathy increased with increasing HbA1c till absolute value of 
8% and with duration of diabetes between 5 and 15 years and reached plateau of 82% 
over 20 years , whereas PDR increased after HbA1c cut off 8% (Stephenson et al., 
1995).   
Diabetic care study in Asian countries found both diabetes duration (OR = 1.1) and 
hypertension (OR = 2.74) to be significantly associated with STDR, but it was not 
related to raised HbA1c (OR = 0.76) (Nitiyanant et al., 2002).   
In New Jersey study by Roy et al diabetic retinopathy in African Americans was 
associated with presence of renal disease, poor glycaemic control, high systolic blood 
pressure, and long duration of diabetes. In DiaComp study any retinopathy and STR 
was 3%, 0.8% with mean diabetic duration of 8 years in Puerto Rica island; and was 
9.4%, 0.7%  with diabetes duration of 10.1 years that increased to 49.4%, 35% 
respectively with diabetes duration of 17.9 years in Caribbean island of Havana. 
The above summary shows that in our study of people with T1D: long duration, higher 
HbA1c and both high systolic & diastolic blood pressure were related to sight 
threatening DR (R2 & R3) (Table 4.13). Also there is wide geographic variation in 
complication rates due to T1D and many of the data that are previously available are not 
derived from population-based samples. The risk factors identified amongst all studies 
are longer duration of diabetes, poor glycaemic and blood pressure control among 
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ethnic minority population remain challenging scenarios for the health providers across 
UK and the rest of the world. So it is necessary to develop community based 
educational program delivered locally to reinforce the need for better compliance with 
medication and adherence to screening program to reduce the burden of this preventable 
sight threatening complications in young and working population and improve the 
quality of life as population continue to live longer. 
4.1.2 Comparative prevalence of diabetic retinopathy in type 2 diabetes and 
systemic risk factors 
In T2D, the overall prevalence of DR was 39.5%, CSMO was 4.7% and STDR was 
8.3% in keeping with estimates generated by contemporary studies in the US and UK 
(Kempen et al., 2004, Wong et al., 2006, Raymond et al., 2009, Younis et al., 2003). 
Though there has been a global increase in the prevalence  of diabetes (Wild et al., 
2004) and anticipated increase in the prevalence of diabetic retinopathy, the prevalence 
of DR in UK have remained constant over last 2 decades despite the changing 
population composition and the improved diagnostic criteria and examination 
techniques. This could be due to both greater awareness and better management of risk 
factors and systemic co-morbidities associated with DR like hypertension and 
hypercholesterolemia both by health providers and end users.  
Overall, the prevalence rate of retinopathy is similar in both Caucasian and South Asian 
populations to previously reported population based studies in UK. However, there is a 
marked increase in prevalence in people of Afro-Caribbeans origin. This could be multi-
factorial from increased population, true increased prevalence of diabetes and known 
risk factors for DR like poor control, hypertension, cholesterol and increased BMI seen 
in this population cohort.  
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A significant percentage of people suffer from sight threatening retinopathy (R2, R3, 
M1 or P) in people with T2D. The prevalence of STR was 12.4% in this population 
cohort with significantly higher rates among Afro-Caribbean (17.9%) and South Asians 
(17.7%) compared to Caucasians (11.2%) p< 0.001.  
Studies conducted before the UKPDS era that compared the prevalence of DR between 
Afro-Caribbean and Caucasians in the UK did not reveal significant differences 
between the two groups (Chaturvedi et al., 1996a, Cruickshank and Alleyne, 1987). 
However, comparative data in the US show higher rates in people on African descent 
(Emanuele et al., 2005, Klein et al., 2002b, Klein et al., 2002a, Zhang et al., 2010).  
The increased prevalence of CSMO in Afro-Caribbeans in this study was consistent 
with other studies that show at least twice higher rates than that reported in the white 
population (Leske et al., 1999a, Wong et al., 2006). The MESA showed that the risk of 
CSMO was approximately 5 times in African-American than whites (11.1% versus 
2.7%) (Wong et al., 2006).  
When considering the South Asian population, our observations of increased STDR and 
CSMO are consistent with the reports of a recent cross-sectional study in the Midlands 
in UK comparing the prevalence of DR between the UK South Asians and white 
Europeans with T2D (Raymond et al., 2009).  However, well-conducted population 
based studies from South India (Rema et al., 2005, Wong et al., 2006) reported very low 
prevalence rates in DR. It may be argued that ascertainment bias, non-availability of 
screening services and health inequities may account for the lower prevalence in native 
South Asians. However, these differences may also suggest  that prevalence of DR 
within the various ethnic groups defined as ‘South Asians’ in the UK may be different 
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and future studies should attempt to report the prevalence of DR in each ethnic group 
within the Indian subcontinent to better understand these regional differences. 
Furthermore, these observations imply a role of environmental and epigenetic factors 
that may be responsible for higher prevalence in ethnic minority population in 
developed nations compared to the native South Asians.  
The study also showed that increasing age is a risk factor for all categories of DR. 
Though this is a recognised risk factor for T1D, the age effect in T2D remains 
controversial (Kempen et al., 2004, Wong et al., 2006, Klein et al., 1984c). The age-
specific prevalence of diabetes in this study mirrors the APHO diabetes prevalence 
model that indicates that there are a rising number of people with diabetes in the older 
age group. Earlier report on inequalities in uptake of diabetic retinopathy screening 
showed that non-attendance for screening was high among those aged 85 years or 
greater (Gulliford et al., 2010). So this study highlights another priority group that has 
to be focussed to promote equity in DR screening and treatment.  
Male gender was also noted to be a risk factor in this study. Pooled data from 8 
epidemiological studies showed no consistent association of gender with DR or STDR 
in Caucasians and African-Americans (Kempen et al., 2004). However, both the 
CURES (Rema et al., 2005) and SN-DREAMS (Raman et al., 2009) study showed  
significantly higher  prevalence in South Asian males. More than 90% of the population 
with diabetes have T2D. Most of the studies reporting inter-ethnic differences in DR 
were performed in developed states of United States and Europe with predominantly 
native Caucasian population and immigrant ethnic minority groups. High reported 
figures of DR in ethnic minorities are not replicated in population based studies from 
native countries. In UK only two population based studies with identifiable ethnicity of 
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the study cohort have looked at prevalence and inter-ethnic differences in diabetic 
retinopathy.  Most of this comparison has been between native Caucasians and people 
of South Asian origin but the data on the Afro-Caribbean population is limited. The 
UKPD was a multicentre, randomized, controlled clinical trial of therapy in patients 
with newly diagnosed T2D  looking at the effect of tight blood pressure and diabetic 
control on microvascular and macrovascular complications due to diabetes. Baseline 
examination at recruitment entry from 1977 to 1991 and reported results in 1994 
revealed similar rates of 37% for any retinopathy among three ethnic groups mainly 
Caucasian, Afro-Caribbean and South Asians (UKPDS, 1994). However in a more 
recently study, overall prevalence of any retinopathy was 40%  and it was  significantly 
higher among South Asians (45%) than in Caucasians (37%) from a randomised 
community cluster sample of 1035 patients (Raymond et al., 2009). However, the 
results from clinic based studies are in contradiction to population based studies. A 
clinic based study from Leicester, UK in 1984-86 reported prevalence of 11.6% for any 
retinopathy in South Asian Versus 32.3% in Caucasians (Samanta et al., 1991).    
Most of the data from population based studies in the Indian subcontinent report a lower 
prevalence rate of 17-27% for any DR (Ramachandran et al., 1996, Raman et al., 2009, 
Rema et al., 2005). Much of the information on prevalence of DR amongst people of 
Afro-Caribbean ethnicity comes from studies done in the USA. The Barbados Eye 
Study (BES) reported a prevalence of 25.8% in the black Caribbean population (Leske 
et al., 1999a) and similar rates were reported in NHANES III survey with a prevalence 
of 26.5% for African-Americans compared to 18.2% in non-Hispanic white Americans 
aged 40 or older (Zhang et al., 2008b).  Other studies reporting prevalence information 
in Afro-Caribbean with T2D include the Atherosclerosis Risk in Communities Study 
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(ARIC) with a prevalence of 27.7% (Klein et al., 2002b), Cardiovascular Health Study 
(CHS) in adults aged 65 years and older with a prevalence of 35.4% (Klein et al., 
2002a), the Veterans Affairs Diabetes Trial (VADT)  of 29% (Emanuele et al., 2005) 
and MESA study of 36.7% respectively (Wong et al., 2006). Rotimi et al reported a 
prevalence rate of 18% for any DR from Nigeria and Ghana (Rotimi et al., 2003).   
In our study more Afro-Caribbean than South Asians and Caucasians had high risk 
retinopathy (50.2%, 40.8%, 34.4% respectively), presence of maculopathy (39.1%, 
28.9%, 26.4%) and were on treatment with both insulin and oral hypoglycaemic 
medication (30.6%, 29.2%, 23.2%) respectively (Table 3.14), higher HbA1C: > 3rd 
quartile (24.7, 23.6%, 16.5%), higher systolic BP: > 3rd quartile (63.2%, 55%, 51.6%), 
higher Diastolic BP: > 3rd quartile (64.1%, 61.5%, 59%) respectively. South Asians had 
a lower BMI, total cholesterol and HDL compared to Afro-Caribbeans and Caucasians.        
In our study logistic regression analysis revealed ethnicity, diabetes duration, higher 
systolic BP and higher HbA1C as independent risk factors for developing high risk DR 
(R2/R3) (p< 0.001). Afro-Caribbeans (OR1.92) and South Asians (1.31) compared to 
Caucasians were more likely to develop R2/R3. Also, with every 10 year increase in 
duration of diabetes, there was 6 fold increase; every 0.5% in HbA1c increased the risk 
by 1.16 times and every 10 mmHg increase in SBP increased the risk by 1.20 times of 
developing high risk DR (R2/R3) (Table 3.15). 
Population based studies have proved that diabetic retinopathy is related to duration of 
diabetes, uncontrolled hyperglycaemia and systemic blood pressure (Klein et al., 1989c, 
Raman et al., 2009, UKPDS, 1994, Leske et al., 1999a). The UKPDS was a multicentre 
study that looked at the beneficial effects of tight blood pressure and diabetic control on 
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microvascular complication in people with T2D (UKPDS, 1998b, UKPDS, 1998a).   
The relative risk of two step progression of DR was reduced by 21% with intensive 
glucose control and 17% by intensive blood pressure control (<150/85mm Hg). 
Randomised controlled trials have also demonstrated the beneficial effects of lipid 
lowering agents on hard reducing exudates at the macula and progression of retinopathy 
with fewer eyes requiring laser treatment for sight threatening retinopathy (Cullen et al., 
1974, Harrold et al., 1969, Keech et al., 2007, Van Leiden et al., 2002). Analysis of 
clinical and biochemical variables in UKPDS study revealed Asians were younger, 
shorter and had a lower BMI than both the white Caucasian and Afro-Caribbean 
patients but a higher waist-hip ratio after taking age and obesity into account. Blood 
pressure levels were lower in the Asian patients than in the other groups but AC patients 
had significantly higher diastolic blood pressure than the white Caucasians. Also AC 
patients had significantly higher fasting plasma glucose than in other groups.  
Similar findings were reported from UKADS with people of South Asian ethnicity had 
significantly higher systolic, diastolic blood pressure, HbA1C and total cholesterol 
compared to white Caucasians.  
In our study both mean systolic and diastolic blood pressure was higher in Afro-
Caribbean and South Asian than Caucasian population. Similarly higher prevalence 
pattern of macrovascular complication were seen in ethnic minority patients (Table 
4.13. 4.14). Stricter targets for systemic risk factors control, ethnically oriented 
programs delivered locally and measures to motivate patients may achieve desired 
health-care outcomes in such diverse ethnic groups. This will reduce the burden of sight 
threatening retinopathy to the state and loss of working life years in this young people 
with T2D. 
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In summary in our study of people with T2D: male, presence of maculopathy, long 
duration, higher HbA1c, use of insulin, higher low LDL, higher  systolic & diastolic 
blood pressure and low eGFR (impaired kidney function) were related to sight 
threatening DR (R2 & R3) (Table 4.14).   
South East London and Yorkshire are two distinct geographic areas, under the two 
independent strategic health authorities and diabetic screening programme. Similar 
prevalence rate allowed us to collate the information, and provide overall prevalence 
rates for diabetic retinopathy. The study found significant differences in the prevalence 
of DR and VI in ethnic minority population in both T1D and T2D. This information 
possibly represents the overall prevalence rates of DR in UK and could be used by 
health bodies in identifying the high risk ethnic groups in the region, and appropriate 
service design and resource allocation to meet the challenges of rising diabetic epidemic 
and reducing burden of blindness due to DR. Sustained delivery of health information 
and awareness programmes delivered locally and using incentivised scheme have shown 
to improve the success of DR screening programs (Beynat J et al., 2009; Lester H et al., 
2010). Such models could be used to address the systemic comorbidities associated with 
diabetes. There were differences in glycaemic control, cholesterol and blood pressure 
control across all ethnic groups in this study and far from ideal but were better 
controlled in comparison to seen in UKPDS study. Thus the differences observed in this 
study prevalence of DR cannot be solely explained on known systemic diseases. 
Diabetes has long been recognised as a low grade inflammation with increased levels 
and association seen between circulating and locally produced inflammatory 
biomarkers, such as cell adhesion molecules (vascular adhesion cell molecule-1, 
VCAM-1; intracellular adhesion molecule-1, ICAM-1), pro-inflammatory cytokines 
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(interleukin-6, IL-6; tumour necrosis factor-alpha, TNF-α; C-reactive protein, CRP) 
with the development and progression of diabetic micro-vascular complications (Kaul K 
et al., 2010).  Clinically it is seen as beneficial effect of steroids in management of MO 
and improvement in DR (Elman MJ et al., 2011). Other possible causes could be due to 
differential susceptibility and in genetic polymorphism involved in final metabolic 
pathways of diabetes and DR like seen are in aldose reductase and VEGF A (Doria A., 
2010). These factors need further exploration and may hold keys to design of future 
management strategies of DR.               
4.2 Visual Impairment 
 
This study on a substantial dataset demonstrates that the prevalence of visual 
impairment (<6/12) and severe visual impairment (<6/60) are 3.4% and 0.4% in a 
multiracial population of people with diabetes attending screening in the UK. A further 
10.7% people are unilaterally visually impaired. The study merely reports the overall 
visual prevalence and does not separately identify other coexistent disease such as age 
related macular degeneration, cataract, or glaucoma that can independently affect the 
visual status.   
In addition, the study provides overwhelming evidence of inequities in vision healthcare 
in people with diabetes in the UK. People of South Asian and African descent are twice 
at risk of visual impairment in all 3 categories (driving vision, low vision and severe 
visual impairment) compared to Caucasians.  
This study highlights that even though people with diabetes participate in screening of 
DR using digital fundus photography, visual impairment remain a significant public 
health problem in the UK. On the contrary, loss of vision is uncommon in studies from 
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Iceland where the stable and predominantly Caucasian population is carefully screened 
for diabetes mellitus and provided with regular screening for DR since 1983 (Olafsdottir 
et al., 2007, Stefansson et al., 2000). It is still too early for the national systematic 
screening programme for DR in England and Wales to produce such an effect on 
prevalence of visual impairment. Only time will tell if such findings could be translated 
to a multiracial and mobile population.   
The analyses of severity of DR between ethnic groups in this cohort showed that the 
risk of sight threatening DR is also two times higher in the minority groups compared to 
the Caucasian counterpart. People with PDR and persistent maculopathy despite laser 
treatment are especially vulnerable to visual impairment. These observations are 
consistent with the findings of the UKADS study on South Asians that showed that the 
risk of sight threatening retinopathy is significantly higher than Caucasians and that this 
disparity could partly be explained by differential susceptibility to systemic risk factors 
(Raymond et al., 2009). Previous studies evaluating ethnic differences in certifications 
of visual impairment also showed similar results with the proportion of South Asians 
registered blind due to DR being three times that of the Caucasians in the UK (Hayward 
et al., 2002, Pardhan et al., 2004). So DR may contribute significantly to the higher 
prevalence of visual impairment in this minority population. There is very limited data 
on visual impairment in people of African descent with diabetes in the UK. 
Nevertheless, Kahn et al indicated that blacks suffer from a proportionate burden of 
blindness due to diabetes in the United States (Kahn et al., 1977). A similar higher 
prevalence rate of visual impairment has been reported in people of African origin with 
8.9% annual incidence of blindness (WHO criteria) due to DR in the Barbados Eye 
Study (Leske et al., 2010) but a lower rates of  0.17% (Low vision: <6/12) was reported 
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from Bangladesh (Dineen et al., 2003). Cataract and uncorrected refractive error still 
continue to be major cause of visual impairment in native states of ethnic minority 
groups (Dineen et al., 2003). 
Current digital photographic retinal screening for DR may not be sufficient to reduce 
the prevalence of visual impairment in diabetes. Uncorrected refractive error, cataract 
and glaucoma are more common in people with diabetes than the non-diabetic 
population and contribute more to visual impairment than diabetic retinopathy 
(Congdon et al., 2004, Congdon et al., 2003, Leske et al., 1991, Leske et al., 2010, 
Scanlon, 2008). Although people with diabetes are offered free eye-sight test in UK, the 
spectacles are often unaffordable. Studies from around the world also indicate that the 
threshold to correct one’s refraction varies considerably between ethnic groups. 
Furthermore, some of these ocular co-morbidities are more prevalent in certain ethnic 
groups such as cataract in South Asians and glaucoma in the Afro-Caribbean population 
(Miki et al., 2001, Nwosu, 2000b, Nwosu, 2000a, Rotimi et al., 2003). These factors 
may also explain the ethnic differences in visual impairment observed in this study. 
The other risk factors in minor ethnic groups include an earlier age of onset of diabetes 
and poorer health care utilization rates (Broadbent et al., 1999, Harris et al., 1993, Riste 
et al., 2001, Hanif et al., 2008). These findings are of concern, as patients who are at 
highest risk seem to have poorer outcomes. Previous studies on education levels and 
socio-economic status have shown that people with low income and those with lower 
levels of education are at higher risk of visual impairment, cataract and PDR (Klein et 
al., 1994a, Hansson-Lundblad et al., 2002, Chaturvedi et al., 1996b). The effect of race 
on ocular diseases was highlighted as early as 1990 in the United States (Tielsch et al., 
1990) in the Baltimore Eye Survey that showed that people of African descent had, on 
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average, a twofold greater prevalence of blindness and visual impairment compared to 
Caucasians. This effect of race was reduced after adjustment of the socio-economic 
factors. However, previous studies on the South London cohort showed that socio-
economic inequalities based on the Index of Multiple Deprivation score 2007 did not 
determine the rate of retinopathy in those who attended the screening programme 
(Gulliford et al., 2004). So further research into differences observed due to ethnic 
disparity is warranted. 
This study also shows that increasing age is a risk factor for visual impairment in 
diabetes. Although DR is reported to be the commonest cause of visual impairment in 
the working age-group, people aged 65 years and older with diabetes are three times 
more likely to be visually impaired (in all 3 categories- driving vision, low vision and 
severely visually impaired) compared to those between 16-64 years. In the UK there 
was an increase of 5.8% in blind registrations due to DR between 1990-91 to 1999-2000 
in the working age group (16-64 years) (Bunce and Wormald, 2008).  Similar high 
prevalence rates of 3.2% for VI and 6.2% for SVI were reported from Cambridgeshire 
in UK with 1.4%  of VI affecting the working age group (Gordon-Bennett et al., 2009). 
However, Bunce et al observed that the rates of registration (both low vision and 
blindness) due to DR in the elderly have increased significantly in the last two decades 
(Bunce and Wormald, 2008, Bunce et al., 2010). Although this rise is often attributed to 
increased public, professional and political awareness of certifications and support 
provided as part of the VISION 2020 strategy, this study highlights the fact that visual 
impairment is definitely a significant public health issue in the older population and it 
may be postulated that these figures may only reflect the increasing prevalence of 
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diabetes in the older people who mainly suffer from other causes of visual impairment 
especially age related macular degeneration.  
Visual impairment also occurs more frequently in people with T1D compared to T2D. 
Screening and timely management of DR has been shown to reduce the risk of visual 
impairment in people with T1D (Agardh et al., 1993, Stefansson et al., 2000). A similar 
reduction in T2D is more difficult to achieve unless diabetes is diagnosed promptly (de 
Fine et al., 2001, Olafsdottir et al., 2007). In the present study, in people with T1D, VI 
and SVI was 1.0% and 0.2% respectively. Recently Klein et al from Wisconsin eye 
study reported 25 year cumulative incidences rates of 13% and 3%, of any VI and 
severe VI respectively. The cumulative incidence rates were lower and people with 
recently diagnosed T1D had lower prevalence rates of vision impairment when 
controlled for duration of diabetes. This has been independently reported from two 
population based studies (Hovind et al., 2003, Klein et al., 2009c). The diminishing 
incidence could be due to better glycaemic and risk factor control, effective screening 
(Arun et al., 2009)  and timely laser treatment in sight threatening retinopathy from 
proliferative diabetic retinopathy and maculopathy (The Diabetic Retinopathy Study 
Research Group, 1981).   
In summary, this study identifies priorities to reduce the prevalence of visual 
impairment in people with diabetes in the UK. With the increasing population, the 
demographic right shift of the populace and the emerging racial-mix in most cities in 
the UK, it is important that human and financial resources be allocated to implement 
ethnic-specific strategies to reduce this burden. The observed inequalities have a 
substantial impact on the already compromised quality of life of people with diabetes 
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and its complications. They also represent a considerable drain on resources, both of the 
NHS and of care providers. 
Reducing disparities and promoting equity in vision health care in diabetes will require 
several changes at various levels: (1) increase public, professional and political 
awareness of disparities, (2) eliminate barriers to optometric care and correction of 
refractive errors, (3) facilitate efficient eye care services with particular focus on the 
vulnerable groups, and (4) increase the uptake rate of DR screening(Baker et al., 2005, 
Biello et al., 2010).  
The data presented from the DRIVE-UK study could be utilised in planning and 
prioritising strategies for prevention, treatment, and management of this chronic eye 
disease within the UK context. 
4.3 Vitrectomy 
 
End-stage diabetic eye disease is the most important cause of severe visual impairment 
in the working age-group, both globally, in the USA (Resnikoff et al., 2004) and in the 
UK (Bunce and Wormald, 2008). Both the prevalence and severity (Klein et al., 1989a, 
Leske et al., 1999b) of diabetic retinopathy is increasing.  Tractional retinal detachment 
(TRD) and non-clearing vitreous hemorrhage (NCVH) are two complications of 
proliferative diabetic retinopathy (Fine and Patz, 1987) which are treated with vitreo-
retinal surgical repair.  Improvements in  surgical techniques such as the use of wide 
angled viewing systems, use of endolaser during vitrectomy (Flynn, Jr. et al., 1992, 
Williams et al., 1989a) should have improved visual outcome since the first reported 
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randomized controlled diabetic vitrectomy study (DRVS, 1988b, DRVS, 1988a) but this 
requires further investigation. 
Anatomical and visual outcome are quite often unpredictable in vitrectomy for 
proliferative diabetic retinopathy. Anatomical results are often limited by the extent and 
degree of fibrous tissue (Eliott et al., 2006), vitreo-retinal adhesion (Eliott et al., 2006) 
and high rates of iatrogenic tears which complicate surgery (Schrey et al., 2006, Yorston 
et al., 2008). Functional visual outcome are also limited due to severe macular 
dysfunction from a long duration of macular traction and preceding ischemic 
maculopathy (Schrey et al., 2006, Williams et al., 1989b, Miller et al., 1980).  
In our study eyes that underwent vitrectomy overall anatomic success was 87.53%, 
60.5% of all eyes showed ≥ 3 ETDRS line improvement from the baseline and 38.38% 
of all cases had final visual acuity of ≥ 6/12 (20/40). These results represents an 
improvement from DRVS study where 25% achieved ≤ 0.3 logMAR following 
vitrectomy for VH and TRD (Williams et al., 1989b, Yorston et al., 2008).  These 
improved results could be attributed to both improvement in surgical techniques and 
instrumentation and possible early detection of severe sight threatening disease through 
screening programs. These programs are well established in UK and provide uptake 
(www.retinalscreening.nhs.uk) of up to 78% in most regional screening program. Also 
it could be due to improved control in diabetes and better control of systemic factors 
like blood pressure, cholesterol, intensive glycaemic control after the lessons learned 
from DCCT study (DCCT, 1993). When controlled for all other factors ethnicity alone 
did not affect the final outcome implying once the subject had reached end stage retinal 
disease it ceased to be modifying factor. 
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Preoperative visual acuity improved with time suggesting a move to earlier intervention 
and this correlated with improved postoperative visual results. Patients with lower pre-
operative baseline visual acuity achieved greater amount of improvement in LogMAR 
at time of last post-operative visit however patients with better pre-operative visual 
acuities had better final visual acuities. This suggests that patients should be operated 
upon before severe visual loss has occurred. The gradual improvement seen in 
preoperative visual acuities seen in this study may have been as a result of a realization 
of this factor clinically. The early vitrectomy study (DRVS, 1988b, DRVS, 1988a) 
suggested that the results of surgery were better with earlier vitrectomy. The surgical 
method has changed significantly with smaller gauge instruments, better viewing 
system and availability of surgical adjuvants like anti-vascular endothelial growth 
factors since the EVS and there could be a justification for repeating that study with 
modern methods. Both the EVS and our study suggest earlier intervention is preferable, 
our study because patients with better pre-operative vision perform better and the EVS 
because of the better outcomes from surgery performed more quickly after presentation. 
To summarise, surgical management of the late complications of PDR remains a 
common but challenging vitreoretinal procedure and the visual results remain 
unpredictable.  The surgical outcome after diabetic vitrectomy has continued to improve 
with advances in vitreoretinal surgical instrumentation and technique. There was a trend 
for operating patients with better vision over the ten years and this was associated with 
better visual outcomes. 
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4.4 End Stage Renal Disease and Retinopathy  
 
Diabetic nephropathy (DN) is rarely diagnosed using invasive kidney biopsies, the case 
definition of this complication is typically based on the presence of albuminuria (Ng et 
al., 2005). When applying this case definition, it is plausible that there is a substantial 
number of patients who are classified as having DN that actually have non-diabetic 
kidney disease instead (Parving et al., 1988).  Several investigators have proposed that 
to diagnose DN the subject should also have diabetic retinopathy (Canani et al., 2005, 
Remuzzi et al., 2002). Nevertheless, a recent meta-analyses of DN related genetic 
studies showed that the presence of diabetic retinopathy may be of limited practical 
value for defining cases of DN in both T1D and T2D (Ng et al., 2005). It could be 
hypothesized that the mere presence of retinopathy does not provide sufficient 
information to define DN or its progression and that the severity of retinopathy may be 
a better tool to understand the prognosis of DN.   
The relationship between DR and DN is a complex. Several cross-sectional and 
longitudinal studies suggest that the microvascular complications in the retina and 
kidney are closely related as they share the same risk factors including length of 
diabetes, high HbA1c, hypertension and hyperlipidemia (Girach et al., 2006, Orasanu 
and Plutzky, 2009, Romero-Aroca et al., 2010). However, the temporal relation between 
these two microvascular complications remains unclear. Cross sectional studies on T1D 
and T2D indicate that PDR is associated with microalbuminuria (Boelter et al., 2006, 
Chun and Li, 2010).  In fact, after 30 years of T1D, half of the patients develop PDR 
and approximately a quarter develop macroalbuminuria. So it does suggest that 
although microalbuminuria may precede retinopathy, the progression of retinopathy to 
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PDR is faster than the development of macroalbuminuria. This concept is however 
contraindicated in other studies. Mosier et al found no congruence between stages of 
retinal and renal disease (Mosier et al., 1997). Several studies have highlighted severity 
of diabetic retinopathy as an indicator of the risk of gross proteinuria. In WESDR of all 
patients with T1D and diabetes of 10 or more years half of the patients with PDR had 
concomitant proteinuria. Similar findings were noted in a longitudinal population 
studies in American Indians, Asians and Joslin Clinic Study. In our study amongst 
patients with T1D in London cohort 30% of the patients with PDR had ESRD and 
nearly 50% of the patients with ESRD had PDR. Conversely in another study of 211 
patients with T1D the prevalence of PDR was 7% at onset of microalbuminuria that 
increased to 29%, 4 years after onset of microalbuminuria as compared to 5% increase 
over same period in patients without microalbuminuria. In WESDR with T1D presence 
of gross proteinuria at baseline was associated with 95% increased risk of developing 
macular oedema.  
If any patient with diabetes is considered, the risk of ESRD is 0.52% or 5 in a 1000. The 
risk is not higher in patients with non-PDR. However, if one develops PDR, the risk 
increases 16 times and the time to ESRD is shortened to approximately 4 years from 
date of diagnosis of PDR. The risk of PDR has been observed in other studies 
(Cruickshanks et al., 1993, Cusick et al., 2005), However this is the first study to our 
knowledge that investigated the factors that determine the time to ESRD.  
Although ethnic difference in the prevalence of diabetic retinopathy and ESRD is 
increasingly recognised with higher prevalence reported among Afro-Caribbean and 
Asians, this study on a multiracial community in a metropolitan city shows that the rate 
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of conversion to ESRD once a person develops PDR is not influenced by ethnicity 
(Deshpande et al., 2008, Lopes, 2009) .  
In fact, gender seemed to be a more important risk factor in that a male with non-PDR 
takes nearly 10 years to develop ESRD but once a male convert from non-PDR to PDR, 
the rate of progression to ESRD is faster than in females (3 years versus 5 years).  
Alwakeel et al also noted that male gender was associated with a higher risk of ESRD 
(Alwakeel et al., 2008b) but no obvious cause could be found.  
There is no relationship between type of diabetes and ESRD latency as observed in 
other studies (Hasslacher et al., 1993). However the longer the duration of diabetes, the 
higher is the prevalence of ESRD. 
The presence of maculopathy marginally increases the risk of ESRD. The link between 
PDR and the development of ESRD is not clearly understood. Anemia is associated 
with an increased risk of PDR (Davis et al., 1998) and renal insufficiency (Breyer et al., 
1996).  A recent study showed that the severity of retinopathy have increased following 
the use of recombinant erythropoietin (EPO) for chronic renal failure (Diskin et al., 
2007). Recombinant EPO is used routinely in our patients with ESRD. Our study did 
not assess the use of recombinant EPO or the circulating EPO levels but it is useful to 
note that the mean haemoglobin of these patients with ESRD was 11.4%. The present 
day practice is to administer recombinant EPO to patients with ESRD and pre-ESRD 
anaemia to target a haemoglobin level of 12.5g/dl. So a combination of anaemia related 
retinal hypoxia and the direct angiogenic drive of EPO may help explain the high 
prevalence of PDR in our ESRD cohort. This study warrants the need for a multi-
disciplinary approach of patients with ESRD and diabetic retinopathy.    
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In conclusion, although ESRD and PDR share several common risk factors the shorter 
time to ESRD in patients with PDR will help to better identify the high risk group that 
could potentially develop ESRD and preventive strategies may be focussed on this 
group to facilitate global assistance to slow the progression of chronic kidney disease 
and indirectly reduce cardiovascular risks in diabetes.  
 
  
185 
 
4.5 Strength and weakness of the study 
 
The strength of our study is the use of a substantial dataset of a representative multi-
ethnic population with physician diagnosed diabetes and the use of standard national 
quality-assurance protocols for post-mydriatic 2-field high-resolution digital 
photographs and grading of DR.   
The limitation of this study is the use of a grading system that is not universally used in 
epidemiologic studies making it difficult to compare the prevalence of CSMO. 
However, the prevalence of DR in T2D in the white population in DRIVE UK (38%) 
was similar to that found other recent studies in the world that used either the interim or 
final ETDRS scale. Secondly, this study is limited to those who attend screening and 
treatment for DR so it likely that the rates may be an underestimation. Additionally, we 
have not considered retinopathy rates in undiagnosed diabetes. After adjusting for age, 
gender, type of diabetes, ethnicity and region: glycaemic control, duration of diabetes 
and higher blood pressure were found to be other traditional risk factors of high risk 
diabetic retinopathy. It would be useful to observe whether ethnicity remains an 
independent risk factor. Reports on this aspect are conflicting.    
In summary, this study provides data on the frequency of different categories of DR in 
various ethnic groups in the UK. We showed that while one in three Caucasian and 
South Asians with T2D has any retinopathy, one in two persons of African-Caribbean 
have retinopathy.  The risk of STDR and CSMO is two times higher in the Afro-
Caribbeans and South Asians compared to the white counterparts. In T1D, ethnicity was 
not found to be a risk factor for DR.  
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We have focused on presenting vision—that is, visual acuity as used in everyday life by 
the people taking part in DR screening. This measure of visual impairment is the most 
relevant for public health purposes (Evans et al., 2002). Despite that our prevalence may 
be an underestimate of visual impairment in people with diabetes because the study did 
not include non-attenders to the screening programmes and associated eye clinics. 
Previous study on the South London cohort indicated that screening uptake rates were 
particularly poor among the young adults aged 18-34 years and those aged 85 years or 
greater (Gulliford et al., 2010).  
Another limitation of our study is that approximately 30% of the non-participants were 
those referred to hospital eye services for referable DR or unclassifiable retinopathy 
using digital photography due to ungradable images. So it is likely that the actual 
prevalence of visual impairment may again be underestimated. However, the results of 
our study compare well with other studies that examined patients from the local diabetic 
retinopathy screening programmes in predominantly Caucasian-inhabited regions in the 
UK. The Liverpool Eye study in 1999 observed that 3.4% had visual acuity of ≤6/24 
and 0.8% had visual acuity of ≤6/60 (Broadbent et al., 1999).  Prasad et al noted that the 
prevalence of low vision and blindness as per WHO classification in Wirral were 2 % 
and 0.75% in 2000 (Prasad et al., 2001) and in Gloucestershire, Scanlon et al reported 
these to be 2.9% and 0.45% respectively in 2008 (Scanlon, 2008). It is useful to note 
that whatever be the source of data collection (survey of DR screening database or 
register of certifications of visual impairment), the prevalence of visual impairment in 
people with diabetes has been stable in the last decade (Broadbent et al., 1999, Bunce 
and Wormald, 2008, Bunce et al., 2010, Gordon-Bennett et al., 2009, Hayward et al., 
2002, Kumar et al., 2006, Pardhan et al., 2004, Prasad et al., 2001, Scanlon, 2008). 
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Another limitation is the retrospective nature of the diabetic vitrectomy outcome arm of 
the study. However this information is useful for counselling patients before surgery of 
the risks, complications and the likely outcomes of this sight threatening condition.  It 
will also help to council patients the need to keep up with their future appointment to 
ensure visual success and reduce the costs of visual impairment to state.    
Again the study highlighting temporal relation between ESRD and PDR was 
retrospective in nature, the date of ESRD and PDR are recorded from the first 
documentation in the medical records and not determined by a standardized protocol 
and at definite time–points. The results of this study may also be affected by the 
different treatment thresholds maintained by different physicians. Lastly, both PDR and 
ESRD are indicators of mortality and mortality was not censored in this study so it is 
likely that the prevalence of both end-points may be higher.  
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5.1 Conclusion 
 
Diabetic retinopathy is a multifactorial disease. Diabetic Retinopathy in various ethnic 
groups (DRIVE-UK) is a cross sectional population based study that looked at the 
prevalence of diabetic retinopathy and visual impairment in different ethnic groups. 
Both London and Wakefield are cosmopolitan cities with high immigrant populations 
particularly with respect to individuals of Afro-Caribbean and South Asia origin 
respectively. 
There was found to be an increased prevalence of diabetes and with that there was a 
projected increase in prevalence and severity of diabetic retinopathy. However the 
overall prevalence rates for any DR are similar to reported previously reported in 
UKPDS study over a decade ago. There is a decreased prevalence in younger age group 
possibly due to overall better glycaemic control and other risk factors from the lessons 
learnt from DCCT and UKPDS study. This decreased prevalence in native Caucasian 
population is offset by higher rates in ethnic minority and elderly population in these 
two cities. The increase rate in elderly could be due to increased life span and benefits 
of improved risk factor control offset by longer and natural history of the disease. The 
prevalence rates in ethnic minority population is nearly 2 times than reported in large 
population based studies from India and Africa.   
The study also highlights increased prevalence of significantly low vision below the 
driving requirements (< 6/12) in ethnic minority (Southeast Asian> Afro-Caribbean> 
Caucasian) in both T1D and T2D. This could be due to health disparity and poor risk 
factor control amongst this group of population (Gulliford et al., 2010, Nsiah-Kumi et 
al., 2009).  
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The visual and anatomical results have continuously improved across all ethnic groups 
over the last decade following surgical intervention in end stage retinal disease. This is 
been mainly due to improvement in pre-operative vision highlighting possible beneficial 
effects of early identification through national screening programmes and better risk 
factor control. However the uptake rate in most screening program is around 80% and 
there is continuous need to improve and provide services accessible locally in 
community or at GP practices to decrease the incidence from this preventable cause of 
blindness. There is an overall increased prevalence of visual impairment due to DR in 
ethnic minority population but it ceased to be factor in patients undergoing vitrectomy 
for end stage retinal disease. This highlights the importance of better diabetic and risk 
factor control before the disease momentum pushes it to point of no return. Patients who 
were non-compliant with appointments had poor visual outcome following surgery for 
end stage retinal disease. This information could be used for patient counselling at the 
time of operation and informed consent with the use of information leaflets at the time. 
Lastly the study explores the temporal relation between end stage eye disease and renal 
disease secondary to diabetes. The microvascular complications in the retina and eye are 
closely related and share the pathogenic process and same risk factors. The temporal 
relation of shorter time to ESRD in patients with PDR will help to better identify the 
high risk group that could potentially develop ESRD and preventive strategies may be 
focussed. 
This study highlights the need of to deliver diabetic education program at grassroots 
level locally and possibly integrating with local cultural and religious beliefs. 
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5.2 Future Work 
 
1) Further research work is needed to address socio-economic and health 
inequalities that possibly contribute to differences in prevalence rates of DR 
between ethnic groups. 
2) The study did not address the role of environmental and dietary components in 
disease phenotype as higher rates were seen in ethnic minority groups than 
previously reported in native population. There is need to look into modifiable 
factors like monitoring of life style, food habits, nutrients, vitamins  and other 
environmental factors. 
3) This was a cross-sectional study looking at the prevalence rates of diabetic 
retinopathy however longitudinal studies are needed to understand the incidence 
of DR. Also this will help to study temporal changes in prevalence and 
incidence of DR over decade. 
4) There is need to understand the role of novel risk factors- genetics and 
circulatory biomarkers that may explain these ethnic differences. So future 
studies may look at inflammatory markers, mitochondrial factors in patients with 
high risk retinopathy in various ethnic groups. 
5) Future studies are needed to look into the lack of disease awareness in 
community in general and ethnic minority population in particular. This could 
involve use of questionnaire based model to look into health utilisation within 
community.  
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Appendix 3 
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Appendix 4 
  
  Baseline Information 
Date of Birth 
Gender 
Ethnicity 
Type of diabetes 
     Right Eye   Left Eye 
 
 
 
Any other Ocular Co-morbidity 
Comments 
A. R0 
• No Retinopathy 
B. R1 
• Background Retinopathy 
present. 
C. R2  
• Pre-proliferative diabetic 
Retinopathy  
D. R3 
• Proliferative diabetic 
Retinopathy 
M0: No maculopathy 
M1  
Ay macular oedema  
DMO: Diabetic maculae 
oedema
 
 
 
 
Best Corrected Snellen 
Visual Acuity 
  
Grade of Retinopathy A                B            C          D     A            B         C           D  
Macular oedema M0                               M1 M0                               M1                 
Laser Macular         PRP        None Macular         PRP        None     
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Appendix 5   
 
DECS –Specialist Care Feedback System 
Sticker of Patient      Date 
Has the patient been seen in DECS in 2008/2009  Yes/No 
Has the patient been seen in DECS    Yes/No 
     Right Eye   Left Eye 
 
 
Ethnicity 
Any other Ocular Co-morbidity 
Comments 
 
Diabetic Care:   KCH GSTT UHL GP Other 
Was OCT done in this Visit      Yes/No 
Was FFA done in this visit      Yes/No 
A. Mild NPDR 
• At least one 
microaneursym 
B. Moderate NPDR 
• Hemorrhages or 
microaneurysms (H/Ma) 
• Soft exudates, Venous 
beading (VB), and 
intraretinal microvascular 
abnormalities 
(IRMAs) definitely present. 
C. Severe NPDR 
• H/Ma in all 4 quadrants 
• VB in 2 or more quardrants 
• IRMA in at least 1 
quadrant 
D. Very Severe NPDR 
• Any two or more of C 
E. Early PDR 
• New vessels on the retina 
• Definition not met for F 
F. High-Risk PDR 
• New vessels on the disc 
(NVD) of 1/4 to 
1/3 or more of the disc area 
or 
• Any NV and vitreous or 
preretinal or 
vitreous hemorrhage 
M0: No maculopathy 
CSMO: Clinically Significant 
macular edema 
DMO: Diabetic maculae 
edema
Visual Acuity   
Grade of Retinopathy A     B       C       D       E       F A     B       C       D       E       F 
Macular edema M0         CSMO            DMO M0         CSMO            DMO                  
Laser Macular         PRP        None Macular         PRP        None     
Vitrectomy   
IVTA   
Anti-VEGF   
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Appendix 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THANK YOU 
DRIVE-UK 
  
Diabetic Retinopathy in various ethnic groups in UK  
Please complete the following form and return in the 
envelope provided to:  
  
Name and address of where to return to:  
  
Dr Sobha Sivaprasad 
DRIVE-UK 
Ophthalmology 
Normanby Building 
King’s College Hospital 
Identification details (this page to be removed before 
data entry: 
NHS number: ____________________________________________ 
Study Randomisation Number: ______________________________ 
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ID number: (pre-printed) 
Question Please complete data or tick which applies.  If data are not known please comment where possibl  on why the data are missing  
1 Year of birth(leave 
blank if not known) 
  
2 Gender Male  Female         Not 
known 
3 Ethnic group                                                                                                                                                 White British African-Caribbean
   South Asian1 Other        
Not 
known 
4 Smoker Current Ex smoker No 
Not 
known 
5 Type of diabetes Type I Type II  Other      Not 
known 
6 Year of diagnosis of 
diabetes (leave blank 
if not known) 
 
 
7 Medication for 
hyperglycaemia  
Tablets  Insulin Both        None  
Not 
known 
8 Medication for 
cardiovascular 
disease 
 ACE     Anti-platelets   ARB                
Aspirin Beta-blockers  Calcium blockers    
 Diuretics    Statins                     
                                                 No medication  
Not 
known 
10 Diabetes related 
health problems  
 
 Amputation   Angioplasty 
 CABG               Dialysis    
Foot ulcer       Microalbuminuria   
 Myocardial infarction  Stroke 
Peripheral neuropathy                     None 
Not 
known 
For the following items, please record the measurement taken on the date nearest to 
JUNE 30
th
 2009  
11 Body mass index 
(BMI)  
Date: _____/_____/_____.kg/m2  
12 Blood pressure 
mmHg  
Date: ___/___/____/ 
 
13 HbA1c%    Date: ____/____/____                      .  
14 LDL (mmol/litre)  
 
Date: ____/____/____               .  
15 HDL (mmol/litre) 
 
Date: ____/____/____               .  
16 Total cholesterol 
(mmol/litre)    
Date: ____/____/____               .  
17 eGFR (ml/min)    
 
Date: ____/____/____               .  
18 Albumin:creatinine 
ratio (ACR)   
Date: ____/____/___                       .  
 
 
                                                          
* South Asian: people of origin from India, Pakistan, Sri Lanka or Bangladesh 
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